Conditions: Obesity Overweight
Keywords: Obesity Overweight
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 460
Healthy volunteers: no

Brief summary:
This was a dose-finding study that evaluated the change in weight after 24 weeks treatment with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066 and placebo.

Detailed description:

Arms:
arm 1: LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks. arm 2: Matching placebo tablets for 24 weeks arm 3: LIK066 10mg qd (once daily) dosing frequency for 24 weeks arm 4: LIK066 50mg qd (once daily) dosing frequency for 24 weeks arm 5: LIK066 150mg qd (once daily) dosing frequency for 24 weeks arm 6: LIK066 2.5mg bid (once daily) dosing frequency for 24 weeks arm 7: LIK066 5mg bid (once daily) dosing frequency for 24 weeks arm 8: LIK066 25mg bid (once daily) dosing frequency for 24 weeks arm 9: LIK066 50mg bid dosing frequency for 24 weeks arm 10: Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily arm 11: Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily arm 12: Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily arm 13: Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily

Interventions: intervention 1: LIK066 intervention 2: Placebo
Intervention descriptions: intervention 1: LIK066 will be supplied in different doses as tablets to be taken orally. intervention 2: Placebo

Protocol document:
Prot_000.pdf: 
Global Clinical Development - General Medicine 
CLIK066
Clinical Study Protocol CLIK066B2201 / NCT03100058
A randomized, double-blind, dose-finding study to evaluate 
the change in weight after 24 weeks treatment with 8 doses 
of LIK066 compared to placebo in obese or overweight 
adults, followed by 24 weeks treatment with 2 doses of 
LIK066 and placebo
Document type:
Clinical Study Protocol
EUDRACT number:
2016-002868-14
Version number:
v01 (clean)
Clinical study phase:
IIb
Release date:
19-Sep-2017
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis
Clinical Trial Protocol Template Version 3.1 (February 2016)


Novartis
Confidential
Page 2
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Table of contents
Table of contents .................................................................................................................2
List of tables ........................................................................................................................5
List of figures ......................................................................................................................6
List of abbreviations............................................................................................................7
Glossary of terms...............................................................................................................10
Amendment 1 ...........................................................................................................................12
Protocol summary..............................................................................................................14
1
Introduction .......................................................................................................................17
1.1
Background............................................................................................................17
1.2
Purpose ..................................................................................................................17
2
Study objectives and endpoints .........................................................................................17
2.1
Primary objective...................................................................................................17
2.2
Secondary objective(s)...........................................................................................18
18
3
Investigational plan ...........................................................................................................19
3.1
Study design...........................................................................................................19
3.1.1
Epoch 2 (run-in)....................................................................................19
3.1.2
Epoch 3 (treatment)...............................................................................20
3.1.3
Epoch 4..................................................................................................21
3.1.4
PK evaluation........................................................................................21
3.2
Rationale for study design .....................................................................................21
3.3
Rationale for dose/regimen, route of administration and duration of treatment....22
3.4
Rationale for choice of comparator .......................................................................23
3.5
Purpose and timing of interim analyses/design adaptations..................................23
3.6
Risks and benefits..................................................................................................23
4
Population..........................................................................................................................24
4.1
Inclusion criteria ....................................................................................................24
4.2
Exclusion criteria...................................................................................................25
5
Treatment...........................................................................................................................27
5.1
Study treatment......................................................................................................27
5.1.1
Investigational and control drugs..........................................................27
5.1.2
Additional treatment..............................................................................28
5.2
Treatment arms ......................................................................................................28
5.3
Treatment assignment and randomization.............................................................29
5.4
Treatment blinding.................................................................................................29


Novartis
Confidential
Page 3
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
5.5
Treating the subject................................................................................................30
5.5.1
Subject numbering ................................................................................30
5.5.2
Dispensing the study drug.....................................................................31
5.5.3
Handling of study and additional treatment..........................................31
5.5.4
Instructions for prescribing and taking study treatment........................32
5.5.5
Permitted dose adjustments and interruptions of study treatment ........33
5.5.6
Rescue medication ................................................................................33
5.5.7
Concomitant medication .......................................................................33
5.5.8
Prohibited medication ...........................................................................34
5.5.9
Emergency breaking of assigned treatment code..................................34
5.6
Study completion and discontinuation...................................................................35
5.6.1
Study completion and post-study treatment..........................................35
5.6.2
Discontinuation of study treatment .......................................................35
5.6.3
Withdrawal of informed consent...........................................................36
5.6.4
Loss to follow-up ..................................................................................36
5.6.5
Early study termination by the sponsor.................................................37
6
Visit schedule and assessments .........................................................................................37
6.1
Information to be collected on screening failures..................................................41
6.2
Subject demographics/other BL characteristics.....................................................41
6.3
Treatment exposure and compliance .....................................................................41
6.4
Efficacy..................................................................................................................41
6.4.1
Weight...................................................................................................41
6.4.2
Waist circumference..............................................................................42
6.4.3
HbA1c ...................................................................................................42
6.4.4
FPG .......................................................................................................42
6.4.5
BP..........................................................................................................42
6.4.6
Fasting lipid profile & inflammation biomarkers .................................43
6.4.7
24-h urine collection .............................................................................43
6.4.8
Appropriateness of efficacy assessments..............................................43
6.5
Safety.....................................................................................................................43
6.5.1
Physical examination ............................................................................43
6.5.2
Vital signs..............................................................................................44
6.5.3
Laboratory evaluations..........................................................................44
6.5.4
ECG.......................................................................................................45
6.5.5
Pregnancy and assessments of fertility .................................................45
6.5.6
Appropriateness of safety measurements..............................................46


Novartis
Confidential
Page 4
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
6.6
Other assessments..................................................................................................46
46
6.6.2
Resource utilization...............................................................................46
6.6.3
PK..........................................................................................................47
7
Safety monitoring ..............................................................................................................47
7.1
AEs ........................................................................................................................47
7.2
SAE........................................................................................................................49
7.2.1
Definition of SAE .................................................................................49
7.2.2
SAE reporting........................................................................................50
7.3
Liver safety monitoring .........................................................................................50
7.4
Renal safety monitoring.........................................................................................51
7.5
Reporting of study treatment errors including misuse/abuse ................................52
7.6
Pregnancy reporting...............................................................................................52
7.7
Prospective suicidality assessment ........................................................................53
7.8
AEs of special interest ...........................................................................................53
7.8.1
Ketoacidosis ..........................................................................................53
7.8.2
Hypoglycemia .......................................................................................53
8
Data review and database management.............................................................................54
8.1
Site monitoring ......................................................................................................54
8.2
Data collection.......................................................................................................55
8.3
Database management and quality control............................................................56
8.4
Data monitoring committee ...................................................................................56
8.5
Adjudication committee.........................................................................................56
9
Data analysis......................................................................................................................56
9.1
Analysis sets ..........................................................................................................57
9.2
Subject demographics and other BL characteristics..............................................58
9.3
Treatments .............................................................................................................58
9.4
Analysis of the primary variable(s) .......................................................................59
9.4.1
Variable(s).............................................................................................59
9.4.2
Statistical model, hypothesis, and method of analysis..........................59
9.4.3
Handling of missing values/censoring/discontinuations.......................61
9.4.4
Supportive analyses...............................................................................62
9.5
Analysis of secondary variables ............................................................................62
9.5.1
Efficacy variables..................................................................................62
9.5.2
Safety variables .....................................................................................64
9.5.3
Resource utilization...............................................................................66


Novartis
Confidential
Page 5
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
9.5.4
PK..........................................................................................................66
9.5.5
DNA......................................................................................................66
9.5.6
Biomarkers ............................................................................................66
66
9.7
Interim analyses .....................................................................................................67
9.8
Sample size calculation..........................................................................................68
10 Ethical considerations........................................................................................................69
10.1
Regulatory and ethical compliance........................................................................69
10.2
Informed consent procedures.................................................................................69
10.3
Responsibilities of the investigator and IRB/IEC..................................................70
10.4
Publication of study protocol and results...............................................................70
10.5
Quality control and quality assurance....................................................................70
11 Protocol adherence ............................................................................................................70
11.1
Protocol amendments.............................................................................................71
12 References .........................................................................................................................71
13 Appendix 1: clinically notable laboratory values and vital signs......................................71
14 Appendix 2: liver event and laboratory trigger definitions and follow-up 
requirements ......................................................................................................................72
15 Appendix 3: specific renal alert criteria and actions .........................................................74
List of tables
Table 5-1
Rescue criteria for FPG or HbA1c (subjects with T2DM) ...................33
Table 5-2
Prohibited medication ...........................................................................34
Table 6-1
Assessment schedule.............................................................................38
Table 6-2
Fasting lipid profile, TG & inflammation biomarkers..........................43
Table 6-3
Hematology evaluations........................................................................44
Table 6-4
Clinical chemistry .................................................................................44
Table 6-5
Urinalysis ..............................................................................................45
Table 6-6
Biomarkers ............................................................................................45
Table 7-1
Guidance for capturing the study treatment errors including 
misuse/abuse .........................................................................................52
Table 9-1
Candidate dose-response models in consideration................................60
Table 9-2
Power for detecting a significant dose response signal*.......................68
Table 13-1
Vital signs notable range deviations .....................................................72
Table 14-1
Liver event and laboratory trigger definitions ......................................72
Table 14-2
Follow up requirements for liver events and laboratory triggers..........72


Novartis
Confidential
Page 6
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Table 15-1
Specific renal alert criteria and actions .................................................74
List of figures
Figure 3-1
Study design..........................................................................................21
Figure 9-1
Dose-response curve of candidate models (left panel: qd regimen) .....60


Novartis
Confidential
Page 7
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
List of abbreviations
ACEi
angiotensin-converting enzyme inhibitor
ACR
albumin creatinine ratio
AE
adverse event
ALT
alanine aminotransferase
ANCOVA
analysis of covariance
ARB
angiotensin receptor blocker
AST
aspartate aminotransferase
ATC
anatomical therapeutic chemical classification system
AUC
area under the curve
bid
bis in die (twice a day)
BL
baseline
BMI
body mass index (kg.m-2)
BP
blood pressure
β-hCG
β-human chorionic gonadotropin
CDER
center for drug evaluation and research
CFR
US code of federal regulations 
Cmax
maximum concentration observed
CRO
contract research organization
CV
cardiovascular
CYP3A4
cytochrome P450 3A4
DBP
diastolic blood pressure
DNA
deoxyribonucleic acid
DPP-4
dipeptidyl-peptidase-4
DS&E
drug safety & epidemiology
DSPP
development safety profiling plan
ECG
electrocardiogram
EDC
electronic data capture
eCRF
case report/record form (paper or electronic)
eGFR
estimated glomerular filtration rate
ENR
enrolled set
EU
European Union
FAS
full analysis set
FDA
Food & Drug Administration
FPG
fasting plasma glucose
GCP
good clinical practice
GI
gastro-intestinal
GLP-1
glucagon-like peptide-1
HbA1c
glycated hemoglobin A1c


Novartis
Confidential
Page 8
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
HDL
high density lipoprotein
hsCRP
high sensitivity C-reactive protein
IB
investigator brochure
ICF
informed consent form
ICH
International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
ID
identification
IEC
independent ethics committee
IN
investigator notification
INR
international normalized ratio
IRB
institutional review board
IRT
interactive response technology
LDL
low density lipoprotein
LFT
liver function test
LLOQ
lower limit of quantification
LS
least squares
MAR
missing at random
MDRD
modified diet in renal disease
MedDRA
medical dictionary for regulatory activities 
NOAEL
no-observed-adverse-effect-level
NOEL
no-effect-level
NYHA
New York heart association
OAD
oral anti-diabetic drug
PCR
protein creatinine ratio
PK
pharmacokinetics
PPS
per-protocol set
PT
prothrombin time
qd
quaque die (once daily)
SAE
serious adverse event
SAF
safety set
SBP
systolic blood pressure
SD
standard deviation
SGLT1
sodium-glucose co-transporter-1 
SGLT2
sodium-glucose co-transporter-2
SU
sulfonylurea
SUSAR
suspected unexpected serious adverse reactions
T2DM
type 2 diabetes mellitus
TD
study treatment discontinuation
TG
triglycerides
TSH
thyroid stimulating hormone
UGE
urinary glucose excretion
UGT
uridine-5’-diphosphoglucoronosyltransferase


Novartis
Confidential
Page 9
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
ULN
upper limit of normal
US
United States
UTI
urinary tract infection
VLDL
very low density lipoprotein
WBC
white blood cell
WHO
world health organization 


Novartis
Confidential
Page 10
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Glossary of terms
Baseline (BL)
Randomization (Visit 201) will be considered BL in this study.
Dosage
Dose of the study treatment given to the subject in a time unit (eg 25 mg
once a day, 50 mg twice a day (bid),…).
Electronic data capture 
(EDC)
EDC is the electronic acquisition of clinical study data using data 
collection systems, such as Web-based applications, interactive voice 
response systems and clinical laboratory interfaces.
EDC includes the use of electronic case report forms (eCRFs) which are 
used to capture data transcribed from primary sources used at the point 
of care.
End of study analysis
Statistical analyses performed at the end of the study including those 
specified in the statistical analysis plan and any data driven analyses 
that are performed at study end. The end of study analysis will take 
place after the last subject has completed Epoch 4 at Week 48.
Enrollment
Time of subject entry into the study at which the informed consent must 
be obtained (eg prior to starting any of the procedures described in the 
protocol). In this protocol, this will be at Visit 1 in Epoch 1.
Epoch
A portion of the study which serves a specific purpose. In this study, the 
4 epochs are: screening, run-in, randomization & treatment, and follow-
up.
eSource
eSource direct data entry refers to the capture of clinical study data 
electronically, at the point of care. eSource platform/applications reduce 
the use of paper capture source data during clinical visits. 
eSource combines source documents and case report forms into one 
application, allowing for the real time collection of clinical study 
information to sponsors and other oversight authorities, as appropriate.
Investigational drug
The drug of which the properties are being tested in the study; this 
definition is consistent with Unites States code of federal regulations 
(CFR) 21 Section 312.3 and is synonymous with “investigational new 
drug” or “investigational medicinal product”. In this study, the 
investigational drug is LIK066.
Medication pack number
A unique identifier on the label of each investigational drug package.
Randomization number
A unique identifier assigned to each randomized subject, corresponding 
to a specific treatment arm assignment (see Section 5.3).
Rescue medication
Rescue medication is medication that can be used to treat those
subjects with type 2 diabetes mellitus (T2DM) whose glycemic control is 
deteriorating. In this protocol a dipeptidyl-peptidase-4 (DPP-4) inhibitor 
or insulin should be used as rescue medication (see Section 5.5.6).
Run-in period
In this study, the run-in period is Epoch 2, where subjects who were 
successfully screened will receive placebo medication.
Source data/document
Source data refers to the initial record, document, or primary location 
from where data comes. The data source can be a database, a dataset, 
a spreadsheet or even hard-coded data, such as paper or eSource.
Study drug/treatment
Any single drug or combination of drugs administered to the subject as 
part of the required study procedures; includes investigational drug(s), 
placebo/comparator active drug run-ins or background therapy.
Study treatment 
discontinuation (TD)
When the subject permanently stops taking study treatment prior to the 
defined study treatment completion date 


Novartis
Confidential
Page 11
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Subject identification (ID)
A unique number assigned to each subject upon signing the informed 
consent form (ICF). See Section 5.5.1.
Variable
A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being 
tested in the study.
Week 24 analysis
Statistical analyses performed at the end of Epoch 3 at Week 24 
including those specified in the statistical analysis plan and any data 
driven analyses that are performed at Week 24. The Week 24 analysis 
will take place after the last subject has completed Epoch 3 at Week 24 
(see Section 5.4 and Section 9).
Withdrawal of consent
Withdrawal of consent from the study is defined as when a subject does 
not want to participate in the study any longer, and does not want any 
further visits or assessments, and does not want any further study 
related contact, and does not allow analysis of already obtained biologic 
material (see Section 5.6.3).


Novartis
Confidential
Page 12
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Amendment 1
Amendment rationale
The protocol is being amended to provide information related to a new risk recently identified 
from data of the SGLT-2 inhibitor canagliflozin where more cases of lower limb amputations 
(mainly of the toe) have been observed in the canagliflozin group compared to the placebo 
group. No lower limb amputations have been seen in LIK066 studies, but this risk may 
constitute a possible class-effect. Patients with a history of lower limb amputation will be 
excluded from enrollment into the study.
As a precautionary measure, patients with any history of ketoacidosis, lactic acidosis, or 
hyperosmolar coma will be excluded from enrollment into the study as well.
Furthermore, some minor changes and corrections of inconsistencies and typographical errors 
have been done.
Changes to the protocol
Section 3.1 has been amended regarding the duration of Epoch 1 and Epoch 2, as these epochs 
are now approximately 2 and 4 weeks respectively.
Section 3.6 has been updated to add a newly identified risk (lower limb amputation) observed 
with the SGLT-2 inhibitor canagliflozin and preventive measures are provided; this was also 
updated in other sections of the protocol (e.g. Section 6.5.1).
The exclusion criterion on ketoacidosis, lactic acidosis or hyperosmolar coma in Section 4.2
was amended to also exclude any history of the condition. Furthermore, a typo was corrected 
in this section with regards to the units for hemoglobin, and in addition history of lower limb 
amputation was added to the exclusion criteria as a precautionary measure.
Section 5.5.5 was changed to clarify that dose adjustments are not permitted (masked 
treatment) but that interruptions can be done for safety reasons.
In Section 5.6.2 lower limb amputation was added as a condition when study treatment has to 
be discontinued.
In Section 6.4.1 it is explained that it is allowed for sites to use their own calibrated scale for 
measurement of overweight or obese subjects. Subjects must be in underwear or use a hospital 
gown when their weight is being assessed.
In Section 6.4.4 the definition of overnight fast was updated. 
In Section 6.4.5 the use of alternative blood pressure devices is now allowed if an automated 
device cannot be used (for instance when the cuff on the automated device is too small for the
subject’s arm).
Section 7.8.2 was improved and clarifications were provided.
In Section 9 some minor typographical corrections were made.


Novartis
Confidential
Page 13
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
In Section 10.5 the old name of the audit department was updated to the new name (Global 
Development Quality Audit).
In Section 12 new references have been added.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol are substantial and require IRB/IEC approval 
prior to implementation.


Novartis
Confidential
Page 14
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Protocol summary
Protocol number
CLIK066B2201
Title
A randomized, double-blind, dose-finding study to evaluate the change in 
weight after 24 weeks treatment with 8 doses of LIK066 compared to 
placebo in obese or overweight adults, followed by 24 weeks treatment with 
2 doses of LIK066 and placebo.
Brief title
A dose-finding study to evaluate the change in weight after treatment with 
LIK066 compared to placebo in obese or overweight adults.
Sponsor & clinical 
phase
Novartis Phase 2b
Investigation type
Drug
Study type
Interventional
Purpose and rationale
Evaluate the efficacy, tolerability and safety of LIK066 to support dose 
selection for Phase 3 development in overweight and obese adults.
Primary objective(s) 
To determine the dose-response signal and assess the dose-response 
relationship of two dose regimens of LIK066 as measured by the percent 
change from baseline (BL) in body weight relative to placebo after 24 
weeks of treatment.
Secondary objectives
1. To assess the responder rates according to percent decrease in body 
weight either ≥5 % or ≥10 %, from BL at Week 24, for the overall 
population and each of the subgroups (normoglycemic subjects, 
dysglycemic subjects and subjects with type 2 diabetes mellitus 
(T2DM)).
2. To assess the dose-response relationship for weight loss in 
normoglycemic subjects, dysglycemic subjects and subjects with T2DM 
after 24 weeks of treatment.
3. To evaluate the effect of all LIK066 doses and regimens vs placebo for 
the overall population and by subgroups (normoglycemic subjects, 
dysglycemic subjects and subjects with T2DM) after 24 weeks of 
treatment on:

Waist circumference.

Change from BL in glycated hemoglobin A1c (HbA1c).

Change from BL in fasting plasma glucose (FPG).

Changes in systolic blood pressure (SBP) and diastolic blood 
pressure (DBP).

Changes in the fasting lipid profile and high sensitivity C-reactive 
protein (hs-CRP).

24-h urinary glucose excretion (UGE) in a subset of subjects.
4. To evaluate the change in weight and other efficacy parameters listed in 
#3 in the overall population and by subgroups by LIK066 treatment vs
placebo between Week 24 and Week 48 (in Epoch 4).
5. To evaluate safety (adverse events (AEs) and laboratory parameters) 
and tolerability of LIK066 over 24 weeks of treatment and over 48 
weeks of treatment for all subjects.
6. To evaluate AEs of interest and laboratory data in subjects treated with 
LIK066 or placebo between Week 24 and Week 48 (during Epoch 4).
7. To evaluate 24-h urinary calcium and phosphorus excretion after 24 
weeks of treatment and after 48 weeks of treatment in a subset of 


Novartis
Confidential
Page 15
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
subjects.
8. To evaluate the pharmacokinetics (PK) of LIK066.
Study design
Multi-center, randomized, double-blind, parallel-group dose-finding study 
evaluating the effect on weight, tolerability and safety of LIK066 vs placebo. 
Following a screening visit, eligible subjects will enter the run-in. After the 
run-in period, eligible subjects will be randomized and will complete two 
periods of 24 weeks duration each. The total duration of the study is up to 
54 weeks.
Population
Approximately 432 female and male subjects ≥18 and ≤75 years old.
Key inclusion criteria

Male and female, age 18 to 75 years old, both inclusive. 

Body mass index (BMI) ≥30 kg/m2 or BMI ≥27 kg/m2 combined with at 
least one obesity-related comorbidity (eg history of cardiovascular (CV)
disease, hypertension, dyslipidemia, dysglycemia (pre-diabetes or 
T2DM), sleep-apnea syndrome).

Agreement to comply with the study-required life-style intervention and 
treatment during the study.
Key exclusion criteria

Use of pharmacologically active weight-loss medications, glucagon-like 
peptide-1 (GLP-1) agonists or sodium-glucose co-transporter-2 
(SGLT2) inhibitors within 3 months of screening, or between screening 
and randomization.

Bariatric surgery.

Lack of compliance with lifestyle intervention (defined as weight gain 
during the run-in (Epoch 2)), or with study medication (defined as 
< 80 % study drug intake during the run-in) assessed at randomization. 

History of ketoacidosis, lactic acidosis, or hyperosmolar coma, or any of 
these occurring between Visit 1 and Visit 201.

Symptomatic genital infection or urinary tract infection (UTI) in the 4 
weeks prior to screening, or between screening and randomization.

Gastro-intestinal (GI) disorders associated with chronic diarrhea.

Congestive heart failure, New York Heart Association (NYHA) class III 
or IV.
Study treatment

LIK066.

Placebo.
Efficacy assessments

Body weight.

Waist circumference.

HbA1c.

FPG.

Blood pressure (BP).

Fasting lipid profile and hsCRP.

24-h UGE in a subset of subjects.
Key safety 
assessments

Physical examinations.

Vital signs.

Monitoring of laboratory markers in blood and urine.

Electrocardiogram.

AE monitoring.

Liver & renal safety monitoring.
Other assessments

PK.


Novartis
Confidential
Page 16
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201

 

AEs of special interest (hypoglycemia & ketoacidosis).
Data analysis
The primary analysis of this study aims to detect a dose response signal for 
the percentage reduction in body weight after 24 weeks of treatment using 
data from all doses across the different dosing regimens (once daily (qd)
and bid) to model the dose-response curve for each regimen and to provide 
sufficient information to choose the doses and dosing regimens for the 
further development of the drug. 
Hence, the following null and alternative hypotheses will be tested at a one-
sided significance level of 2.5 %:

H01: there is no dose-response relationship for LIK066 given once daily
(ie the dose response relationship is flat).

H11: there is a dose-response relationship for LIK066 given once daily
(ie as dose increases, the percent weight decreases).

H02: there is no dose response relationship for LIK066 given twice daily
(ie the dose response relationship is flat).

H12: there is a dose-response relationship for LIK066 given twice daily 
(ie as dose increases, the percent weight decreases).
The Multiple Comparison Procedure-Modeling methodology will be used to 
analyze the primary endpoint of percent change from BL in body weight at 
Week 24 in order to test these dose-response hypotheses and determine 
the dose-response relationship. 
A set of the dose-response candidate models will be defined for each 
dosing regimen separately. In order to preserve the family-wise error rate at 
one-sided significance level of 2.5 %, the optimal contrasts derived from 
the model candidate set for each dosing regimen will be individually 
compared to the critical value derived using a multiplicity adjustment 
accounts for all tests of comparing LIK066 doses to placebo across 
regimens simultaneously. The rejection of the null hypothesis for each 
dosing regimen will be achieved using the maximum test statistic in each 
dosing regimen from each estimated contrast test in the candidate set.
The analysis to derive the test statistics is based on an analysis of 
covariance (ANCOVA) model with the percent change in body weight from 
BL to Week 24 as a response variable, treatment (placebo and all LIK066 
doses from each regimen), stratification factor of glycemic status at 
screening (dysglycemic, normoglycemic and T2DM) and pooled 
center/region as factors and BL weight as a covariate.
Model averaging approach will be used to estimate the dose-response in 
each dosing regimen separately.
The primary analysis will be conducted on the full analysis set. Missing 
values of body weight at Week 24 will be imputed using the multiple 
imputation approach under a missing at random (MAR) assumption.
Key words
Obese, overweight, T2DM, interventional study, weight loss


Novartis
Confidential
Page 17
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
1
Introduction
1.1
Background 
Overweight and obesity represent a rapidly growing threat to the health of populations 
worldwide. Obesity raises the risk of morbidity from hypertension, dyslipidemia, type 2 
diabetes mellitus (T2DM), coronary heart disease, stroke, gallbladder disease, osteoarthritis, 
sleep apnea and respiratory problems, and some cancers. Obesity is also associated with 
increased risk in all-cause and cardiovascular (CV) disease mortality. The biomedical, 
psychosocial, and economic consequences of obesity have substantial implications for the 
health and well-being of the person with obesity (AACE 2016).
Diet and behavior modification have been shown to be useful in producing effective, but 
modest weight loss leading to amelioration of comorbid medical problems. Addition of 
weight loss medications reinforces behavioral strategies; however clinical challenges remain 
with the magnitude of weight reduction (up to ~5 % vs placebo) and the maintenance of the 
achieved weight loss. Some of the available treatments have limitations for long term use due 
to their gastro-intestinal (GI) adverse effects, others – due to central nervous system adverse 
effects. Therefore, there is a substantial opportunity and real need to develop weight loss 
medicines which will be more effective and better tolerated.
LIK066 is an inhibitor of the sodium-glucose co-transporter-1 (SGLT1) and sodium-glucose 
co-transporter-2 (SGLT2). The
dual mechanism (renal and intestinal) to reduce 
re-absorption/absorption of glucose leads to loss of calories (calorie-loss enhancer). It also has 
the potential to reduce food intake via central mechanisms mediated by an increase in incretin 
hormones (glucagon-like peptide-1 (GLP-1) and peptide YY). In a Phase I study with normo-
and dysglycemic adults with body mass index (BMI) ≥35 kg/m2, LIK066 150 mg once daily 
(qd) resulted in mean 5.7 % placebo subtracted weight loss at 12 weeks. Diarrhea was a very 
common adverse effect in this study [Data on file]. It is therefore important to find the optimal 
efficacy-tolerability dose of LIK066 for further clinical development.
The current study is designed to evaluate the efficacy, tolerability and safety of a dose-range 
of LIK066 as part of a development program for the use of LIK066 in overweight and obese 
adults.
1.2
Purpose 
The purpose of the study is to evaluate the efficacy, tolerability and safety of LIK066 to 
support dose selection for Phase 3 development in overweight and obese adults.
2
Study objectives and endpoints
2.1
Primary objective
To determine the dose-response signal (see Section 9.4.2) and assess the dose-response 
relationship of two dose regimens of LIK066 (see Section 5.2 & Section 3.1.2: 2.5 mg, 10 mg, 
50 mg and 150 mg qd, 2.5 mg, 5 mg, 25 mg and 50 mg twice daily (bid)) as measured by the 


Novartis
Confidential
Page 18
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
percent change from baseline (BL) in body weight relative to placebo after 24 weeks of 
treatment.
2.2
Secondary objective(s)
1. To assess the responder rates according to percent decrease in body weight either ≥5 %
or ≥10 %, from BL at Week 24, for the overall population and each of the subgroups
(normoglycemic subjects, dysglycemic subjects and subjects with T2DM, see Section 
9.5.1).
2. To assess the dose-response relationship for weight loss in normoglycemic subjects, 
dysglycemic subjects and subjects with T2DM after 24 weeks of treatment (see Section 
9.5.1).
3. To evaluate the effect of all LIK066 doses and regimens vs placebo (see Section 9.5.1) for 
the overall population and by subgroups (normoglycemic subjects, dysglycemic subjects 
and subjects with T2DM, see Section 3.1) after 24 weeks of treatment and between 
Week 24 and Week 48 on:

Waist circumference, see Section 6.4.2.

Change from BL in glycated hemoglobin A1c (HbA1c), see Section 6.4.3.

Change from BL in fasting plasma glucose (FPG), see Section 6.4.4.

Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), see 
Section 6.4.5.

Changes in the fasting lipid profile and high sensitivity C-reactive protein (hsCRP, 
see Section 6.4.6).

24-h urinary glucose excretion (UGE) in a subset of subjects (see Section 6.4.7).
4. To evaluate the change in weight and other efficacy parameters listed in #3 in the overall 
population and by subgroups by LIK066 treatment vs placebo (see Section 9.5.1.2)
between Week 24 and Week 48 (in Epoch 4, see Section 3.1.3).
5. To evaluate safety (adverse events (AEs) and laboratory parameters) and tolerability of 
LIK066 over 24 weeks of treatment and over 48 weeks of treatment for all subjects (see 
Section 9.5.2).
6. To evaluate AEs of interest and laboratory data (see Section 9.5.2.2) in subjects treated 
with LIK066 25 mg qd, 35 mg qd or placebo between Week 24 and Week 48 (during 
Epoch 4).
7. To evaluate 24-h urinary calcium and phosphorus excretion after 24 weeks of treatment
and after 48 weeks of treatment in a subset of subjects.
8. To evaluate the pharmacokinetics (PK) of LIK066 (see Section 6.6.3 and Section 9.5.4).


Novartis
Confidential
Page 19
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
3
Investigational plan
3.1
Study design
This is a multi-center, randomized, double-blind, parallel-group dose-finding study evaluating 
the effect on weight, tolerability and safety of 8 doses/regimens of LIK066 vs placebo (see 
Figure 3-1 & Section 5.2). Following a screening visit (Visit 1) and a screening period of 
approximately 2 weeks (Epoch 1), subjects meeting all eligibility criteria will enter the run-in 
Epoch 2 at Visit 101.
3.1.1
Epoch 2 (run-in)
Subjects meeting the eligibility criteria defined in Section 4 will enter the placebo run-in 
(Epoch 2). During the approximately 4 weeks duration of Epoch 2, subjects will receive the 
placebo run-in medication as described in Section 5.1.
At Visit 101, the subject’s volume status must be assessed (see Section 6.5.1) and 
hypovolemia must be corrected during the run-in in the elderly, in subjects with low SBP, or 
if on diuretics, angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor 
blockers (ARBs).
At the start of Visit 101, all subjects will receive the following advice for lifestyle intervention
(Look AHEAD Research Group 2013):

Subjects with weight < 114 kg (250 lbs) will be advised to follow a 1200 to 1500 kcal/day 
diet; subjects with weight ≥114 kg (250 lbs) will be advised to follow a 1500 to 
1800 kcal/day diet. Consumption of 30 % or fewer kcal from fat of which < 10 % kcal are 
from saturated fat will be recommended.

Subjects will be advised to gradually increase their physical activity to reach a goal of 
175min of moderate intensity physical activity per week, preferably distributed over 5 
days.
Compliance with the lifestyle intervention shall be reviewed and re-enforced at every study 
visit.
Subjects with T2DM
Subjects with T2DM will continue their usual treatment, except for subjects taking 
sulfonylurea (SU) or insulin. These subjects may be at an increased risk of hypoglycemia due 
to the combination of the SU or insulin and weight loss, with or without consequent treatment 
with LIK066 in Epoch 3. Therefore:

The dose of SUs for subjects with T2DM (see Section 3.1.2 & Section 5.3) using such 
medication (either as monotherapy or in combination with other oral anti-diabetic drugs 
(OADs)) must be reduced by 50 %, or as close to 50 % as possible based on dose options 
available locally. In case of persistent deterioration in glycemic control, the concomitant 
background OAD should be initially escalated to the maximal approved dose, followed by 
addition of rescue medication when required (see Section 5.5.6). To limit the number of 
subjects with early deterioration of glycemic control who would meet the FPG rescue 


Novartis
Confidential
Page 20
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
criteria early after randomization (see Section 5.5.6), an FPG randomization criterion is 
included in Section 4.2. 

For subjects on insulin, initial dose reduction of the total daily insulin dose by 10 % or 
more may be considered at investigator’s discretion based on subject’s total daily dose and 
glycemic control. In case of deterioration in glycemic control, insulin can be up-titrated
(see Section 5.5.6).
3.1.2
Epoch 3 (treatment)
After the run-in Epoch 2, eligible subjects will be randomized in the ratio of 1:1:1:2:1:1:1:2:2 
to one of the following regimes at Visit 201 (randomization):

2.5 mg qd LIK066.

10 mg qd LIK066.

50 mg qd LIK066.

150 mg qd LIK066.

2.5 mg bid LIK066.

5 mg bid LIK066.

25 mg bid LIK066.

50 mg bid LIK066.

Placebo.
At Visit 201, subjects will be randomized simultaneously to one of the nine Epoch 3 treatment 
schedules and to the subsequent treatment group/arm in Epoch 4 as follows:

Patients receiving one of the four LIK066 doses in the qd regimen in Epoch 3 will receive 
25 mg qd in Epoch 4.

Patients receiving one of the four LIK066 doses in the bid regimen in Epoch 3 will receive 
35 mg qd in Epoch 4.

Patients receiving placebo in Epoch 3 will either receive in a 1:1 ratio 25 mg qd or placebo 
in Epoch 4.
At randomization, subjects will be stratified according to their glycemic status at screening
using the following criteria (see also Section 5.3):

Normoglycemic: no prior clinical diagnosis of T2DM, FPG < 5.6 mM (100 mg/dL) and 
HbA1c < 5.7 % at Visit 1 (screening).

T2DM: prior diagnosis of T2DM, or subjects without prior diagnosis of T2DM with 
HbA1c ≥ 6.5 % and FPG ≥ 7.0 mmol/L (126 mg/dL) at Visit 1 (screening).

Dysglycemic: all subjects not meeting criteria for normoglycemic or T2DM at Visit 1 
(screening).
Following randomization, subjects will attend study visits in Epoch 3 (24 weeks) for 
assessment of efficacy, tolerability and safety parameters as defined in Table 6-1. During 
Epoch 3, subjects will take the study medication as described in Section 5.5.4.


Novartis
Confidential
Page 21
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
The doses of antidiabetic and antihypertensive medications should be adjusted in patients who, 
according to the investigator, could be at a safety risk (e.g. repetitive or severe hypoglycemia, 
symptoms and signs of volume depletion, etc.).
Figure 3-1
Study design
3.1.3
Epoch 4
After completing the procedures required at the last study visit of Epoch 3 (Visit 299), 
subjects in active study drug Epoch 3 arms will be switched to receive either LIK066 25 mg
qd or LIK066 35 mg qd for another 24 weeks (see Figure 3-1). 
The Epoch 3 placebo arm subjects will either continue the placebo treatment regimen or 
switch to LIK066 25 mg qd in a 1:1 ratio. 
Except for the placebo arm, the switch will results in 2 study groups, active drug 25 mg qd 
or 35 mg qd, in which longer-term safety, tolerability and efficacy of LIK066 following 
LIK066 treatment will be assessed. The rationale for the study design is presented in 
Section 3.2.
The doses of antidiabetic and antihypertensive medications should be adjusted in patients who, 
according to the investigator, could be at a safety risk (e.g. repetitive or severe hypoglycemia, 
symptoms and signs of volume depletion, etc.).
3.1.4
PK evaluation
PK sampling will be performed at visits indicated in Table 6-1 (see also Section 6.6.3).
3.2
Rationale for study design
The study is designed as a standard placebo-controlled, parallel-group study to obtain efficacy, 
tolerability and safety data in an unbiased fashion and determine the dose-response 
Run-in
50 mg qd
2.5 mg qd
2.5 mg bid
150 mg qd
10 mg qd
25 mg bid
50 mg bid
Placebo
Epoch 2
Epoch 3
Epoch 4
4 weeks
24 weeks
24 weeks
2 wks
Epoch 1: Screening (n = ~600)
V1
V101
V202
V203
V204
V205
V206
V302
V303
V304
V399
Randomization (n=432)
25 mg qd
35 mg qd
25 mg qd or placebo qd
5 mg bid
V299 & V301
V199 & V201


Novartis
Confidential
Page 22
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
characteristics of the investigated drug. A single-blind placebo run-in period is included to 
facilitate the implementation of lifestyle measures, as well as assess the compliance with 
study treatment. Twenty-four weeks of treatment in Epoch 3 are considered sufficient to reach 
sub-maximal or maximal weight loss. The last 24 weeks of the study will provide information
about the effect of two doses of LIK066 on weight, and also LIK066 safety and tolerability 
over a longer period (48 weeks). In addition to collection of trough PK samples in all subjects, 
PK sampling will be performed in a subset of subjects to enable characterization of the PK of 
LIK066 in the studied population and, if possible, from all tested doses and regimens in the 
study (see Section 6.6.3).
3.3
Rationale for dose/regimen, route of administration and duration 
of treatment
PK data with oral intake of LIK066 showed a sufficiently long half-life (approximately 16h) 
to allow for once-daily LIK066 dosing. LIK066 150 mg qd was used in a Phase 1 study of 12 
weeks duration, at a dose which is approximately 23 times below the safety margin for 
aneugenicity (see Section 3.6), and expected not to limit compliance due to GI effects. In this 
study, significant weight reduction of approximately 6 % vs placebo was observed, but it was 
commonly associated with diarrhea events, predominantly mild, at a frequency which reduced 
over time in most subjects. Therefore a dose of 150 mg qd is selected as the highest qd dose in 
the current study. Twice daily dosing will be explored to evaluate whether increased 
frequency of LIK066 exposure in the intestines could result in greater weight loss and whether 
tolerability would be improved compared with same/similar total daily once daily dosings. 
Administration of LIK066 three times daily did not result in better weight loss or tolerability 
[data on file] compared to bid dosing and therefore is not included in this study.
The eight active treatment regimens consist of four qd regimens and four bid regimens. The 
four qd regimens have been selected to cover one low dose (2.5 mg qd) at which some renal 
effect is present and no major gut effect is expected, two doses (10 mg qd and 50 mg qd) with 
sub-maximal/maximal renal and medium gut effect, and one qd dose (150 mg qd) with 
maximal renal and gut effects contributing to weight loss.
The four bid regimens have been selected to cover two low doses (2.5 mg and 5 mg bid) at 
which some renal effect is present and no major gut effect is expected, one dose (25 mg bid) 
with sub-maximal renal and medium gut effect, and one dose (50 mg bid) with maximal renal 
and gut effects contributing to weight loss.
Including both qd and bid dosing allows for thorough exploration of the LIK066 dose-
response curve of a drug with a dual mechanism of action (ie gut and renal).
During Epoch 4, subjects will receive 25 mg qd or 35 mg qd LIK066. These doses provide 
sub-maximal/maximal renal effect and a moderate gut effect and are expected to provide for 
good maintenance of the weight loss achieved in Epoch 3.
The oral route of administration has been chosen, as in previous studies, to ensure that active 
drug is present in the gut lumen.


Novartis
Confidential
Page 23
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
3.4
Rationale for choice of comparator
A placebo group is a standard comparator in Phase 2 studies and is included to account for 
study effect and the lifestyle interventions described in Section 3.1.1.
3.5
Purpose and timing of interim analyses/design adaptations
Not applicable.
3.6
Risks and benefits 
The risk to subjects in this study will be minimized by compliance with the eligibility criteria 
and study procedures, and close clinical monitoring.
The potential risks of treatment with LIK066 are based on the observed safety and toxicology 
results of LIK066 in the pre-clinical studies, the Phase 1 clinical studies, and in published 
reports on SGLT2 inhibition in humans. LIK066 administration in repeated dose preclinical 
safety studies up to 13 weeks in duration was associated with GI side effects in dogs (diarrhea) 
and rats (adaptive change of cecum with hypertrophy/hyperplasia) which is consistent with 
SGLT1 inhibition. Other findings included reversible weight loss, increased calcium excretion 
(rats and dogs), increase in trabecular bone formation (rats), and renal changes (mineralization 
and hyperplasia in rats) likely due to increased calcium absorption in the intestines. Adaptive, 
reversible changes in liver glycogen were present in both rats and dogs which were associated 
with changes in glucose utilization. Reversible decreases in red blood cell count were present 
in both rats (doses ≥30 mg/kg) and dogs (doses ≥5 mg/kg). The no-observed-adverse-effect-
level (NOAEL) was 5 mg/kg/day in rats and 0.5 mg/kg/day in dogs. In dogs, there was 
histological evidence of slight to moderate pyelonephritis in the mid and high dose groups, 
which was thought to be secondary to glucosuria and urinary catheterization for urine 
collection. No animals succumbed or required treatment for infection. Genotoxicity studies 
indicated that LIK066 is an aneugen ie a compound that produces aneuploidy (abnormal 
chromosome number) in dividing cells due to an effect on the spindle apparatus. There was no 
evidence in any assay that LIK066 directly damaged deoxyribonucleic acid (DNA). 
Aneugenicity is a threshold event and does not pose a risk for genotoxicity as long as 
exposure remains below the threshold. LIK066 is not genotoxic at the 150 mg clinical dose 
which results in an exposure ~23 times below the threshold for aneugenicity. The highest 
selected LIK066 dose will maintain at least a 10 times safety margin relative to the exposures 
associated with the NOAEL for micronucleus induction. 
In embryo-fetal development studies conducted in rats and rabbits, no teratogenicity was 
observed in either species. Embryo-fetal toxicity or lethality in the absence of maternal 
toxicity was not observed in either species. In both species the embryo-fetal no-effect-level 
(NOEL) was higher than the maternal NOEL, indicating that maternal toxicity preceded any 
adverse fetal effects.
Based on the results of embryo-fetal development studies in rats and rabbits and a fertility 
study in rats, LIK066 is not anticipated to increase the risk of adverse developmental or 
reproductive outcomes in humans when administered at the maximum clinical dose of 150 mg. 
Women of child bearing potential must use basic contraception methods during the study (see 
Section 4.2). No such restriction exists for male subjects. 


Novartis
Confidential
Page 24
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
SGLT1 receptors are expressed in the heart, but their role is not well understood. In s hort-
term studies (up to 12 weeks) of LIK066 150 mg qd in obese subjects, including subjects with 
T2DM, LIK066 was safe and well tolerated; GI side effects (ie flatulence, diarrhea, 
predominantly mild) were reported, but their incidence decreased over time in most subjects.
Publications on SGLT2 inhibition in subjects with T2DM treated with selective SGLT2 
inhibitors reported higher incidences of urinary tract infections (UTIs) and genital mycotic 
infections compared with placebo (Bailey et al 2010, Nauck et al 2011, Nyirjesy et al 2012). 
SGLT2 inhibition may result in hypotension in elderly subjects, in subjects with low blood 
systolic pressure, or if on diuretics, ACEi, or ARB. Patients with T2DM treated with 
antidiabetic agents, especially with sulphonylurea or insulin, may be at an increased risk of 
hypoglycemia, which can be more pronounced with significant weight loss. In rare cases 
treatment with SGLT2 inhibitors may be complicated by ketoacidosis (Rosenstock et al 2015). 
However, this has not been seen to date in clinical studies with LIK066. In long-term clinical 
studies in patients with T2DM with CVD or at high risk for CVD, an increase in cases of 
lower limb amputation (primarily of the toe) has been observed with the SGLT-2 inhibitor 
canagliflozin (Neal et al, 2017). No lower limb amputations have been seen in LIK066 studies 
to date, but since this risk may constitute a possible class-effect, patients with a higher risk for 
amputation events should be instructed on routine preventative foot care and maintaining 
adequate hydration. The only preclinical/class safety issues which have been seen in clinical 
studies with LIK066 are the GI side effects and genital and UTIs. A detailed description of 
safety and tolerability in humans with LIK066 is found in the LIK066 investigator brochure 
(IB).
Hematology and biochemistry tests will be monitored at each study visit after randomization 
and study drug can be discontinued for clinically significant laboratory change or abnormality 
as per investigator’s judgment. Detailed criteria for follow-up in case of a liver event are 
defined in Section 7.3 and Appendix 2. To prevent UTIs and genital infections, subjects will 
be instructed to pay attention to genital hygiene and have appropriate hydration. If UTI and/or
genital infections occur, treatment will be initiated as appropriate at the investigator’s 
discretion.
Benefits to participation in the study may include weight reduction and, potentially, 
improvement in some cardio-metabolic markers such as blood pressure (BP), lipids or blood 
glucose.
4
Population
The study population will consist of male and female subjects. Approximately 432 subjects
will be randomized at approximately 90 study sites. A screening failure rate of about 30 % is 
expected, hence about 600 subjects will be screened.
4.1
Inclusion criteria
Subjects eligible for inclusion in this study must fulfill all of the following criteria:
1. Written informed consent must be obtained before any assessment is performed. 
2. Male and female, age 18 to 75 years old, both inclusive. 


Novartis
Confidential
Page 25
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
3. BMI ≥30 kg/m2 or BMI ≥27 kg/m2 combined with at least one obesity-related
comorbidity (eg history of CV disease, hypertension, dyslipidemia, dysglycemia (pre-
diabetes or T2DM), sleep-apnea syndrome).
4. Agreement to comply with the study-required life-style intervention and treatment during 
the full duration of the study.
4.2
Exclusion criteria
Subjects fulfilling any of the following criteria are not eligible for inclusion in this study. No 
additional exclusions may be applied by the investigator, in order to ensure that the study 
population will be representative of all eligible subjects.
1. Use of other investigational drugs within 5 half-lives of Visit 1 or within 30 days, 
whichever is longer.
2. History of hypersensitivity to any of the study drugs or their excipients or to drugs of 
similar chemical classes.
3. History or current diagnosis of electrocardiogram (ECG) abnormalities indicating 
significant risk of safety for subjects participating in the study such as:

Concomitant clinically significant cardiac arrhythmias, eg, sustained ventricular 
tachycardia, and clinically significant second or third degree atrio-ventricular block 
without a pacemaker

History of familial long QT syndrome or known family history of torsades de pointes
4. Subjects taking medications prohibited by the protocol (see Section 5.5.8,
Table 5-2)
5. History of malignancy of any organ system (other than localized basal cell carcinoma of 
the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless 
of whether there is evidence of local recurrence or metastases.
6. Pregnant or nursing (lactating) women.
7. Women of child-bearing potential, defined as all women physiologically capable of 
becoming pregnant, unless they are using basic methods of contraception during dosing of 
investigational drug. Basic contraception methods include:

Total abstinence (when this is in line with the preferred and usual lifestyle of the 
subject). Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception.

Female sterilization (have had surgical bilateral oophorectomy with or without 
hysterectomy), total hysterectomy or tubal ligation at least 6 weeks before taking 
investigational drug. In case of oophorectomy alone, only when the reproductive 
status of the woman has been confirmed by follow-up hormone level assessment.

Male sterilization (at least 6 months prior to screening). For female subjects on the 
study, the vasectomized male partner should be the sole partner for that subject.

Barrier methods of contraception: condom or occlusive cap (diaphragm or 
cervical/vault caps). For United Kingdom: with spermicidal foam/gel/film/cream/
vaginal suppository.

Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or other forms of hormonal contraception that have comparable efficacy 


Novartis
Confidential
Page 26
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
(failure rate < 1 %), for example hormone vaginal ring or transdermal hormone 
contraception or placement of an intrauterine device or intrauterine system. In case of 
use of oral contraception women should have been stable on the same pill for a 
minimum of 3 months before taking investigational drug.

Women are considered post-menopausal and not of child bearing potential if they have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(eg age appropriate, history of vasomotor symptoms) or have had surgical bilateral 
oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least 
6 weeks ago. In the case of oophorectomy alone, only when the reproductive status of the 
woman has been confirmed by follow up hormone level assessment is she considered not 
of child bearing potential. 
8. Use of pharmacologically active weight-loss medications, GLP-1 agonists or SGLT2 
inhibitors within 3 months of Visit 1, or between Visit 1 and Visit 199/201
(randomization).
9. Bariatric surgery.
10. Lack of compliance with lifestyle intervention (defined as weight gain during Epoch 2), or 
with study medication (defined as < 80 % study drug intake during Epoch 2), assessed at 
Visit 199/201 (randomization). 
11. History of ketoacidosis, lactic acidosis, or hyperosmolar coma, or any of these occurring 
between Visit 1 and Visit 199/201 (randomization).
12. Symptomatic genital infection or UTI in the 4 weeks prior to Visit 1, or between Visit 1 
and Visit 199/201 (randomization).
13. GI disorders associated with chronic diarrhea.
14. Congestive heart failure, New York heart association (NYHA) class III or IV.
15. Myocardial infarction, stroke, surgery for heart disease, percutaneous coronary 
intervention in the 6 months prior to Visit 199/201 (randomization).
16. Unstable angina within 3 months of Visit 1, or between Visit 1 and Visit 199/201
(randomization).
17. Acute or chronic liver disease (except liver steatosis), such as hepatitis, cirrhosis or portal 
hypertension at Visit 1 or Visit 199/201 (randomization).
18. History of hepatitis B or C, or Hepatitis A or B vaccination in the last 3 months prior to 
Visit 1, or between Visit 1 and Visit 199/201 (randomization). 
19. Active substance abuse, alcohol abuse (as defined by consumption of more than 24 
alcohol units per week) or history of alcohol-related disease within the past 2 years. 
20. Chronic treatment with medication which has a hepatotoxic potential.
21. Chronic use of anti-retroviral therapies.
22. Chronic use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (eg clarithromycin, 
telithromycin, itraconazole, ketoconazole, voriconazole or posaconazole) or chronic use of 


Novartis
Confidential
Page 27
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
strong uridine-5’-diphosphoglucoronosyltransferase (UGT) inhibitors (eg probenecid,
valproic acid or mefenamic acid).
23. Concurrent medical conditions that may interfere with the interpretation of efficacy and 
safety data.
24. Clinically significant thyroid stimulating hormone (TSH) outside of the normal range at 
Visit 1.
25. HbA1c > 10.0 % at Visit 1 (screening).
26. For subjects treated with SUs or insulin, self-measured FPG > 13.3 mM (240 mg/dL) on 2 
occasions within one week of Visit 199/201 (randomization).
27. Estimated glomerular filtration rate (eGFR, calculated via the modified diet in renal 
disease (MDRD) formula) < 60 mL/min/1.73m2 at Visit 1.
28. Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) more than two-fold 
above upper limit of normal (ULN) (> 2 × ULN), or total bilirubin/direct bilirubin > 1.5 ×
ULN) at Visit 1, confirmed by repeat measurement within 5 working days of the 
respective visit.
29. Hemoglobin < 12 g/dL in men, < 11 g/dL in women at Visit 1 (screening).
30. Platelet count < 100 000/μL and/or white blood cell (WBC) count < 4000/μL at Visit 1
(screening).
31. Hematuria determined by dipstick measurement at Visit 1 (screening).
32. Elevated fasting triglycerides (TGs) > 5.6 mM (500 mg/dL), at Visit 1 (screening), 
confirmed by repeat measurement within 3 working days of the respective visit.
33. Clinically significant laboratory abnormalities which, in the opinion of the investigator, 
cause the subject to be considered inappropriate for inclusion in the study.
34. History of lower limb amputation (including toe amputation), or if occurring between 
Visit 1 and Visit 201 (randomization).
5
Treatment
5.1
Study treatment
5.1.1
Investigational and control drugs
Epoch 2 (placebo run-in)
The sponsor will provide the following single-blind study medication for Epoch 2:

LIK066 matching placebo tablets
All subjects will take 3 tablets in the morning and 2 tablets in the evening. The medication 
will be prepared for the placebo run-in in medication wallets.


Novartis
Confidential
Page 28
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Epoch 3 (treatment)
The sponsor will provide the following double-blind study medication for Epoch 3:

LIK066 2.5 mg tablets.

LIK066 10 mg tablets.

LIK066 25 mg tablets.

LIK066 50 mg tablets.

LIK066 matching placebo tablets.
For each treatment arm (see Section 5.2), subjects will receive a combination of the tablets 
described above. All subjects will take 3 tablets in the morning and 2 tablets in the evening, 
and the dose regimens will be prepared for each treatment arm in medication wallets.
Epoch 4
The sponsor will provide the following double-blind study medication for Epoch 4:

LIK066 10 mg tablets.

LIK066 25 mg tablets.

LIK066 matching placebo tablets.
For each treatment arm in Epoch 4, subjects will receive a combination of the tablets 
described above to compose the 25 mg qd, 35 mg qd or placebo regimen. Subjects will take 2
tablets in the morning, and the dose regimens will be prepared for each treatment arm in 
medication wallets.
No other drugs will be supplied. Sufficient medication will be supplied for treatment 
according to the study protocol.
5.1.2
Additional treatment
No additional study treatment beyond investigational drug and placebo are included in this 
study.
5.2
Treatment arms
All subjects entering Epoch 2 (run-in) will receive placebo.
At Visit 201 (randomization), subjects eligible for randomization will be assigned 
1:1:1:2:1:1:1:2:2 to one of the following treatment arms in Epoch 3 (see Section 3.1.2):

2.5 mg qd LIK066 (approx. 36 subjects).

10 mg qd LIK066 (approx. 36 subjects).

50 mg qd LIK066 (approx. 36 subjects).

150 mg qd LIK066 (approx. 72 subjects).

2.5 mg bid LIK066 (approx. 36 subjects).

5 mg bid LIK066 (approx. 36 subjects).

25 mg bid LIK066 (approx. 36 subjects).

50 mg bid LIK066 (approx. 72 subjects).


Novartis
Confidential
Page 29
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201

Placebo (approx. 72 subjects).
At the end of Epoch 3, subjects from each of the four qd arms will enter Epoch 4 and will 
receive 25 mg qd LIK066. Subjects from each of the four bid arms in Epoch 3 will 
receive 35 mg qd LIK066 in Epoch 4.
The subjects from the Epoch 3 placebo arm will receive placebo or 25 mg qd LIK066 in 
Epoch 4 in a 1:1 fashion (see Section 3.1.3).
5.3
Treatment assignment and randomization 
At Visit 201 (randomization), all eligible subjects will be randomized via Interactive 
Response Technology (IRT) to one of the treatment arms for Epoch 3, and within that 
treatment arm to one of the regimens in Epoch 4. The investigator or his/her delegate will 
contact the IRT system after confirming that the subject fulfills all the inclusion/exclusion 
criteria (see Section 4). The IRT system will assign a randomization number to the subject, 
which will be used to link the subject to a treatment arm and will specify a unique medication 
number for the first package of study drug to be dispensed to the subject. The randomization 
number will not be communicated to the user.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from subjects and investigator staff. A 
subject randomization list will be produced by the IRT provider using a validated system that 
automates the random assignment of subject numbers to randomization numbers. These 
randomization numbers are linked to the different treatment arms, which in turn are linked to 
medication numbers. A separate medication list will be produced by or under the 
responsibility of Novartis drug supply management using a validated system that automates 
the random assignment of medication numbers to packs containing the investigational drug(s). 
Randomization will be stratified into (see Section 3.1.2):

Normoglycemic.

T2DM.

Dysglycemic.
Efforts will be made by close monitoring of the enrollment through the IRT system to ensure 
each of the three stratification sub-groups with at least 30 % of total subjects enrolled in the 
study.
The randomization scheme for subjects will be reviewed and approved by a member of the
Novartis randomization office.
5.4
Treatment blinding
Subjects, investigator staff and persons performing the assessments will remain masked to the 
identity of the treatment from the time of randomization until the final database lock, using 
the following methods:
1. Randomization data are kept strictly confidential until the time of unblinding, and will not 
be accessible by anyone else involved in the study with the following exceptions: the 


Novartis
Confidential
Page 30
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
randomization codes associated with subjects from whom PK samples are taken will be 
disclosed to PK analysts who will keep the PK results confidential until database lock. 
2. The identity of the treatments will be concealed by the use of study drug that are all 
identical in packaging, labeling, schedule of administration, appearance, taste and odor.
Unmasking will only occur in the case of subject emergencies (see Section 5.6.2), at the time 
of Week 24 analysis (see Section 9) and at the conclusion of the study. 
The analysis group (statisticians/programmers), who will be unmasked to perform the Week 
24 analysis, will not be involved in any study conduct activities related to the study Week 24 
to Week 48 period (Epoch 4) after the unmasking. A separate analysis group, who does not 
have access to the analysis results and the identity of treatments at Week 24 analysis, will 
perform the pre-planned final analysis at the end of the study.
The core study team (including the study leader(s), study physician and data manager), who 
are directly involved in study conduct activities during the study Week 24 to Week 48 period 
(Epoch 4), will not have access to the subject level data with identity of treatments such as 
subject listings at Week 24 analysis.
The Week 24 analysis results and the identity of treatments will not be shared with the study 
site personnel until after the final database lock at the end of study.
5.5
Treating the subject
Sponsor qualified medical personnel will be readily available to advise on study related 
medical questions or problems.
5.5.1
Subject numbering
Each subject is uniquely identified by a subject number which is composed by the site number 
assigned by Novartis and a sequential number assigned by the investigator. Once assigned to a 
subject, a subject number will not be reused.
Upon signing the informed consent form (ICF), the subject is assigned the next sequential 
number by the investigator. The investigator or his/her staff will contact the IRT system and 
provide the requested identifying information for the subject to register them into the IRT 
system. The site must select the case report/record form (paper or electronic) (eCRF) book 
with a matching subject number from the electronic data capture (EDC) system to enter data. 
If for any reason the subject fails to be treated with study medication after randomization, the 
IRT must be notified within 2 days that the subject was not treated. The reason for not being 
treated will be entered on the Run-in Epoch Disposition eCRF.
Each subject is uniquely identified in the study by a combination of his/her center number and 
subject number. The center number is assigned by Novartis to the investigative site. Upon 
signing the informed consent form, the subject is assigned a subject number by the 
investigator. At each site, the first subject is assigned subject number 1, and subsequent 
subjects are assigned consecutive numbers (eg the second subject is assigned subject
number 2, the third subject is assigned subject number 3). The investigator or his/her staff will 
contact the IRT system and provide the requested identifying information for the subject to 
register them into the IRT system. For studies using eCRFs, only the assigned subject number 


Novartis
Confidential
Page 31
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
must be entered in the field labeled “Patient identification (ID)” on the EDC data entry screen 
(eg enter ‘1’, ‘2’, etc.). Once assigned to a subject, the subject number will not be reused. If 
the subject fails to be randomized for any reason, the IRT must be notified within 2 days that 
the subject was not randomized. The reason for not being randomized will be entered on the 
Screening Log, and the Demography eCRF must also be completed.
5.5.2
Dispensing the study drug
Each study site will be supplied by Novartis with study drug. The study drug packaging has 
a 2-part label. A unique number is printed on each part of this label which corresponds to one 
of the treatment arms (see Section 5.2). Investigator staff will identify the study drug 
package(s) to dispense to the subject by contacting the IRT system and obtaining the 
medication number(s). Immediately before dispensing the package to the subject, investigator 
staff will detach the outer part of the label from the packaging and affix it t o the source 
document (drug label form) for that subject’s unique subject number.
All drug kits assigned by the IRT system will be recorded in the IRT database. Each study site 
will be supplied with study drug in packaging of identical appearance. 
5.5.3
Handling of study and additional treatment
5.5.3.1
Handling of study treatment
Study treatment must be received by a designated person at the study site, handled and stored 
safely and properly, and kept in a secured location to which only the investigator and 
designees have access. Upon receipt, all study treatment must be stored according to the 
instructions specified on the labels. Clinical supplies are to be dispensed only in accordance 
with the protocol. Technical complaints are to be reported to the respective Novartis country 
pharma organization quality assurance department.
Medication labels will be in the local language and comply with the legal requirements of 
each country. They will include storage conditions for the study treatment but no information 
about the subject except for the medication number.
The investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability log. Monitoring of drug accountability will be performed by 
monitors during site visits or remotely and at the completion of the study. Previously 
dispensed study medication wallets, including any remaining study medication, must be 
returned to the study center at each study visit and where applicable, at the time of 
discontinuation from study treatment.
At the conclusion of the study, and as appropriate during the course of the study, the 
investigator will return all unused study treatment, packaging, drug labels, and a copy of the 
completed drug accountability log to the Novartis monitor or to the Novartis address provided 
in the investigator folder at each site.
5.5.3.2
Handling of additional treatment
Not applicable.


Novartis
Confidential
Page 32
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
5.5.4
Instructions for prescribing and taking study treatment
The investigator should ensure that the subject clearly understands the dosing instructions 
outlined below.

At Visit 101 (Epoch 2), each subject will be dispensed study drug wallets containing 
blisters with study medication. The blisters are constructed to easily deliver the daily 
required number of tablets for the morning dose and the tablets for the evening dose. The 
wallets contain sufficient medication for the run-in period of up to 4 weeks until Visit 
199/201.

From Visit 201 till Visit 299 (Epoch 3), subjects will be dispensed study drug wallets 
containing blisters with study medication. The blisters are constructed to easily deliver the 
daily required number of tablets for the morning dose and the tablets for the evening dose. 
The wallets contain sufficient medication for the time between each visit according to 
Table 6-1.

From Visit 301 till Visit 399 (Epoch 4), subjects will be dispensed study drug wallets 
containing blisters with study medication. The blisters are constructed to easily deliver the 
daily required number of tablets for the morning dose. The wallets contain sufficient 
medication for the time between each visit according to Table 6-1.
In Epoch 2 and Epoch 3, subjects will be instructed to take 3 tablets LIK066 (or matching 
placebo) in the morning and 2 tablets in the evening, immediately before the meal. Study drug 
should be taken the same time throughout the study.
In Epoch 4, subjects will be instructed to take 2 tablets LIK066 (or matching placebo) in the 
morning only, immediately before the meal.
No study drug should be taken on the morning of a study visit; subjects with T2DM should 
not take their anti-diabetic treatment. Subjects should arrive in the fasting state; ie no food or 
drinks (except water) for a minimum of 8h before the next scheduled visit. The study 
medication (and anti-diabetic medication, if applicable) will be taken after the completion of 
all study procedures for that visit prior to the first meal of the day (for subjects participating in 
the PK substudy, see Section 6.6.3). If the subject has not fasted for an adequate period of 
time, the collection of fasting laboratory evaluations must be rescheduled. The study drug 
regimen (and, if applicable, rescue medication as defined in Section 5.5.6) should not be taken 
prior to obtaining the fasting laboratory test samples.
If a dose is missed and the subject realizes this within 4h, the study drugs should be taken 
otherwise the subject should take the next scheduled dose.
Previously dispensed study medication wallets, including any remaining study medication, 
must be returned to the study center at each study visit.
All prescribed dosages and all dose changes during the study must be recorded on the 
appropriate study drug Dosage Administration Record eCRF(s). All kits of study treatment 
assigned by the IRT system will be recorded/databased in the IRT system.
During each study visit, the investigator should encourage compliance with study medication 
by instructing the subject to take the study drug exactly as prescribed to maintain the validity 
of the study and to optimize any potential effect of the study drug regimen. The subject should 


Novartis
Confidential
Page 33
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
be instructed to contact the investigator if he/she is unable for any reason to take the study 
drug regimen as prescribed.
5.5.5
Permitted dose adjustments and interruptions of study treatment 
Study drug dose adjustments are not permitted. Dose interruptions are not permitted unless 
for safety reasons (see Section 7.1).
5.5.6
Rescue medication
During Epoch 3 and Epoch 4, rescue medication may be used in addition to ongoing study 
medication for those subjects with T2DM whose glycemic control is deteriorating. The 
subject must come in for an unscheduled visit to have a sample drawn for FPG & HbA1c
measurement performed by the central laboratory if:

Self-measured FPG on two consecutive occasions exceeds the limits in Table 5-1.

The result from a blood sample analyzed by the central laboratory exceeds the limits 
described in Table 5-1.
Table 5-1
Rescue criteria for FPG or HbA1c (subjects with T2DM)
Timeframe
Parameter
Value
Action
Between V201 (Randomization) 
and V204 (Week 8)
FPG
> 240 mg/dL
(13.3 mM)
Unscheduled visit for central 
laboratory parameter measurement.
If elevation confirmed by central 
laboratory: background OAD to 
escalate to the maximum approved 
dose, followed by addition of another 
allowed OAD (eg a DPP-4 inhibitor 
used according to the label or insulin 
as per the investigator’s discretion)
Between V204 (Week 8) and 
V205 (Week 12)
FPG
> 220 mg/dL 
(12.2 mM)
Between V205 (Week 12) and 
V399 (Week 48)
FPG
> 200 mg/dL 
(11.1 mM)
Between V205 (Week 12) and 
V399 (Week 48)
HbA1c
> 8 %
If the results confirm the exceeded limits, first the background OAD should be escalated to 
the maximal approved dose in steps if clinically indicated, followed by addition of rescue 
medication. 
Rescue medication, a dipeptidyl peptidase-4 (DPP-4) inhibitor or insulin, should be used 
according to the local label. Rescue medication must be provided locally.
Rescued subjects will continue to participate in the study to allow for assessment of exposure 
and safety of LIK066.
Use of rescue medication must be recorded on the Rescue Medication eCRF.
5.5.7
Concomitant medication
The investigator must instruct the subject to notify the study site about any new medications 
they take after being enrolled into the study. All medications, procedures and significant non-
drug therapies (including physical therapy and blood transfusions) administered after the 
subject
was 
enrolled 
into 
the 
study 
must 
be 
recorded
in 
the 
Concomitant 
Medications/Significant Non-Drug Therapies eCRF.


Novartis
Confidential
Page 34
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Each concomitant medication must be individually assessed against all exclusion criteria and 
prohibited medications. If in doubt the investigator should contact the Novartis medical 
monitor before randomizing a subject or allowing a new medication to be started.
5.5.8
Prohibited medication
Use of the treatments displayed in Table 5-2 is not allowed after subjects have become 
eligible for participation into the study during the screening period. At the latest, subjects 
should stop using the medications listed in Table 5-2 at the start of Epoch 2.
Table 5-2
Prohibited medication
Medication/product
Prohibition period
Action taken
St. John’s wort (strong CYP3A 
inducer)
Entire study
Discontinue prohibited medication during 
the screening period once subject is 
eligible for participation in the study
GLP-1 agonists
Entire study
Discontinue prohibited medication during 
the screening period once subject is 
eligible for participation in the study
SGLT2 inhibitors other than study 
medication
Entire study
Discontinue prohibited medication during 
the screening period once subject is 
eligible for participation in the study
Pharmacologically active weight-
loss medication
Entire study
Discontinue prohibited medication during 
the screening period once subject is 
eligible for participation in the study
Some medications or products must be used with caution:

Use of grapefruit juice (strong inhibitor of CYP3A4) should be discouraged and its 
consumption must not happen within 2h of study medication intake.

Use of antibiotic or antifungal medications that are strong inhibitors of CYP3A4 should be 
limited to 10 days during the study. Examples of such medications are clarithromycin, 
telithromycin, itraconazole, ketoconazole, voriconazole or posaconazole.

Use of strong UGT inhibitors such as probenecid, valproic acid or mefenamic acid should
be limited to 10 days during the study.
5.5.9
Emergency breaking of assigned treatment code
Emergency code breaks must only be undertaken when it is required in order to treat the 
subject safely. Most often, study treatment discontinuation (TD) and knowledge of the 
possible treatment assignments are sufficient to treat a study subject who presents with an 
emergency condition. Emergency treatment code breaks are performed using the IRT system. 
When the investigator contacts the system to break a treatment code for a subject, the 
requested subject identifying information must be provided and the necessity to break the 
treatment code must be confirmed. The investigator will then receive details of the 
investigational drug treatment for the specified subject and a communication confirming this 
information. The system will automatically inform the Novartis monitor for the site and the 
study team that the code has been broken.


Novartis
Confidential
Page 35
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
It is the investigator’s responsibility to ensure that there is a dependable procedure in p lace to 
allow access to the IRT system at any time in case of emergency. The investigator will 
provide the protocol number, the study drug name (if available) and the subject number.
In addition, oral and written information to the subject must be provided on how to contact the 
investigator’s backup in case of emergency, or when the investigator is unavailable, to ensure 
that un-masking can be performed at any time. 
Subjects whose treatment has been unmasked must be discontinued from the study treatment
(see Section 5.6.2).
5.6
Study completion and discontinuation 
5.6.1
Study completion and post-study treatment
A subject will be considered to have completed the study when the subject has completed the 
last planned visit (see Table 6-1). The study as a whole will be considered completed when all 
randomized subjects have completed the last visit planned in the protocol (see Table 6-1) or 
have discontinued the study prematurely.
For subjects who are loss to follow-up, see Section 5.6.4.
The investigator must provide follow-up medical care for all subjects who are prematurely 
withdrawn from the study, or must refer them for appropriate ongoing care.
5.6.2
Discontinuation of study treatment
Discontinuation of study treatment for a subject occurs when study drug is stopped earlier 
than the protocol planned duration, and can be initiated by either the subject, the investigator
or the sponsor (see Section 5.6.5). 
The investigator must discontinue study treatment for a given subject if, on balance, she/he 
believes that continuation would negatively impact the risk/benefit of study participation.
Study treatment must be discontinued under the following circumstances: 

Subject wish.

Pregnancy, see Section 6.5.5 and Section 7.6.

Use of prohibited treatment, see Section 5.5.8.

Any situation in which study participation might result in a safety risk to the subject.

Emergence of the following AE: ketoacidosis (see also Section 7.8.1) or lower limb 
amputation (including toe amputation).

Any laboratory abnormalities that in the judgment of the investigator, taking into 
consideration the subject’s overall status, prevents the subject from continuing 
participation in the study.

Subjects whose study treatment has been unmasked (see Section 5.5.9).

Withdrawal of consent (see Section 5.6.3).
If discontinuation of study treatment occurs, the subject should not be considered withdrawn 
from the study. The subject should return to the study site as soon as possible after 


Novartis
Confidential
Page 36
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
discontinuation of study drug for a study treatment discontinuation visit (see Table 6-1). TD
visit assessments detailed in Table 6-1 should be completed and recorded in the eCRF. The 
investigator must determine the primary reason for the subject’s premature discontinuation of 
study treatment and record this information on the appropriate eCRF.
After study treatment discontinuation, at a minimum, in abbreviated visits, the following data 
should to be collected at study site visits or via telephone contact: 

New and/or concomitant treatments.

AEs/Serious AEs (SAEs).
If the subject cannot or is unwilling to attend any visit(s), the site staff should maintain regular 
telephone contact with the subject, or with a person pre-designated by the subject. This 
telephone contact should preferably be done according to the study visit schedule (Table 6-1). 
The investigator must also contact the IRT system to register the subject’s discontinuation 
from study treatment. If study drug discontinuation occurs because treatment code has been 
broken, please refer to Section 5.5.9.
5.6.3
Withdrawal of informed consent
Subjects may voluntarily withdraw consent to participate in the study for any reason at any 
time. Withdrawal of consent from the study is defined as when all of the following apply: 

A subject does not want to participate in the study anymore and

Does not want any further visits or assessments and

Does not want any further study related contacts and

Does not allow analysis of already obtained biologic material.
In this situation, the investigator must make every effort (eg telephone, e-mail, letter) to 
determine the primary reason for the subject’s decision to withdraw their consent and record 
this information. 
Study treatment must be discontinued (see Section 5.6.2) and no further assessments 
conducted, and the data that would have been collected at subsequent visits will be considered 
missing. Further attempts to contact the subject in the context of the study are not allowed 
unless safety findings require communicating or follow-up.
All efforts should be made to complete the assessments prior to study withdrawal. A final 
evaluation at the time of the subject’s study withdrawal should be made as per Table 6-1.
5.6.4
Loss to follow-up
For subjects whose status is unclear because they fail to appear for study visits without stating 
an intention to discontinue or withdraw, the investigator should show "due diligence" by 
documenting in the eSource system (where applicable) or the source documents steps taken to 
contact the subject, eg dates of telephone calls, registered letters, etc. A subject cannot be 
considered as loss to follow-up until the time point of their scheduled end of study visit has 
passed.


Novartis
Confidential
Page 37
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
5.6.5
Early study termination by the sponsor
The study can be terminated by Novartis at any time for any reason. This may include reasons 
related to the benefit risk assessment of participating in the study, practical reasons, or for 
regulatory or medical reasons (including slow enrolment). Should this be necessary, the 
subject must be seen as soon as possible and treated as a prematurely withdrawn subject (see 
Section 5.6.2). The investigator may be informed of additional procedures to be followed in 
order to ensure that adequate consideration is given to the protection of the subject’s interests. 
The investigator will be
responsible for informing the institutional review board
(IRB)/independent ethics committee (IEC) of the early termination of the study.
6
Visit schedule and assessments
Table 6-1 lists all of the visits and assessments and indicates with an “X” when the 
assessments are performed.
Subjects should be seen for all visits on the designated day, or as close to it as possible. 
Missed or rescheduled visits should not lead to automatic discontinuation. Subjects who 
prematurely discontinue the study for any reason should be scheduled for a visit as soon a s 
possible, at which time all of the assessments listed for the final visit will be performed. At 
this final visit, all dispensed investigational product should be reconciled and the AE and 
concomitant medications reconciled on the eCRF.
Subjects will be contacted for safety evaluations during the 30 days following the last 
administration of study treatment. 


Novartis
Confidential
Page 38
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Table 6-1
Assessment schedule
Epoch
1
2
3
4
Visit
1 
Screen
101 
Run-in
199
201
RND/ 
BL
202
203
204
205
206
299/301
302
303
304
399*
TD/ 
PSD/
EOS
Week
-6
-4
0
2
4
8
12
18
24
28
34
40
48
Screening assessments
Informed consent
X
Inclusion/exclusion (Section 4)
X
X
X
Subject demographics (Section 6.2)
X
Medical history
X
Medical history: protocol solicited events
X
Smoking & alcohol history (Section 6.2)
X
Efficacy
Height (Section 6.4.1)
X
Weight (Section 6.4.1)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Waist circumference (Section 6.4.2)
X
X
X
X
X
X
X
X
X
X
X
X
X
BP (SBP & DBP) (Section 6.4.5)
X
X
X
X
X
X
X
X
X
X
X
X
X
HbA1c (Section 6.4.3)
X
X
X
X
X
X
FPG (Section 6.4.4)
X
X
X
X
X
X
Fasting lipid profile (Section 6.4.6)
X
X
X
X
X
hsCRP (Section 6.4.6)
X
X
X
X
X
Safety
Complete physical exam (Section 6.5.1)
S
S
Short physical exam (Section 6.5.1)
S
S
S
S
S
S
S
S
S
S
S
S


Novartis
Confidential
Page 39
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Epoch
1
2
3
4
Visit
1 
Screen
101 
Run-in
199
201
RND/ 
BL
202
203
204
205
206
299/301
302
303
304
399*
TD/ 
PSD/
EOS
Week
-6
-4
0
2
4
8
12
18
24
28
34
40
48
Vital signs (Section 6.5.2)
X
X
X
X
X
X
X
X
X
X
X
X
X
Hematology (Section 6.5.3)
X
X
X
X
X
X
X
X
Biochemistry (Section 6.5.3)
X
X
X
X
X
X
X
X
TSH (Section 6.5.3)
X
Pregnancy test (serum, Section 6.5.5)
X
Pregnancy (urine dipstick, Section 6.5.5)
X
X
X
X
X
Hematuria (urine dipstick, Section 6.5.3)
X
Urinalysis (Section 6.5.3)
X
X
X
X
X
Urine albumin/creatinine (Section 6.5.3)
X
X
X
X
X
X
X
PK trough (Section 6.6.3.1)
X
X
X
ECG (Section 6.5.4)
X
X
X
AEs (Section 7.1)
X
X
X
X
X
X
X
X
X
X
X
X
X
SAEs (Section 7.2)
X
X
X
X
X
X
X
X
X
X
X
X
X
Ketoacidosis AEs (Section 7.8.1)
X
X
X
X
X
X
X
X
X
X
X
X
X
Hypoglycemia AEs (Section 7.8.2)
X
X
X
X
X
X
X
X
X
X
X
X
X
Medication records
Prior & concomitant medications
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Surgical and medical procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
Dose administration record
X
X
X
X
X
X
X
X
X
X
X
X
X
Administrative procedures
IRT system
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Lifestyle instructions (Section 3.1)
S
S
S
S
S
S
S
S
S
S
S
Dispense glucometer (T2DM subjects)
S
Glycemia diary (T2DM subjects)
S
S
S
S
S
S
S
S
S
S
S
S


Novartis
Confidential
Page 40
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Epoch
1
2
3
4
Visit
1 
Screen
101 
Run-in
199
201
RND/ 
BL
202
203
204
205
206
299/301
302
303
304
399*
TD/ 
PSD/
EOS
Week
-6
-4
0
2
4
8
12
18
24
28
34
40
48
Study drug accountability
S
S
S
S
S
S
S
S
S
S
S
S
Screening phase disposition
X
Run-in phase disposition
X
Epoch 3 phase disposition
X†
Study completion
X
Sub-studies
PK informed consent (Section 6.6.3.2)
X
PK sampling (Section 6.6.3.2)
X
Safety (subset of subjects)
Bone biomarkers (Section 6.5.3.4)
X
X
X
X
X
Renal biomarkers (Section 6.5.3.4)
X
X
X
X
X
Efficacy (subset of subjects)
24-h urinary glucose excretion (Section 
6.4.7) 
X
X
X
X
TD = Study treatment discontinuation; PSD = Premature subject discontinuation; X = assessment to be recorded on clinical data base; S = assessment to be recorded on source 
documentation only; RND = Randomization visit; EOS = end of study; * These assessments are also to be conducted for subjects who prematurely withdraw from the study ; † Applicable for 
Visit 299 only


Novartis
Confidential
Page 41
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
6.1
Information to be collected on screening failures
All subjects who have signed the ICF but fail the screening will have the Screening Phase 
Disposition eCRF for the screening epoch, demographics, inclusion/exclusion, and SAE data 
collected. AEs that are not serious will be followed by the investigator and collected only in 
the source data.
6.2
Subject demographics/other BL characteristics
Demographic and BL characteristics data to be collected on all subjects include: date of birth, 
age, sex, race, ethnicity, source of subject referral, relevant medical history/current medical 
conditions present before signing informed consent including smoking and alcohol history. 
Where possible, diagnoses and notable symptoms will be recorded. 
Investigators will have the discretion to record abnormal test findings on the medical history 
eCRF whenever in their judgment, the test abnormality occurred prior to the ICF signature.
6.3
Treatment exposure and compliance
Compliance will be assessed by the investigator and/or study personnel at each visit using pill 
counts and information provided by the subject. This information should be captured in the 
source documents at each visit. All study treatment dispensed and returned must be recorded 
in the Drug Accountability Log. The site will also be required to complete the appropriate 
Dosage Administration Record eCRF to record any study drug regimen changes or 
interruptions.
On-treatment medication
For all medications (other than the study drug regimen) initiated after the start of study, the 
reason for prescribing the medication, and the start and, where applicable, end dates will be 
recorded on the Concomitant Medications/Significant Non-Drug Therapies eCRF.
Rescue medication
Information regarding the administration of rescue medication as per Section 5.5.6 will be 
recorded on the appropriate eCRF.
6.4
Efficacy
6.4.1
Weight
Body weight will be measured to the nearest 0.1 kg at visits indicated in Table 6-1 on a 
calibrated scale provided by the sponsor (sites that already possess a calibrated scale for 
weight measurement of overweight or obese subjects can use their own scale). The 
measurement will be performed with the study subject in underwear (or a hospital gown) and 
without shoes. Voiding before weight measurement is required.
Height will be measured at Visit 1 and will be used to calculate BMI.


Novartis
Confidential
Page 42
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
6.4.2
Waist circumference
Waist circumference will be measured to the nearest 0.1cm at visits indicated in Table 6-1 in a 
standing position, at the end of a normal expiration, using a tape at the level of the iliac crest.
6.4.3
HbA1c
HbA1c will be measured from a blood sample obtained at visits indicated in Table 6-1 and 
analyzed using a National Glycohemoglobin Standardization Program certified method at a 
central laboratory.
6.4.4
FPG
FPG will be measured from a blood sample obtained after an overnight fast (patients should 
not eat or drink anything (except water) for at least 8h before each study visit ) at visits 
indicated in Table 6-1 and analyzed at a central laboratory.
6.4.5
BP
Arterial BP, pulse rate readings and signs and symptoms of orthostasis will be assessed with 
an automated BP device. If an automated device cannot be used, the BP will be measured with 
an alternative device.
Three sitting BP measurements and one standing BP measurement will be performed at visits 
indicated in Table 6-1. Every effort should be made to have the same staff member obtain BP 
measurements for a given subject, at the same time of day, using the same equipment, at each 
visit.
Sitting BP and standing measurements must be performed prior to any procedure (eg blood 
draw) or medication intake. At Visit 1 (screening) BP must be measured at both arms. The 
arm with the higher SBP reading must be used for the BP measurements at Visit 1 and the 
same arm must be used at all subsequent visits. The arm used at each visit must be 
documented in the source documentation.
The subject should be in a relaxed setting and measurements should not be taken immediately 
after exertion or the consumption of coffee. At each study visit, after the subject has been 
sitting for 5 minutes with the back supported and both feet placed on the floor, SBP and DBP 
will be measured three times using the BP device and an appropriate size cuff. The bladder of 
the cuff should be large enough to encircle 80 % of the arm. The cuff should be placed so its 
bottom is 1 to 2cm above the elbow and the arm should be supported so that the bottom of the 
cuff is at the level of the heart. The tube should run down the center of the arm, approximately 
in line with the middle finger. The subject should be asked to relax his/her arm and turn the 
palm upward. The subject should not speak or move their arm during the measurement 
deflation of the cuff. Three separate sitting BP should be obtained with a full two-minute 
interval between measurements and with the cuff fully deflated between measurements. The 
subject will then stand, and after standing for two minutes, one BP measurement will be taken
(see also Section 6.5.2). 


Novartis
Confidential
Page 43
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
All 3 sitting BP measurements and the single standing measurement will be recorded and 
documented in the eCRF and in the subject’s source documents. All 3 sitting BP readings will 
be used for evaluation of sitting BP.
6.4.6
Fasting lipid profile & inflammation biomarkers
Fasting lipid profile, TG and hsCRP as described in Table 6-2 will be measured on blood 
samples obtained after an overnight fast at visits indicated in Table 6-1 and analyzed at a 
central laboratory.
Table 6-2
Fasting lipid profile, TG & inflammation biomarkers
Category
Parameter(s)
Fasting lipid profile & TGs
TG, total cholesterol, HDL cholesterol, LDL cholesterol, lipoproteins 
(apolipoprotein A-I, apolipoprotein B), calculated VLDL cholesterol and 
non-HDL cholesterol.
LDL cholesterol will be calculated if TG ≤400 mg/dL, if TG > 400 mg/dL 
then direct LDL cholesterol measurement will be done.
Inflammation biomarkers
hsCRP
6.4.7
24-h urine collection
UGE will be measured from 24-h urinary collection from subjects participating in the PK sub-
study (see Section 6.6.3.2) at visits indicated in Table 6-1 and analyzed at a central laboratory. 
Results will not be communicated to the study sites or the sponsor to avoid unmasking.
Urinary bone biomarkers (urinary calcium and phosphate excretion) will be measured from 
the same urine collection (see Section 6.5.3.3), as well as urine albumin to creatinine ratio.
Detailed instructions for urine collection will be provided to subjects, and handling of the 
urine sample will be described in the laboratory manual.
6.4.8
Appropriateness of efficacy assessments 
Measurements of weight, waist circumference, HbA1c, FPG, BP and fasting lipids are 
standard measures to assess the efficacy of a weight loss drug and its effect on cardio-
metabolic parameters. UGE measurement allows for evaluation of LIK066’s primary mode of 
action’s contribution to weight loss.
6.5
Safety 
6.5.1
Physical examination
A complete physical examination will be performed at visits indicated in Table 6-1 and 
includes the examination of general appearance, skin, neck (including thyroid), eyes, ears, 
nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities (including feet), vascular
status, neurological status and volume status (see Section 3.1.1). If indicated based on medical 
history and/or symptoms, rectal, external genitalia, breast, and pelvic examinations will be 
performed.


Novartis
Confidential
Page 44
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
A short physical exam will include the examination of general appearance (including feet) and 
assessments described in Section 6.4.5. They will be performed at all scheduled visits 
indicated in Table 6-1 and at unscheduled study visits.
Information for all physical examinations must be included in the source documentation at the 
study site. Clinically relevant findings that are present prior to signing the ICF must be 
included in the medical history part of the eCRF. Significant findings made after first 
administration of investigational drug which meet the definition of an AE must be recorded on 
the AE section of the eCRF.
6.5.2
Vital signs 
BP will be measured as described in Section 6.4.5 at visits indicated in Table 6-1. The pulse 
rate from the last sitting BP measurement will be recorded. Respiratory rate will also be 
measured. Clinically notable vital signs are defined in Appendix 1.
6.5.3
Laboratory evaluations
Laboratory evaluations for safety will be performed at visits indicated in Table 6-1 and all 
specimens collected will be analyzed at a central laboratory. Details on the collection, 
shipment of samples, reporting of results by the central laboratory as well as laboratory 
notable range deviations are provided in the laboratory manual.
6.5.3.1
Hematology
Samples for analysis of hematology (see Table 6-3) will be collected at visits indicated in 
Table 6-1.
Table 6-3
Hematology evaluations
Category
Parameter(s)
Hematology
RBC (total), WBC (total), platelet count (direct), hemoglobin, hematocrit, 
basophils (absolute, %), eosinophils (absolute, %), lymphocytes 
(absolute, %), monocytes (absolute, %), neutrophils (absolute, %)
6.5.3.2
Clinical chemistry
Samples for analysis of clinical chemistry (see Table 6-4) will be collected at visits indicated 
in Table 6-1. 
Table 6-4
Clinical chemistry
Category
Parameter(s)
Biochemistry
ALT, albumin, alkaline phosphatase (ALP), AST, bicarbonates, bilirubin 
(direct, total), blood urea nitrogen (BUN), calcium (total), chloride, 
creatinine, cystatin C, eGFR (MDRD), magnesium, phosphates, 
potassium, protein (total), sodium, uric acid, γ-GT, amylase, lipase
Chemistry (TSH)
TSH
Chemistry (pregnancy)
Serum β-HCG


Novartis
Confidential
Page 45
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
6.5.3.3
Urinalysis
Urine samples will be collected for analysis of parameters listed in Table 6-5 at visits 
indicated in Table 6-1. Urine will be used to assess pregnancy and hematuria (dipstick) at 
visits indicated in Table 6-1 as well. Glucosuria results will not be communicated to the study 
sites or the Novartis study team to avoid unmasking.
Table 6-5
Urinalysis
Category
Parameter(s)
Urinalysis
pH, specific gravity, protein, glucose, ketones, nitrites, blood, leucocytes
Urinalysis
Urine albumin to creatinine ratio (spot urine)
Urine (dipstick)
Hematuria
Urine (dipstick)
Pregnancy test (β-hCG)
6.5.3.4
Bone and renal biomarkers
Serum samples for bone and renal biomarkers (see Table 6-6) will be collected at visits 
indicated in Table 6-1 from subjects who participate in the PK substudy (see Section 6.6.3.2). 
Urine samples for bone biomarkers will be collected as described in Section 6.4.7.
Table 6-6
Biomarkers
Category
Parameter(s)
Bone biomarkers
β-c-terminal telopeptide (β-CTX1), serum procollagen type 1 N-
propeptide (sP1NP), ), intact parathyroid hormone (iPTH), 25-hydroxy 
vitamin D, 1,25 dihydroxy vitamin D, osteocalcin, estradiol, calcium, 
magnesium, phosphates (see also Table 6-4)
Renal biomarkers
Serum cystatin, urinary cystatin cystatin C/creatinine ratio (spot urine)
6.5.4
ECG
ECGs must be recorded after 10 minutes rest in the supine position to ensure a stable ECG 
baseline. The preferred sequence of cardiovascular data collection during study visits is ECG 
collection first, followed by vital signs, and blood sampling.
Single 12 lead ECGs are collected and interpreted by the principal investigator or their 
designee. The Fridericia QT correction formula should be used to assess the QT interval.
Each ECG tracing must be labeled with study number, subject initials, subject number, date 
and time, and filed in the study site source documents. For any ECGs with subject safety 
concerns, two additional ECGs must be performed to confirm the safety.
Clinically significant abnormalities must be recorded on the relevant section of the Medical 
History/Current Medical Conditions/AE eCRF(s) as appropriate.
6.5.5
Pregnancy and assessments of fertility
All pre-menopausal women who are not surgically sterile will have pregnancy testing (see 
Section 6.5.3.2 & Section 6.5.3.3). Additional pregnancy testing might be performed if 
requested by local requirements.


Novartis
Confidential
Page 46
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
A positive urine pregnancy test requires immediate interruption of study drug until serum β-
human chorionic gonadotropin (β-hCG) is performed and found to be negative. If positive, the 
subject must be discontinued from the study treatment (see Section 5.6.2).
6.5.6
Appropriateness of safety measurements 
The safety assessments are standard for this indication/subject population. The following 
additional assessments are included to document and evaluate risks identified with SGLT2
inhibitors or during the LIK066 clinical program:

Bone biomarkers will evaluate the effect of LIK066 on bone re-modeling. 

Renal biomarkers will evaluate if LIK066 may cause kidney injury due to its dual 
SGLT1/2 inhibition. 
6.6
Other assessments
No additional tests will be performed on subjects entered into this study.
6.6.2
Resource utilization
Not applicable.


Novartis
Confidential
Page 47
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
6.6.3
PK
6.6.3.1
PK trough sampling
PK trough sampling will be performed in all subjects at time-points indicated in Table 6-1. At 
the morning of the visit, subjects must be in a fasting state (see Section 5.5.4). Details on PK 
trough sample collection, numbering, processing and shipment is explained in the laboratory 
manual.
6.6.3.2
PK substudy
Subjects eligible for participation in the study will be invited to participate in the PK 
evaluation substudy (see Section 3.1.4). In total, approximately 120 subjects will participate in 
the substudy at selected study sites. 
PK sampling will be performed at visits indicated in Table 6-1. At the morning of the visit, 
subjects must be in a fasting state (see Section 5.5.4). Blood samples will be collected at 
following time-points: 0h (pre-dose) and approximately 1h, 2h, 4h and 6h post dose.
After the first sample, the study medication will be administered followed by a standard meal.
All samples will be assayed for LIK066 concentrations by Novartis or a designated contract 
research organization (CRO). 
 
 
Details on PK sample collection, numbering, processing and shipment are explained in the 
laboratory manual.
7
Safety monitoring
7.1
AEs
An AE is any untoward medical occurrence (eg, any unfavorable and unintended sign 
including abnormal laboratory findings, symptom or disease) in a subject or clinical 
investigation subject after providing written informed consent for participation in the study 
until the end of study visit. Therefore, an AE may or may not be temporally or causally 
associated with the use of a medicinal (investigational) product.
In addition, all reports of intentional misuse and abuse of the product are also considered an 
AE irrespective of whether a clinical event has occurred (see Section 7.5).
The occurrence of AEs must be sought by non-directive questioning of the subject at each 
visit during the study. AEs also may be detected when they are volunteered by the subject
during or between visits or through physical examination findings, laboratory test findings, or 
other assessments.
Abnormal laboratory values or test results constitute AEs only if they fulfill at least one of the 
following criteria:


Novartis
Confidential
Page 48
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201

They induce clinical signs or symptoms.

They are considered clinically significant.

They require therapy. 
Clinically significant abnormal laboratory values or test results must be identified through a 
review of values outside of normal ranges/clinically notable ranges, significant changes from 
BL or the previous visit, or values which are considered to be non-typical in subjects with 
underlying disease. Investigators have the responsibility for managing the safety of individual 
subjects and identifying AEs. Alert ranges for selected laboratory and other test abnormalities 
are included in Appendix 1.
AEs must be recorded in the AE eCRF under the signs, symptoms or diagnosis associated 
with them, accompanied by the following information:

The severity grade:

Mild: usually transient in nature and generally not interfering with normal activities.

Moderate: sufficiently discomforting to interfere with normal activities.

Severe: prevents normal activities.

Its relationship to the study treatment

Yes.

No.

Its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported.

Whether it constitutes an SAE (see Section 7.2) and which seriousness criteria have been 
met.

Action taken regarding investigational treatment.
All AEs must be treated appropriately. Treatment may include one or more of the following: 

No action taken (eg further observation only).

Investigational treatment dosage increased/reduced.

Investigational treatment interrupted/withdrawn.

Concomitant medication or non-drug therapy given.

Non-drug therapy given.

Subject hospitalized/subject’s hospitalization prolonged (see Section 7.2).

Its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved with sequelae; fatal; or unknown).
Once an AE is detected, it must be followed until its resolution or until it is judged to be 
permanent, and assessment must be made at each visit (or more frequently, if necessary) of 
any changes in severity, the suspected relationship to the study drug, the interventions 
required to treat it, and the outcome.
Information about common side effects already known about the investigational drug can be 
found in the IB. This information will be included in the subject ICF and should be discussed 
with the subject during the study as needed. Any new information regarding the safety profile 


Novartis
Confidential
Page 49
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
of the medicinal product that is identified between IB updates will be communicated as 
appropriate, for example, via an investigator notification (IN) or an aggregate safety finding. 
New information might require an update to the informed consent and has then to be 
discussed with the subject.
The investigator must also instruct each subject to report any new AE (beyond the protocol 
observation period) that the subject, or the subject’s personal physician, believes might 
reasonably be related to study treatment. This information must be recorded in the 
investigator’s source documents; however, if the AE meets the criteria of an SAE, it must be 
reported to Novartis.
7.2
SAE
7.2.1
Definition of SAE
An SAE is defined as any AE appearance of (or worsening of any pre-existing) undesirable 
sign(s), symptom(s) or medical conditions(s)) which meets any one of the following criteria:

Is fatal or life-threatening.

Results in persistent or significant disability/incapacity.

Constitutes a congenital anomaly/birth defect.

Requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for:

Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition (specify what this includes).

Elective or pre-planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since signing the ICF.

Treatment on an emergency outpatient basis for an event not fulfilling any of the 
definitions of a SAE given above and not resulting in hospital admission.

Social reasons and respite care in the absence of any deterioration in the subject’s 
general condition.

Is medically significant, eg defined as an event that jeopardizes the subject or may require 
medical or surgical intervention.
All malignant neoplasms will be assessed as serious under “medically significant” if other 
seriousness criteria are not met.
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically might have 
caused death if it were more severe (see Annex IV, ICH-E2D Guideline).
Medical and scientific judgment should be exercised in deciding whether other situations 
should be considered serious reactions, such as important medical events that might not be 
immediately life threatening or result in death or hospitalization but might jeopardize the 
subject or might require intervention to prevent one of the other outcomes listed above. 
Examples of such events are intensive treatment in an emergency room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization or 
development of dependency or abuse (see Annex IV, ICH-E2D Guideline).


Novartis
Confidential
Page 50
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
7.2.2
SAE reporting
To ensure subject safety, every SAE, regardless of causality, occurring after the subject has 
signed the ICF and until 30 days after the last study visit must be reported to Novartis within 
24-h of learning of its occurrence. Any SAEs experienced after the 30 day period after the last 
study visit should only be reported to Novartis if the investigator suspects a causal 
relationship to study treatment. 
All follow-up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow-up to the original episode 
within 24-h of the investigator receiving the follow-up information. An SAE occurring at a 
different time interval or otherwise considered completely unrelated to a previously reported 
one must be reported separately as a new event.
Information about all SAEs is collected and recorded on the SAE report form; all applicable 
sections of the form must be completed in order to provide a clinically thorough report. The 
investigator must assess the relationship of each SAE to each specific component of study 
treatment, complete the SAE report form in English, and submit the completed form within 
24-h to Novartis. Detailed instructions regarding the submission process and requirements for 
signature are to be found in the investigator folder provided to each site. 
Follow-up information is submitted as instructed in the investigator folder. Each re-
occurrence, complication, or progression of the original event must be reported as a follow-up 
to that event regardless of when it occurs. The follow-up information should describe whether 
the event has resolved or continues, if and how it was treated, whether the blind was broken or 
not, and whether the subject continued or withdrew from study participation.
If the SAE is not previously documented in the IB (new occurrence) and is thought to be 
related to the study treatment a Novartis drug safety & epidemiology (DS&E) department 
associate may urgently require further information from the investigator for health authority 
reporting. Novartis may need to issue an IN to inform all investigators involved in any study 
with the same study treatment that this SAE has been reported. Suspected unexpected serious 
adverse reactions (SUSARs) will be collected and reported to the competent authorities and 
relevant ethics committees in accordance with European Union (EU) Guidance 2011/C 
172/01 or as per national regulatory requirements in participating countries.
7.3
Liver safety monitoring
To ensure subject safety and enhance reliability in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed. 
The following two categories of abnormalities and AEs have to be considered during the 
course of the study (irrespective of whether classified or reported as serious):

Liver laboratory triggers, which will require repeated assessments of the abnormal 
laboratory parameter.


Novartis
Confidential
Page 51
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201

Liver events, which will require close observation, follow-up monitoring and completion 
of the standard base liver eCRF pages.
Please refer to Table 14-1 in Appendix 2 for complete definitions of liver laboratory triggers 
and liver events. 
Every liver laboratory trigger or liver event as defined in Table 14-1 in Appendix 2 should be 
followed up by the investigator or designated personal at the study site as summarized below. 
Detailed information is outlined in Table 14-2 in Appendix 2.
For the liver laboratory trigger:

Repeating the liver function test (LFT) within the next week to confirm elevation.
These LFT repeats must be performed using the central laboratory if possible. If this is not 
possible, then the repeats can be performed at a local laboratory to monitor the safety of the 
subject. Repeat laboratory must then be performed at central laboratory as soon as possible. If 
a liver event is subsequently reported, any local LFTs previously conducted that are 
associated with this event must be reported on the Liver eCRF pages.

If the elevation is confirmed, close observation of the subject will be initiated, including 
consideration of treatment interruption if deemed appropriate.
For the liver events:

Repeating the LFT to confirm elevation as appropriate.

Discontinuation of the investigational drug if appropriate.

Hospitalization of the subject if appropriate.

A causality assessment of the liver event via exclusion of alternative causes (eg, disease, 
co-medications).

An investigation of the liver event which needs to be followed until resolution. 
These investigations can include serology tests, imaging and pathology assessments, 
hepatologist’s consultancy, based on investigator’s discretion. All follow-up information, and 
the procedures performed must be recorded on appropriate eCRF pages, including the liver 
event overview eCRF pages.
7.4
Renal safety monitoring
The following two categories of abnormal renal laboratory values have to be considered 
during the course of the study:

Serum event:

Confirmed (after ≥ 24-h) increase in serum creatinine of ≥25 % compared to BL
during normal hydration status.

Urine event:

New onset (≥1+) proteinuria; confirmed by doubling in the urinary albumin-
creatinine ratio.

New onset (≥1+) hematuria.


Novartis
Confidential
Page 52
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Every renal laboratory trigger or renal event as defined in Table 15-1 in Appendix 3 should be 
followed up by the investigator or designated personnel at the study site as summarized in 
Appendix 3. 
7.5
Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, subject or 
consumer (European Medicines Agency definition).
Misuse refers to situations where the medicinal product is intentionally and inappropriately 
used not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by harmful physical or psychological effects.
Study treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the Dose Administration Record eCRF irrespective of whether or not associated with an 
AE/SAE and reported to DS&E only if associated with an SAE. Misuse or abuse will be 
collected and reported in the safety database irrespective of it being associated with an 
AE/SAE.
Table 7-1
Guidance for capturing the study treatment errors including 
misuse/abuse
Treatment error 
type
Document in DAR
eCRF (Yes/No)
Document in AE 
eCRF
Complete SAE form
Unintentional study 
treatment error
Yes
Only if associated with 
an AE
Only if associated with an 
SAE
Misuse/Abuse
Yes
Yes
Yes, even if not associated 
with a SAE
7.6
Pregnancy reporting
To ensure subject safety, each pregnancy occurring after signing the ICF must be reported to
Novartis within 24-h of learning of its occurrence. In such instance, study treatment should be 
handled as per Section 5.6.2. The pregnancy should be followed up to determine outcome, 
including spontaneous or voluntary termination, details of the birth, and the presence or 
absence of any birth defects, congenital abnormalities, or maternal and/or newborn 
complications.
Pregnancy must be recorded on the Pharmacovigilance Pregnancy Form and reported by the 
investigator to the local Novartis DS&E department. Pregnancy follow-up should be recorded 
on the same form and should include an assessment of the possible relationship to the study 
treatment. 
Any SAE experienced during the pregnancy and unrelated to the pregnancy must be reported 
on a SAE form.


Novartis
Confidential
Page 53
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
7.7
Prospective suicidality assessment
Not applicable.
7.8
AEs of special interest
7.8.1
Ketoacidosis
In rare cases, SGLT-2 inhibitors can lead to ketoacidosis. Therefore, investigators must pay 
close attention for any signs of ketoacidosis. Signs and symptoms of ketoacidosis may include 
deep and rapid breathing, nausea, vomiting, severe abdominal pain, confusion, unusual fatigue 
or sleepiness, and coma. All signs and/or symptoms and results from relevant laboratory tests 
must be reported on the AE eCRF. If ketoacidosis is confirmed, the study treatment should be 
handled as per Section 5.6.2 and appropriate measures must be taken to correct the acidosis 
and monitor glucose levels.
Every case of ketoacidosis must be reported to the Ketoacidosis adjudication committee (see 
Section 8.5), and the Ketoacidosis Adjudication eCRF must be completed.
7.8.2
Hypoglycemia
Patients with T2DM treated with anti-diabetic agents may be at an increased risk of 
hypoglycemia due to the expected weight loss. All patients with diabetes must be educated 
regarding hypoglycemic symptoms and treatment. This education should include general 
review of hypoglycemia:

Explanation of possible triggers of hypoglycemia (eg, strenuous exercise, delayed meals, 
changes in meal composition, illness, ramadan-period, etc.).

Identification of the symptoms of hypoglycemia (eg, central symptoms such as dizziness, 
lightheadedness; adrenergic symptoms such as fast heart rate, palpitations, heart 
racing/pounding, shakiness; cholinergic symptoms such as sweating, hunger, blurred 
vision, impairment of motor function, confusion or inappropriate behavior).

Review of appropriate treatment for events (oral glucose intake).
A home glucose monitor will be provided with all appropriate supplies and its use will be 
explained to the subject. Blood glucose should be measured each time the subject experiences 
symptoms which may be suggestive of hypoglycemia, as well as other time points as
recommended by the investigator to inform about the need for reducing or discontinuing anti-
diabetic treatment to prevent severe hypoglycemic events.
Any time the subject experiences symptoms which they suspect are related to hypoglycemia, 
the subject should treat the event as appropriate. Subjects should record the event in the 
glycemia study diary, including: 

The glucose value.

Precipitating factors (strenuous exercise, delayed or missed meals, changes in meal 
composition, illness, ramadan-period, etc.).

Time of occurrence in relation to the last medication and to the last meal intake.

The treatment used.


Novartis
Confidential
Page 54
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201

The response to the treatment used.

Need for assistance to treat the hypoglycemia event.

Additionally, if a subject performs routine self-monitoring of blood glucose, any 
asymptomatic plasma glucose < 70 mg/dL (< 3.9 mM) should be treated and recorded in 
the glycemia study diary.

The glycemia study diaries will be dispensed at run-in (V101) and at following visits. The 
subject must return the completed study diary at each following visit.
Subjects without diabetes must have the symptoms of hypoglycemia explained and will be 
asked to report them at every study visit, if such occur. These subjects will not be provided 
with blood glucose meters or diaries.
Data entry
The glycemia study diary will be reviewed by the investigator at each visit and any 
hypoglycemia must be recorded on the Hypoglycemic Events eCRF.
8
Data review and database management
In this study, eSource is the data collection system intended to be used. The system allows 
electronic capture of source and study data as required per protocol. The eSource system 
replaces the need for using an eCRF. If it is not possible to use eSource for source data 
capture due to exceptional circumstances, data capture and data management will revert to 
other electronic methods as appropriate.
8.1
Site monitoring
Before study initiation, at a site initiation visit or at an investigator’s meeting, a Novartis 
representative will review the protocol and data capture requirements (ie eSource or eCRFs) 
with the investigators and their staff. During the study, Novartis employs several methods of 
ensuring protocol and good clinical practice (GCP) compliance and the quality/integrity of the 
sites’ data. The field monitor will visit the site to check the completeness of subject records, 
the accuracy of data capture/data entry, the adherence to the protocol and to GCP, the progress 
of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for 
according to specifications. Key study personnel must be available to assist the field monitor 
during these visits. Continuous remote monitoring of each site’s data may be performed by a 
centralized Novartis clinical research associate organization. Additionally, a central analytics 
organization may analyze data and identify risks and trends for site operational parameters, 
and provide reports to Novartis clinical teams to assist with study oversight.
The investigator must maintain source documents for each subject in the study, consisting of 
case and visit notes (hospital or site medical records) containing demographic and medical 
information, laboratory data, ECGs, and the results of any other tests or assessments. All 
information on eCRFs must be traceable to these source documents in the subject's file. The 
investigator must also keep the original ICF signed by the subject (a signed copy is given to 
the subject).


Novartis
Confidential
Page 55
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency with the data capture and/or data entry. Novartis monitoring standards 
require full verification for the presence of informed consent, adherence to the 
inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all 
primary variables. Additional checks of the consistency of the source data with the CRFs are 
performed according to the study-specific monitoring plan. No information in source 
documents about the identity of the subjects will be disclosed.
8.2
Data collection
This study will incorporate technology (eSource) to capture source documents and source data 
electronically, consistent with final Food & Drug Administration (FDA) guidance (Center for 
drug evaluation and research (CDER) 2013) regarding electronic source and regulations 
related to the maintenance of adequate subject case histories (21 Code of Federal Regulations 
(CFR) 312.62 [b]). All electronic source documentation and data collected in this study will
“ meet the same fundamental elements of data quality (eg, attributable, legible, 
contemporaneous, original, and accurate) that are expected of paper records”into a system 
that is fully validated and conforms to 21 CFR Part 11 requirements. Investigator site staff 
will not be given access to the system(s) until they have been appropriately trained.
Study sites using eSource will be supplied with a tablet personal computer to directly record 
subject data and clinical observations on electronic forms with a similar look, feel, and 
behavior to paper forms. The system will permit the collection of both structured and 
unstructured information including ad-hoc comments, drawings, and relevant clinical notes 
the investigative site deems important. Information to be originally captured and reviewed 
electronically shall include details of the subject visit and the protocol required assessments 
performed as a part of these visits, medical history, and concomitant medications.
Certain data may be captured via other source documentation (such as safety laboratory data 
report, imaging) and then transcribed, uploaded or transferred into the eSource system. This, 
and any additional data treated in this manner, will be source data verified by the study field 
monitor per the monitoring plan and the location of source data (ie, source, paper or a local 
electronic system) will be documented prior to study start in the Data Handling Plan. The 
eSource system has the ability to illustrate when a document has been entered from another 
source. When using an electronic source record as the original point of data capture, there is 
no additional data entry step for the site for data collected directly into the application; rather, 
the electronic source record directly populates the study database. 
Automatic validation programs check for data discrepancies and, by generating appropriate 
error messages, allow the data to be confirmed or corrected before transfer of the data to the 
vendor working on behalf of Novartis.
Remote monitoring of the original electronic source records will take place, however on-site 
monitoring inspections will continue to take place in order to review data entry of source 
documentation directly captured on paper and transcribed into the system, to ensure protocol 
adherence, to assess site operational capabilities, and to perform other monitoring activities 
that cannot be performed remotely.


Novartis
Confidential
Page 56
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
The investigator must certify that the data entered into eSource are complete and accurate. 
After database lock, the investigator will receive copies of the subject data for archiving at the 
investigational site. 
8.3
Database management and quality control
The study will use electronic source documents and source data, and data entry will be done 
by the sites directly into eSource.
Concomitant medications entered into the database will be coded using the world health 
organization (WHO) Drug Reference List, which employs the anatomical therapeutic 
chemical (ATC) classification system. Concomitant procedures, non-drug therapies and 
adverse events will be coded using the medical dictionary for regulatory activities (MedDRA) 
terminology.
Laboratory samples will be processed centrally and the results will be sent electronically to 
Novartis (or a designated CRO).
Where applicable, diary data may be entered into an electronic diary by the subject or subjects 
will complete
data on a site based tablet. The system will be 
supplied by a vendor(s), who will also manage the database. The database will be sent 
electronically to Novartis personnel (or designated CRO).
Randomization codes and data about all study drug(s) dispensed to the subject and all dosage 
changes will be tracked using an IRT system (see Section 5.3). The system will be supplied by 
a vendor, who will also manage the database. The database will be sent electronically to 
Novartis (or a designated CRO). For occurrence of code breaks see Section 5.5.9. 
The occurrence of relevant protocol deviations will be determined. After these actions have 
been completed and the database has been declared to be complete and accurate, it will be 
locked and the treatment codes will be unblinded and made available for data analysis. Any 
changes to the database after that time can only be made after written agreement by Novartis 
Development management.
8.4
Data monitoring committee
Not applicable.
8.5
Adjudication committee
A Ketoacidosis adjudication committee will review cases suspected for ketoacidosis as 
defined in the adjudication charter (see also Section 7.8.1).
9
Data analysis 
The main analysis will be performed at the end of Epoch 3 when all subjects complete their 
treatment at Week 24 after randomization and data collected up to and including Week 24
(Visit 299) are cleaned (referred to as “Week 24 analysis” in sections below).
Data collected during Epoch 4 will be analyzed after the study ends, and will be presented in a 
separate report (referred to as “End of study analysis” in sections below).


Novartis
Confidential
Page 57
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
For Week 24 analysis, the treatment groups presented are:

LIK066 2.5 mg qd.

LIK066 10 mg qd.

LIK066 50 mg qd.

LIK066 150 mg qd.

LIK066 2.5 mg bid.

LIK066 5 mg bid.

LIK066 25 mg bid.

LIK066 50 mg bid.

Placebo.

Total (if applicable).
For End of study analysis, unless specified otherwise, the following treatment grouping 
strategy will be used, expressed as per the Epoch 3 treatment/Epoch 4 treatments a subject is 
assigned to at randomization:

LIK066 qd any dose/LIK066 25 mg qd, shortened as LIK066/LIK066 25 mg qd.

LIK066 bid any dose/LIK066 35 mg qd, shortened as LIK066/LIK066 35 mg qd.

Placebo/LIK066 25 mg qd.

Placebo/placebo, shortened as placebo.

Total (if applicable).
9.1
Analysis sets
The following analysis sets will be used for the statistical analyses:
Enrolled set (ENR): all subjects who signed the ICF.
Full analysis set (FAS): the FAS comprises of all subjects to whom study treatment has been 
assigned, except those who are not qualified for randomization but were inadvertently 
randomized into the study and did not take any study drug. Following the intent-to-treat 
principle, subjects will be analyzed according to the treatment assigned to at randomization. 
Safety set (SAF): the SAF includes all subjects who received at least one dose of study 
medication. Subjects will be analyzed according to treatment received. Note that the safety set 
allows the inclusion of non-randomized subjects who received the study drug in error.
The per-protocol set (PPS) is a subset of the FAS. It consists of all randomized subjects in 
the FAS who took at least one dose of study medication and have no major protocol 
deviations affecting the primary endpoint analysis.
Major protocol deviations will be pre-specified prior to un-blinding treatment codes for 
analyses.


Novartis
Confidential
Page 58
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
9.2
Subject demographics and other BL characteristics
Week 24 analysis
The number of enrolled subjects, randomized subjects and screen failed subjects, as well as 
the number of subjects in each analysis set will be summarized.
Demographics, BL characteristics, disease history and medical history will be summarized 
overall (total) and by treatment group for the FAS. Descriptive statistics (mean, Q1, median, 
Q3, standard deviation, minimum and maximum) will be presented for continuous variables 
for each treatment group and for all subjects (total). The number and percentage of subjects in 
each category will be presented for categorical variables for each treatment group and all 
subjects (total). Demographics and BL characteristics will be similarly summarized by the 
stratification factor (glycemic status at screening) as well.
End of study analysis
Demographics and other BL characteristics including medical history will be similarly 
summarized for FAS subjects who enter the study Week 24 to Week 48 period (Epoch 4) as 
for the Week 24 analysis.
9.3
Treatments
Week 24 analysis
The duration of double-blind treatment exposure (days) in Epoch 3 will be summarized by 
treatment group both descriptively (ie mean, standard deviation, median, Q1 (25th percentile), 
Q3 (75th percentile), minimum and maximum) and by duration category for the safety set.
The number and percentage of subjects receiving prior and concomitant medications will be 
summarized by treatment group and overall in SAF in separate tables according to the 
hierarchy levels of the WHO coding dictionary. Prior medications are defined as drugs taken 
and stopped prior to first dose of study medication. Any medication given at least once 
between the day of first dose of double-blind study medication and the end of Epoch 3 visit 
will be a concomitant medication, including those which were started pre-BL and continued 
into the treatment period.
The number and percentage of subjects taking rescue medication, and duration of exposure to 
rescue medication during Epoch 3 will be summarized by treatment group.
The use of prohibited medication, if any, will also be summarized.
End of study analysis
The duration of overall treatment period (Epoch 3 + Epoch 4) as well as the duration of Epoch 
4 will be summarized by treatment group both descriptively and by duration-category for 
subjects in the SAF who enter the study Week 24 to Week 48 period (Epoch 4), respectively.
Concomitant medications and rescue medications subjects take during Epoch 4 will be 
similarly summarized for subjects in SAF who enter Epoch 4.


Novartis
Confidential
Page 59
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
9.4
Analysis of the primary variable(s)
9.4.1
Variable(s)
The primary analysis variable is the percent change in body weight (kg) from BL at Week 24. 
BL is defined as the last body weight value measured prior to or at the randomization visit 
(Visit 201). This analysis will be carried out on the FAS, with missing Week 24 values 
imputed as described in Section 9.4.3.
9.4.2
Statistical model, hypothesis, and method of analysis
The objective of determination of a dose response signal and dose-response relationship in 
either qd or bid dosing regimen compared to placebo will be evaluated using an optimally 
weighted contrast test following the methodology described in Pinheiro et al (2006) and
Pinheiro et al (2014). To this end, a candidate model set is defined corresponding to the range 
of expected mean response in each of the dosing regimens. The candidate model set is used to 
generate a set of weights for the calculation of optimal contrasts between the responses in the 
studied dose groups and the placebo group. A statistical test comparing all doses in the 
different dosing regimens simultaneously to the control group is used, hence a multiplicity 
adjustment is applied that accounts for the multiple possible dose response behavior 
considered as well as the common placebo between the dosing regimens. A critical value is 
derived from a multivariate t-distribution using the correlation matrix induced by the 
correlations between the weights corresponding to the candidate sets as well as the correlation 
between the tests of shapes in the dosing regimens to the common placebo group.
Test of the dose response signal
The null hypothesis of a flat dose-response relationship for the percentage reduction in body 
weight compared to placebo will be tested at a one-sided significance level of 2.5 % against 
the alternative hypothesis of a dose-response relationship leading to a significant decrease in 
percent body weight. 
Hence, the following null and alternative hypotheses will be tested:

H01: there is no dose-response relationship for LIK066 given qd (ie the dose response 
relationship is flat).

H11: there is a dose-response relationship for LIK066 given qd (ie as dose increases, the 
percent weight decreases).

H02: there is no dose response relationship for LIK066 given bid (ie the dose response 
relationship is flat).

H12: there is a dose-response relationship for LIK066 given bid (ie as dose increases, the 
percent weight decreases).
Given that we suspect the dose-response may behave differently between qd and bid regimens 
based on the data we have seen from the proof-of-concept study LIK066X2201, we define 
separate sets of the dose-response candidate models for each dosing regimen. In order to 
preserve the family-wise error rate at one-sided significance level of 2.5 %, the optimal 
contrasts derived from the model candidate set for each dosing regimen will be individually 


Novartis
Confidential
Page 60
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
compared to the critical value derived using a multiplicity adjustment accounts for all tests of 
comparing LIK066 doses to placebo across regimens simultaneously as described above. The 
rejection of the null hypothesis for each dosing regimen will be achieved using the maximum 
test statistic in each dosing regimen from each estimated contrast test in the candidate set.
The candidate models generating the contrast weights are described in Table 9-1 and depicted 
in Figure 9-1, with the doses used to define parameters of interest being defined as total daily 
dose.
Table 9-1
Candidate dose-response models in consideration
#
Candidate models for qd regimen
Candidate models for bid regimen
1
Emax model: ED50 = 5 mg
Emax model: ED50 = 5 mg
2
Emax model: ED50 = 50 mg
Emax model: ED50 = 50 mg
3
Sigmoid Emax: ED50 = 75 mg, H = 3.5
Sigmoid Emax: ED50 = 75 mg, H = 3.2
4
Sigmoid Emax: ED50 = 25 mg, H = 0.7
Linear log-dose: null, c = 0.8
5
β-model: α = 0.8, β = 0.2, scale = 180
Linear
6
Exponential: λ = 125
Quadratic: δ = -0.007
Figure 9-1
Dose-response curve of candidate models (left panel: qd regimen)
   
The analysis to derive the test statistics is based on an analysis of covariance (ANCOVA) 
model with the percent change in body weight from BL to Week 24 as a response variable, 
treatment (placebo and all LIK066 doses from each regimen), stratum indicator (dysglycemic/ 
normoglycemic/T2DM) and pooled center/region as factors and BL weight as a covariate. As 
needed, centers will be pooled according to country and region for the purpose of analysis. 


Novartis
Confidential
Page 61
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
The response variable of percent change in body weight from BL to Week 24 used in the 
above ANCOVA is from an imputed dataset, where the missing Week 24 weight is imputed 
using the multiple imputation method as described in Section 9.4.3. In order to account for the 
imputation uncertainty, this ANCOVA model will be repeated for each imputed dataset, 
which results in a set of least squares (LS) mean estimates for all dose groups for the two 
regimens and the related covariance matrices. Rubin’s rule will be used to combine the 
multiple sets of LS mean estimates and the related covariance matrices to a single set of LS 
mean estimates of percent changes of body weight at Week 24 for all dose groups and the 
related covariance matrix. 
The optimal contrasts derived from the candidate model sets will be applied to the combined 
estimated dose means and covariance matrix to obtain the t statistics for each candidate model 
in the two regimens and the common critical value C0.025. C0.025 is the common critical value 
derived from the reference multivariate t-distribution with the 12 × 12 correlation matrix 
induced by testing the candidate dose response models with respect to comparing all 
candidate models in both dosing regimens to the common placebo group.
The intersection hypotheses H01 and H02 will be rejected and the statistical significance of 
dose-response in body weight reduction is established if the max(t1, t2, t3, …, t11, t12) 
≥C0.025. In other words, the intersecting null hypothesis requires the rejection of either H01 or 
H02.
Model averaging to obtain the dose responses for qd and bid dosing regimens
The response data in each imputed data set, including relevant covariates, will be used to fit 
the models in the candidate set within each dosing regimen. The estimated dose-response in 
each dosing regimen will be derived by using model averaging methods on a subset of 
candidate models, for which the associated contrast tests are statistically significant. If there 
are more than three candidate models that are statistically significant, then only the top three 
candidate models with the largest test statistics will be selected. Model averaging will be 
carried out for each imputed data set, and the resulting mean efficacy estimates and 
confidence intervals will be derived using the combination variance that accounts for the 
uncertainty of the imputed data using Rubin’s combination rules. Comparisons between 
LIK066 doses and placebo in each dosing regimen will be simultaneously derived for the 
model averaged estimates together with confidence intervals reflecting the imputation 
procedure applied.
Target dose selection will be based on the model averaged dose response estimates of mean 
weight lowering efficacy of LIK066 over the dose range studied in the Phase 2B study.
9.4.3
Handling of missing values/censoring/discontinuations
Missing data for the primary endpoint will be imputed using a multiple imputation approach 
that assumes that the missingness mechanism can be retrieved from observed data (missing at 
random; MAR). The imputation model will include the longitudinal sequence of body weight 
data collected at each visit up to and including Week 24 visit and BL covariates (eg
randomization stratification factor, FPG, age, gender, race), imputing missing visit 
observations for each dose group separately. 


Novartis
Confidential
Page 62
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
The full detailed information about the multiple imputation algorithms will be specified in a 
separate statistical analysis plan.
9.4.4
Supportive analyses
As a sensitivity analysis, the dose-response modeling as described in Section 9.4.2 will be 
conducted in the PPS as well.
Results based on the single best dose response model fit will also be reported.
Summary statistics for body weight will be presented by visit by treatment for observed and 
imputed values. The summary statistics n, mean, standard deviation (SD), median, minimum, 
maximum, Q1 and Q3 will be presented for the BL values and similarly for absolute values at
and changes from BL to the post-BL visits. Figures will be produced to visually show the raw 
and the imputed mean changes by visit over 24 weeks of Epoch 3 for each treatment group, 
for all subjects and by strata separately.
9.5
Analysis of secondary variables
9.5.1
Efficacy variables
9.5.1.1
Week 24 analysis
Variables 

Responder rates based on percent decrease in body weight from BL at Week 24 ≥5 %, or 
≥10 %.

Dose-response relationship in normoglycemic subjects, dysglycemic subjects and subjects 
with T2DM after 24 weeks of treatment.

Change from BL at Week 24 in waist circumference.

Change from BL at Week 24 in HbA1c.

Change from BL at Week 24 in FPG.

Change from BL at Week 24 in SBP and DBP.

Changes from BL at Week 24 in the fasting lipid profile (TG, total cholesterol, high 
density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, 
lipoproteins, calculated very low density lipoprotein (VLDL) cholesterol and non-HDL 
cholesterol) and hsCRP.

Change from BL at Week 24 in 24-h UGE.
Analysis method: responder analysis
For the responder analysis, a logistic regression model will be performed using the percent 
decrease in body weight from BL at Week 24 ≥5 % or ≥10 % (yes/no) as a response variable, 
treatment, glycemic stratification factor and pooled center as fixed factors and BL body 
weight as a covariate, respectively. The Week 24 missing values will be imputed using the 
multiple imputation method as described in Section 9.4.3. In order to account for the 


Novartis
Confidential
Page 63
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
imputation uncertainty, this logistic regression model will be repeated for each imputed 
dataset, which results in a set of estimated odds ratio and its 95 % confidence interval of an 
LIK066 dose vs placebo for all dose groups for the two regimens. Rubin’s rule will be used to 
combine the multiple sets of odds ratios and 95 % confidence intervals to a single set of odds 
ratio and its 95 % confidence interval of an LIK066 dose vs placebo. Similar analysis by 
glycemic status stratification factor will be performed to assess the responder across each of 
the subgroups (normoglycemic subjects, dysglycemic subjects and subjects with T2DM).
In addition, subjects meeting the predefined response criteria (percent decrease in body 
weight from BL at Week 24 ≥5 % or ≥10 %) will be summarized by treatment for all 
subjects and by glycemic stratification factor. A Cochran-Mantel-Haenszel-test will be 
performed to compare each qd or bid dose to the common placebo.
Analysis method: dose-response relationship by glycemic stratification factor 
For the dose-response relationship in normoglycemic subjects, dysglycemic subjects and 
subjects with T2DM, the dose-response modeling with the same candidate model sets for the 
primary variable as described in Section 9.4.2 will be performed on percent change of body 
weight from BL at Week 24 for these three subsets of subjects separately.
Analysis for other secondary endpoints
For changes from BL at Week 24 in HbA1c, FPG, SBP, DBP, waist circumference and 24-h
UGE, a repeated measure ANCOVA model with treatment, visit, and treatment by visit 
interaction as fixed-effect factors and BL as a covariate, and a common unstructured 
covariance matrix among visits between treatments will be performed separately for each 
variable. The adjusted mean changes at Week 24 within each treatment, the differences in 
mean changes at Week 24 between the LIK066 and placebo treatments, and their 95 %
confidence intervals obtained from the above model will be presented. The analysis is based 
on likelihood method with an assumption of MAR for missing data.
In addition, a repeated measure ANCOVA model with treatment, visit, stratification factor 
(normoglycemic, dysglycemic, T2DM) and treatment by visit, treatment by stratification 
factor and treatment by visit by stratification factor interactions as fixed-effect factors and BL 
as a covariate, and a common unstructured covariance matrix among visits between 
treatments will be performed for the primary and secondary efficacy variables, respectively. 
The adjusted mean changes at Week 24 within each treatment, the differences in mean 
changes at Week 24 between the LIK066 and placebo treatments for each stratum, and their 
95 % confidence intervals obtained from the above models will be presented by strata for each 
efficacy endpoint.
Similar repeated measure ANCOVA models will be performed for percent changes of lipid 
parameters and hsCRP from BL at Week 24.
Summaries of absolute values and change from BL by treatment group and visit will be 
presented for all secondary efficacy variables for all subjects and by strata. Figures will be 
produced to visually show the raw mean changes by visit over 24 weeks of Epoch 3 for each 
treatment group, for overall and by strata separately. 
All analyses on secondary variables will be performed in the FAS.


Novartis
Confidential
Page 64
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
9.5.1.2
End of study analysis
A repeated measure ANCOVA model with treatment, visit, the stratification factor, pooled 
center or region, and treatment by visit interaction as fixed-effect factors and BL as a 
covariate, and a common unstructured covariance matrix among visits between treatment will 
be performed separately for the changes from Week 24 to study end in each efficacy variable 
(body weight, FPG, HbA1c, SBP, DBP, lipid parameters, hsCRP, 24-h UGE and waist 
circumference). The adjusted mean changes from Week 24 to Week 48 within each treatment, 
the differences in mean changes from Week 24 to Week 48 between the LIK066 and placebo 
treatments, and their 95 % confidence intervals obtained from the above models will be 
presented. The analysis is based on likelihood method with an assumption of MAR for 
missing data.
A similar repeated measure ANCOVA model with additional glycemic stratification factor by 
treatment interaction and treatment by visit by stratification factor interaction terms will be 
performed to assess the body weight change from Week 24 to study end across each of the 
subgroups (normoglycemic subjects, dysglycemic subjects and subjects with T2DM). The p-
value for the interaction of treatment by stratification factor at Week 24 will be calculated 
from this model as well.
Note that for lipid parameters, the percent changes (instead of absolute change) from Week 24 
to study end will be used as a response variable in the above repeated measure ANCOVA 
model.
Summaries of absolute values and changes (and/or percent changes for body weight and lipid 
parameters) from Week 24 by treatment group and visit will be presented for all efficacy 
variables, for all subjects and by stratification strata, respectively. Changes from BL will be 
similarly summarized as well. Figures will be produced to visually show the raw mean 
changes by visit over entire study period of 48 weeks for each treatment group. 
All analyses will be performed in subjects in the FAS who enter Epoch 4.
9.5.2
Safety variables
9.5.2.1
Week 24 analysis
All safety analyses will be performed in the SAF.
AEs
Treatment emergent AEs will be summarized. A treatment-emergent AE is defined as any AE 
that develops after initiation of the study treatments or any event already present that worsens 
following exposure to the study treatment. The number and percentage of subjects having AEs 
will be presented by treatment group and different hierarchy levels of the MedDRA coding 
dictionary. Summaries will also be presented by greatest severity, for AEs suspected to be 
related to study drug, serious AEs, AEs leading to discontinuation, to dosage adjustment, to 
death and other significant AEs. The hypoglycemic events will be similarly summarized. 
Further information related to hypoglycemic events (eg if third party assistance required, was 
medical assistance received, etc.) may be provided as well.


Novartis
Confidential
Page 65
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
AEs related to identified and potential risks as specified in the development safety profiling 
plan (DSPP) will be summarized and presented separately.
The frequencies and percentages of the adjudication confirmed ketoacidosis events will be 
provided by treatment.
In addition, for selected AEs including hypotension, hypoglycemia, hyperkalemia, diarrhea, 
and genital and UTI, a by-stratification factor of BL glycemic status subgroup analysis will be 
provided.
Laboratory data, vital signs, ECG and bone markers
Descriptive summary statistics including for the change from BL to each study visit up to and 
including Week 24 visit will be presented by treatment group for each laboratory parameter, 
as well as for the maximum change from BL. In addition, shift tables will be provided for all 
parameters with available ranges to compare a subject’s BL laboratory evaluation relative to 
the most extreme post-BL value. For the shift tables, normal ranges as well as specifically 
defined clinically notable/abnormality limits, if available – will be used.
The vital sign and ECG data collected during Epoch 3 will be descriptively summarized by 
treatment as appropriate.
The change from BL in the 24-h urinary calcium and phosphorus excretion will be 
descriptively summarized by treatment and visit for a subset of subjects participating in the 
PK analysis.
9.5.2.2
End of study analysis
All safety analyses will be performed for subjects in the SAF who enter Epoch 4.
AEs
The number and percentage of subjects having AEs, SAEs, AEs leading to study medication 
permanent discontinuation and other significant AEs occurred during Epoch 4 will be 
summarized and presented by treatment. Similar summaries will be provided for events 
occurred during the overall 48 weeks of Epoch 3 plus Epoch 4.
The AEs of interest, including those related to potential/identified risks as specified in the 
DSPP, will be summarized as appropriate separately.
Laboratory data, vital signs and ECG
Descriptive summary statistics including for the change from Week 24 to each post-Week 24 
study visit during Epoch 4 will be presented by treatment group for each parameter, as well as 
for the maximum change from BL. In addition, shift tables will be provided for all parameters 
with available ranges to compare a subject’s Week 24 laboratory evaluation relative to the 
most extreme post-Week 24 value.
The change from Week 24 in the 24-h urinary calcium and phosphorus excretion will be 
descriptively summarized by treatment and visit (for post-Week 24 visits only) for a subset of 
subjects participating in the PK analysis.


Novartis
Confidential
Page 66
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
9.5.3
Resource utilization
Not applicable.
9.5.4
PK
The following PK parameters will be determined using the actual recorded sampling times 
and non-compartmental method(s) with Phoenix WinNonlin (Version 6.2 or higher): 
maximum concentration
observed
(Cmax), maximum time (Tmax), last non-zero 
concentration area under the curve (AUClast), AUC0-t. Additional PK parameters may be 
calculated as appropriate. The linear trapezoidal rule will be used for AUC calculation.
Descriptive summary statistics will be provided by treatment and visit/sampling time point. 
Summary statistics will include mean (arithmetic and geometric), SD, CV (arithmetic and 
geometric), median, minimum and maximum. An exception to this is Tmax where median, 
minimum and maximum will be presented.
Concentrations below the lower limit of quantification (LLOQ) will be treated as zero in 
summary statistics and for PK parameter calculations. A geometric mean will not be reported 
if the dataset includes zero values.
Individual LIK066 plasma concentration data will be listed by treatment, subject, and 
visit/sampling time point. PK parameters will also be listed by treatment and subject.
9.5.5
DNA
Not applicable.
9.5.6
Biomarkers
Week 24 analysis
Summaries of absolute values and change from BL in each of the bone, renal and 
inflammatory biomarkers by treatment group and visit will be presented using statistics: n, 
mean, SD, median, minimum, maximum, Q1, Q3, geometric mean and coefficient of variation. 
Figures will be produced to visually show the mean values by visit over 24 weeks of treatment 
in Epoch 3 for each treatment group. 
End of study analysis
The absolute values and change from Week 24 in each of the bone, renal and inflammatory 
biomarkers will be similarly summarized and depicted as for the Week 24 analysis.


Novartis
Confidential
Page 67
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
9.7
Interim analyses
Not applicable.


Novartis
Confidential
Page 68
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
9.8
Sample size calculation
The study planned to randomize approximately 432 subjects in total, allocated in the ratio of 
1:1:1:1:1:2:1:1:1:2 to the following ten Epoch 3/Epoch 4 treatment groups:
1. placebo/placebo
2. placebo/LIK066 25 mg qd
3. LIK066 2.5 mg qd/25 mg qd 
4. LIK066 10 mg qd/25 mg qd 
5. LIK066 50 mg qd/25 mg qd 
6. LIK066 150 mg qd/25 mg qd 
7. LIK066 2.5 mg bid/35 mg qd 
8. LIK066 5 mg bid/35 mg qd 
9. LIK066 25 mg bid/35 mg qd 
10. LIK066 50 mg bid/35 mg qd 
This randomization scheme implies that the Epoch 3 treatment and Epoch 4 treatment for a 
specific subject is determined simultaneously at randomization visit. The randomization will 
be stratified by subjects’ glycemic status at screening: normoglycemic, dysglycemic and 
T2DM (see Section 3.1.2).
As the dose-response assessment is conducted in qd and bid regimens separately (while an 
overall family-wise type I error is controlled at a one-sided significance level of 2.5 %), 
power calculation was done for testing dose-response signal by regimen as well. Table 9-2
summarizes the average power and the lowest power across the candidate dose response
shapes in Figure 9-1 by regimen, under different scenarios with the assumptions on effect size 
of body weight loss (percent change from BL) for the dose of maximum effect, and the related 
standard deviations.
Note that a dose-response signal is detected (ie the primary objective is met) as long as either 
of the dose-response signals for the two regimens is detected. Therefore, the overall study 
power is at least the maximum of the powers between two regimens for each scenario 
considered.
It was assumed that the effect of losses to follow-up is equivalent to effectively having 15 %
fewer subjects than randomized, even if the multiple imputation approach used to handle 
missing values should be able to recover some information for such subjects.
Table 9-2
Power for detecting a significant dose response signal*
Dose regimen
Effect size for best dose
SD
Average power**
Minimum power†
qd
5 %
5.5 %
99.99 %
99.98 %
5 %
6.5 %
99.71 %
99.57 %
6 %
5.5 %
99.99 %
99.99 %
6 %
6.5 %
99.99 %
99.98 %


Novartis
Confidential
Page 69
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Dose regimen
Effect size for best dose
SD
Average power**
Minimum power†
bid
5 %
5.5 %
99.16 %
95.84 %
5 %
6.5 %
96.50 %
86.79 %
6 %
5.5 %
99.90 %
99.43 %
6 %
6.5 %
99.28 %
96.36 %
* Assumes 432 subjects in LIK066 and placebo arms with effective sample size of 367 subjects due to an effect of 
missing data equivalent to 15 % fewer subjects. Calculations were performed using the DoseFinding package in R.
† Power for a significant dose-response contrast test across all scenarios within each regimen in Table 9-1. The 
candidate model #5 in bid regimen has the lowest power.
10
Ethical considerations
10.1
Regulatory and ethical compliance
This clinical study was designed and shall be implemented, executed and reported in 
accordance with the International Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use (ICH) Harmonized Tripartite Guidelines 
for Good Clinical Practice, with applicable local regulations (including European Directive 
2001/20/EC, United States (US) CFR 21, and Japanese Ministry of Health, Labor, and 
Welfare), and with the ethical principles laid down in the Declaration of Helsinki.
10.2
Informed consent procedures
Eligible subjects may only be included in the study after providing written (witnessed, where 
required by law or regulation), IRB/IEC-approved informed consent, or, if incapable of doing 
so, after such consent has been provided by a legally acceptable representative(s) of the 
subject. In cases where the subject’s representative gives consent, the subject must be 
informed about the study to the extent possible given his/her understanding. If the subject is 
capable of doing so, she/he must indicate assent by personally signing and dating the written 
ICF or a separate assent form. Informed consent must be obtained before conducting any 
study-specific procedures (eg all of the procedures described in the protocol). The process of 
obtaining informed consent must be documented in the subject source documents. 
Novartis will provide to investigators in a separate document a proposed ICF that complies 
with the ICH GCP guidelines and regulatory requirements and is considered appropriate for 
this study. Any changes to the proposed ICF suggested by the investigator must be agreed to 
by Novartis before submission to the IRB/IEC, and a copy of the approved version must be 
provided to the Novartis monitor after IRB/IEC approval.
Women of child bearing potential must be informed that taking the study treatment may 
involve unknown risks to the fetus if pregnancy were to occur during the study and agree that 
in order to participate in the study they must adhere to the contraception requirement for the 
duration of the study. If there is any question that the subject will not reliably comply, they 
must not be entered in the study.


Novartis
Confidential
Page 70
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
10.3
Responsibilities of the investigator and IRB/IEC
Before initiating a study, the investigator/institution must obtain approval/favorable opinion 
from the IRB/IEC for the study protocol, written ICF, consent form updates, subject 
recruitment procedures (eg, advertisements) and any other written information to be provided 
to subjects. Prior to study start, the investigator is required to sign a protocol signature page 
confirming her/his agreement to conduct the study in accordance with these documents and all 
of the instructions and procedures found in this protocol and to give access to all relevant data 
and records to Novartis monitors, auditors, Novartis Quality Assurance representatives, 
designated agents of Novartis, IRBs/IECs, and regulatory authorities as required. If an 
inspection of the clinical site is requested by a regulatory authority, the investigator must 
inform Novartis immediately that this request has been made.
10.4
Publication of study protocol and results
The key design elements of this protocol will be posted in a publicly accessible database such 
as clinicaltrials.gov. In addition, upon study completion and finalization of the study report 
the results of this study will be either submitted for publication and/or posted in a publicly 
accessible database of clinical study results.
10.5
Quality control and quality assurance
Novartis maintains a robust Quality Management system that includes all activities involved 
in quality assurance and quality control, including the assignment of roles and responsibilities, 
the reporting of results, and the documentation of actions and escalation of issues identified 
during the review of quality metrics, incidents, audits and inspections.
Audits of investigator sites, vendors, and Novartis systems are performed by Novartis Global 
Development Quality Audit, a group independent from those involved in conducting, 
monitoring or performing quality control of the clinical study. The clinical audit process uses 
a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal standard operation procedures, and are performed according to written 
Novartis processes.
11
Protocol adherence
This protocol defines the study objectives, the study procedures and the data to be collected 
on study participants. Additional assessments required to ensure safety of subjects should be 
administered as deemed necessary on a case by case basis. Under no circumstances is an 
investigator allowed to collect additional data or conduct any additional procedures for any 
research related purpose involving any investigational drugs under the protocol.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC and health authorities, where required, it cannot be 
implemented. 


Novartis
Confidential
Page 71
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
11.1
Protocol amendments 
Any change or addition to the protocol can only be made in a written protocol amendment that 
must be approved by Novartis, health authorities where required, and the IRB/IEC prior to 
implementation. Only amendments that are intended to eliminate an apparent immediate 
hazard to subjects may be implemented immediately provided the health authorities are 
subsequently notified by protocol amendment and the reviewing IRB/IEC is notified. 
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety of any subject included in this 
study, even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in Section 7 must be followed.
12
References
AACE (2016) Clinical practice guidelines for comprehensive medical care of patients with 
obesity. Endocrine Practice; DOI: 10.4158/EP161365.GL.
Bailey CJ, Gross JL, Pieters A, et al (2010) Effect of dapagliflozin in patients with type 2 
diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, 
placebo-controlled trial. Lancet; 375: 2223-33.
Look AHEAD Research Group (2013) Cardiovascular effects of intensive lifestyle 
intervention in type 2 diabetes. N Engl J Med; 369:145-54. 
Nauck MA, Del Prato S, Meier JJ, et al (2011) Dapagliflozin vs glipizide as add-on therapy in 
patients with type 2 diabetes who have inadequate glycemic control with metformin. Diabetes 
Care; 34(9): 2015-22.
Neal B, Prekovic V, Mahaffey KW et al (2017) Canagliflozin and Cardiovascular and Renal 
Events in Type 2 Diabetes. NEJM; doi: 10.1056/NEJMoa1611925
Nyirjesy P, Zhao Y, Ways K, et al (2012) Evaluation of vulvovaginal symptoms and Candida 
colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium 
glucose co-transporter 2 inhibitor. Current Medical Research and Opinion; 28(7): 1173-8.
Pinheiro J, Bornkamp B, Bretz F (2006) Design and analysis of dose finding studies 
combining multiple comparisons and modeling procedures. Journal of Biopharmaceutical 
Statistics; 16(5): 639-56.
Pinheiro J, Bornkamp B, Glimm E, et al (2014) Model-based dose finding under model 
uncertainty using general parametric models. Statistics in Medicine; 33(10): 1646-661.
Rosenstock J and Ferrannini E (2015) Euglycemic diabetic ketoacidosis: a predictable, 
detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care; 38:1638–
1642
References are available upon request.
13
Appendix 1: clinically notable laboratory values and vital 
signs
Vital signs range deviations are defined as per Table 13-1.


Novartis
Confidential
Page 72
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Table 13-1
Vital signs notable range deviations
Vital sign
Notable abnormalities
Pulse (beats/min)
either 120 + increase25* or > 130
either 50 + decrease30* or < 40 
BP (mmHg)
systolic
either 180 + increase30* or > 200
either 90 + decrease30* or < 75
diastolic
either 105 + increase20* or > 115
either 50 + decrease20* or < 40
* Refers to post-BL value as compared to BL value.
14
Appendix 2: liver event and laboratory trigger definitions 
and follow-up requirements
Table 14-1
Liver event and laboratory trigger definitions
Definition/ threshold
Liver laboratory triggers

3 × ULN < ALT/AST 5 x ULN

1.5 x ULN < total bilirubin 2 x ULN
Liver events

ALT or AST > 5 × ULN

ALP > 2 × ULN (in the absence of known bone pathology)

Total bilirubin > 2 × ULN (in the absence of known Gilbert 
syndrome)

ALT or AST > 3 × ULN and INR > 1.5 

Potential Hy’s law cases (defined as ALT or AST > 3 × ULN and 
total bilirubin > 2 × ULN [mainly conjugated fraction] without 
notable increase in ALP to > 2 × ULN)

Any clinical event of jaundice (or equivalent term)

ALT or AST > 3 × ULN accompanied by (general) malaise, fatigue, 
abdominal pain, nausea, or vomiting, or rash with eosinophilia

Any AE potentially indicative of a liver toxicity (these events cover 
the following: hepatic failure, fibrosis and cirrhosis, and other liver 
damage-related conditions; the non-infectious hepatitis; the 
benign, malignant and unspecified liver neoplasms)
Table 14-2
Follow up requirements for liver events and laboratory triggers
Criteria
Actions required
Follow-up monitoring
Potential Hy’s law 
casea

Discontinue the study treatment 
immediately

Hospitalize, if clinically appropriate

Establish causality

Complete liver eCRF (see Section 7.3)
ALT, AST, total bilirubin, albumin, 
prothrombin time (PT)/international 
normalized ratio (INR), ALP and γ-GT 
until resolutionc (frequency at 
investigator discretion)
ALT or AST
> 8 × ULN

Discontinue the study treatment 
immediately

Hospitalize if clinically appropriate

Establish causality

Complete liver eCRF (see Section 7.3)
ALT, AST, total bilirubin, albumin, 
PT/INR, ALP and γ-GT until resolutionc
(frequency at investigator discretion)
> 3 × ULN and INR > 

Discontinue the study treatment 
ALT, AST, total bilirubin, albumin, 


Novartis
Confidential
Page 73
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
Criteria
Actions required
Follow-up monitoring
1.5
immediately

Hospitalize, if clinically appropriate

Establish causality

Complete liver eCRF (see Section 7.3)
PT/INR, ALP and γ-GT until resolutionc
(frequency at investigator discretion)
> 5 to ≤ 8 × ULN

Repeat LFT within 48h

If elevation persists, continue follow-up 
monitoring

If elevation persists for more than 2 
weeks, discontinue the study drug

Establish causality

Complete liver eCRF (see Section 7.3)
ALT, AST, total bilirubin, albumin, 
PT/INR, ALP and γ-GT until resolutionc
(frequency at investigator discretion)
> 3 × ULN 
accompanied by 
symptomsb

Discontinue the study treatment 
immediately

Hospitalize if clinically appropriate

Establish causality

Complete liver eCRF (see Section 7.3)
ALT, AST, total bilirubin, albumin, 
PT/INR, ALP and γ-GT until resolutionc
(frequency at investigator discretion)
> 3 to ≤ 5 × ULN 
(subject is 
asymptomatic)

Repeat LFT within the next week

If elevation is confirmed, initiate close 
observation of the subject
Investigator discretion
Monitor LFT within 1 to 4 weeks 
ALP (isolated)
> 2 × ULN (in the 
absence of known 
bone pathology)

Repeat LFT within 48h

If elevation persists, establish causality

Complete liver eCRF (see Section 7.3)
Investigator discretion
Monitor LFT within 1 to 4 weeks or at 
next visit
Total bilirubin (isolated)
> 2 × ULN (in the 
absence of known 
Gilbert syndrome)

Repeat LFT within 48h

If elevation persists, discontinue the study 
drug immediately

Hospitalize if clinically appropriate

Establish causality

Complete liver eCRF (see Section 7.3)
ALT, AST, total bilirubin, albumin, 
PT/INR, ALP and γ-GT until resolutionc
(frequency at investigator discretion)
Test for hemolysis (eg, reticulocytes, 
haptoglobin, unconjugated [indirect] 
bilirubin)
> 1.5 to ≤ 2 × ULN 
(subject is 
asymptomatic)

Repeat LFT within the next week

If elevation is confirmed, initiate close 
observation of the subject 
Investigator discretion
Monitor LFT within 1 to 4 weeks or at 
next visit
Jaundice

Discontinue the study treatment 
immediately

Hospitalize the subject

Establish causality

Complete liver eCRF (see Section 7.3)
ALT, AST, total bilirubin, albumin, 
PT/INR, ALP and γ-GT until resolutionc
(frequency at investigator discretion)
Any AE potentially 
indicative of a liver 
toxicityd

Consider study treatment interruption or 
discontinuation 

Hospitalization if clinically appropriate

Establish causality

Complete liver eCRF (see Section 7.3)
Investigator discretion
a Elevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN.
b (General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia.
c Resolution is defined as an outcome of one of the following: (1) return to BL values, (2) stable values at three subsequent 
monitoring visits ≥2 weeks apart, (3) remain at elevated level after a max. of 6 months, (4) liver transplantation, and (5) death.
d These events cover hepatic failure, fibrosis and cirrhosis, and other liver damage-related conditions; the non-infectious 
hepatitis; the benign, malignant and unspecified liver neoplasms.


Novartis
Confidential
Page 74
Clinical Study Protocol v01 (clean)
Protocol No. CLIK066B2201
15
Appendix 3: specific renal alert criteria and actions
Table 15-1
Specific renal alert criteria and actions
Criteria
Action required
Serum event
Serum creatinine increase
25 – 49 % compared to BL
Confirm 25 % increase after 24-48h 
Follow up within 2-5 days
Acute kidney injury: serum creatinine increase 50 %
compared to BL
Follow up within 24-48h if possible
Consider study treatment interruption 
Consider subject hospitalization /specialized treatment
Urine event
New dipstick proteinuria ≥1+
Albumin- or protein-creatinine ratio increase ≥2-fold
Albumin-creatinine ratio (ACR) ≥30 mg/g or 
≥3 mg/mmol;
Protein-creatinine ratio (PCR )≥150 mg/g 
or >15 mg/mmol
Confirm value after 24 to 48-h
Perform urine microscopy
Consider study treatment interruption / or discontinuation 
New dipstick hematuria ≥1+ not due to trauma
Urine sediment microscopy
Perform serum creatinine, ACR 
For all renal events
Document contributing factors in the eCRF (see Section 7.4): co-medication, other co-morbidity conditions, and 
additional diagnostic procedures performed.
Monitor subject regularly (frequency at investigator’s discretion) until either: 

event resolution: serum creatinine within 10 % of BL or protein-creatinine ratio within 50 % of BL, or

event stabilization: serum creatinine level with ±10 % variability over last 6 months or protein-creatinine 
ratio stabilization at a new level with ±50 % variability over last 6 months.

SAP_001.pdf: 
Clinical Development 
LIK066 
CLIK066B2201 / NCT03100058 
A randomized, double-blind, dose-finding study to evaluate 
the change in weight after 24 weeks treatment with 8 doses 
of LIK066 compared to placebo in obese or overweight 
adults, followed by 24 weeks treatment with 2 doses of 
LIK066 and placebo 
Statistical Analysis Plan (SAP) 
Author: 
 
Document type: 
SAP Documentation 
Document status: 
Amendment 2 
Release date: 
15-Aug-2018
Number of pages: 
46 
Property of Novartis 
For business use only 
May not be used, divulged, published or otherwise disclosed 
without the consent of Novartis 


Novartis 
For business use only 
Page 2 
SAP 
 
CLIK066B2201 
 
Document History – Changes compared to previous final version of SAP 
Date 
Time point 
Reason for update 
Outcome for update 
Section and 
title impacted 
(Current) 
Apr 12, 2017 
Before DBL 
Prohibited medication list 
was updated to align with 
the protocol 
More prohibited medications 
are included.  
Table 2-2 
Apr 12, 2017 
Before DBL 
Updates on PK analyses 
included in the CSR TFLs.  
More PK parameters are 
included. 
Section 2.10 
Jun 06, 2017 
Before DBL 
Stratification variable was 
missing from the statistical 
model. 
Stratification variable was 
added. 
Section 2.7.2.1 
 
Jun 27, 2017 
Before DBL 
Updated 
the 
repeated 
ANCOVA model planned 
for the subgroup analysis 
A simpler statistical model 
used for the subgroup by 
glycemic status analysis  
Section 2.7.2.1 
Jun 27, 2017 
Before DBL 
Updated planned analyses 
for diarrhea events 
Negative 
binomial 
model 
were to be used for the 
analysis of diarrhea events on 
treatment 
Section 2.8.1.1 
Jul 18, 2017 
Before DBL 
Baseline definition was 
updated 
Both 
scheduled 
and 
unscheduled assessments are 
included 
for 
baseline 
consideration. 
Section 2.1.1 
Sep 21, 2017 
Before DBL 
Project 
standard 
hypoglycemia 
analysis 
was updated. 
Hypoglycemic 
events 
of 
special interest will also be 
summarized by third party 
assistance received 
Section 2.8.1.1 
Sep 25, 2017 
Before DBL 
Baseline definition was 
updated  
Clearly defined the baselines 
for 
different 
analysis 
conducted at Epoch 3 and 4, 
respectively 
Section 2.1.1 
Sep 28, 2017 
Before DBL 
Treatment 
interruption 
was better defined.  
Treatment interruptions were 
defined for QD, BID and 
placebo arms, respectively.  
Section 2.4.1 
Sep 28, 2017 
Before DBL 
Unblinding after Epoch 3 
need to be addressed 
Detailed unblinding plan for 
Week 24 analysis was added. 
Section 5.6 
Oct 20, 2017 
Before DBL 
Anti-diabetic medications 
at BL was updated 
GLP-1 analogues and SGLT2 
inhibitors were dropped, and 
anti-diabetic medication at BL 
will be analyzed by glycemic 
status 
Section 2.4.2 
Oct 26, 2017 
Before DBL 
ECG normal and abnormal 
criteria was missing   
ECG normal and abnormal 
criteria was defined 
Section 2.8.5 


Novartis 
For business use only 
Page 3 
SAP 
 
CLIK066B2201 
 
Date 
Time point 
Reason for update 
Outcome for update 
Section and 
title impacted 
(Current) 
Nov 9, 2017 
Before DBL 
Project-wise updates for 
PPS definition  
PPS included only patients on 
treatment for at least 22 weeks 
Section 2.2 
Nov 9, 2017 
Before DBL 
Project-wise updates for 
supportive analysis of the 
primary endpoint 
On-treatment data will be 
used for the primary endpoint 
analysis 
Section 2.5.2 
Nov 13, 2017 
Before DBL 
Project-wise updates for 
hypoglycemia analysis 
Clinically significant hypo 
events were defined and the 
way of reporting were updated 
Section 2.8.1.1 
Section 5.2 
Dec 4, 2017 
Before DBL 
New PD on life style 
(weight gain>=2kg during 
run in) was added 
The new PD need to be 
excluded from PP set 
Table 5.2 and 
5.3 
Jan 18, 2017 
Before DBL 
Single best fit model is 
less robust 
Single best dose response 
model fit was removed from 
reporting 
Section 2.5.4 
Jan 25, 2017 
Before DBL 
Updated 
multiple 
imputation algorithm 
MCMC 
was 
being 
implemented. 
Section 2.5.3 
Feb 14, 2018 
Before DBL 
Updated Non-PD criteria 
to exclude subjects from 
analysis set 
Not having informed consent 
was removed from Non-PD 
criteria because it was a PD 
Section 5.4 
Feb 14, 2018 
Before DBL 
Updated description on 
PD listing.  
The final PDs for the study 
will be exactly the same as 
Table 5-2 and Table  5-3  
Section 2.2 
Feb 14, 2018 
Before DBL 
Model averaging to obtain 
the dose responses for qd 
and bid dosing regimens 
was updated 
A parametric bootstrap-based 
model averaging approach 
was being implemented 
Section 2.5.2 
Mar 22, 2018 
Before DBL 
Clarified AEs included in 
the analyses   
Updated 
definitions 
for 
treatment emergent AEs and 
defined on-treatment AEs 
Section 2.8.1 
Mar 22, 2018 
Before DBL 
Updated AE listings for 
reporting 
Removed AE listings for 
Week 24 analysis, and added 
for overall analysis 
Section 2.8.1 
May 11, 2018 
Before DBL 
Reduced the final outputs 
because of the Week 24 IA 
results 
and 
updated 
duration 
of 
exposure 
categories 
for 
EoS 
analysis as per decision at 
the TFL review meeting 
Removed subgroup analysis, 
rescue 
medication, 
and 
treatment 
interruption 
for 
overall treatment period for 
the 
EoS 
analysis, 
and 
categories of duration were 
updated as per TFL.  
Section 1.2 
Section 2.4.1 
Section 2.4.2 
Section 2.7.2.2 
Section 2.13 
May 17, 2018 
Before DBL 
Updated treatment arms in 
the safety analysis 
For safety analysis other than 
AE listings only 4 actual 
treatment arms to be used 
Section 2.1.1 
 
 
 
 
 


Novartis 
For business use only 
Page 4 
SAP 
 
CLIK066B2201 
 
Table of contents 
Table of contents ................................................................................................................. 4 
List of abbreviations ............................................................................................................ 6 
1 
Introduction ......................................................................................................................... 7 
1.1 
Study design............................................................................................................. 7 
1.2 
Study objectives and endpoints ............................................................................... 8 
2 
Statistical methods ............................................................................................................. 10 
2.1 
Data analysis general information ......................................................................... 10 
2.1.1 
General definitions ................................................................................ 10 
2.2 
Analysis sets .......................................................................................................... 12 
2.2.1 
Subgroup of interest .............................................................................. 12 
2.3 
Patient disposition, demographics and other baseline characteristics ................... 13 
2.3.1 
Demographics and other baseline characteristics ................................. 13 
2.3.2 
Patient disposition ................................................................................. 14 
2.4 
Treatments (study treatment, rescue medication, concomitant therapies, 
compliance) ............................................................................................................ 15 
2.4.1 
Study treatment / compliance ................................................................ 15 
2.4.2 
Prior, concomitant and post therapies ................................................... 16 
2.5 
Analysis of the primary objective .......................................................................... 18 
2.5.1 
Primary endpoint ................................................................................... 18 
2.5.2 
Statistical hypothesis, model, and method of analysis .......................... 18 
2.5.3 
Handling of missing values/censoring/discontinuations ....................... 21 
2.5.4 
Supportive analyses ............................................................................... 21 
2.6 
Analysis of the key secondary objective ............................................................... 21 
2.7 
Analysis of secondary efficacy objective(s) .......................................................... 21 
2.7.1 
Secondary endpoints ............................................................................. 21 
2.7.2 
Statistical model and method of analysis .............................................. 22 
2.7.3 
Handling of missing values/censoring/discontinuations ....................... 24 
2.8 
Safety analyses ....................................................................................................... 24 
2.8.1 
Adverse events (AEs) ............................................................................ 24 
2.8.2 
Deaths .................................................................................................... 29 
2.8.3 
Laboratory data ..................................................................................... 29 
2.8.4 
Vital signs.............................................................................................. 30 
2.8.5 
ECG ....................................................................................................... 31 
2.8.6 
Liver events ........................................................................................... 32 
2.8.7 
Renal events .......................................................................................... 33 
2.9 
Pharmacokinetic endpoints .................................................................................... 34 


Novartis 
For business use only 
Page 5 
SAP 
 
CLIK066B2201 
 
2.10 
PK analyses ............................................................................................................ 34 
 
 34 
2.12 
Biomarkers ............................................................................................................. 36 
 
37 
2.14 
Interim analysis ...................................................................................................... 37 
3 
Sample size calculation ..................................................................................................... 38 
4 
Change to protocol specified analyses .............................................................................. 39 
5 
Appendix ........................................................................................................................... 40 
5.1 
Imputation rules ..................................................................................................... 40 
5.1.1 
Study drug ............................................................................................. 40 
5.1.2 
AE date imputation ............................................................................... 40 
5.1.3 
Concomitant medication date imputation ............................................. 41 
5.2 
AEs coding/grading ............................................................................................... 42 
5.3 
Laboratory parameters derivations ........................................................................ 42 
5.4 
Rule of exclusion criteria of analysis sets.............................................................. 43 
5.5 
Anti-diabetic medications search criteria .............................................................. 44 
6 
Reference ........................................................................................................................... 46 


Novartis 
For business use only 
Page 6 
SAP 
 
CLIK066B2201 
 
List of abbreviations 
AE 
adverse event 
ANCOVA 
analysis of covariance 
ATC 
anatomical therapeutic classification 
AUC 
area under the curve 
bid 
bis in diem/twice a day 
BL 
baseline 
BMI 
body mass index 
CSR 
clinical study report 
CTC 
common toxicity criteria 
CTCAE 
common terminology criteria for adverse events 
DB 
database 
DBP 
diastolic blood pressure 
DMC 
data monitoring committee  
DSPP 
development safety profiling plan 
FAS 
full analysis set 
FPG 
fasting plasma glucose 
eCRF 
electronic case report form 
 
 
HbA1c 
hemoglobin A1c 
hsCRP 
high sensitivity C-reactive protein 
IVR 
interactive voice response 
IWR 
interactive web response 
LOCF 
last observation carry forward 
LS 
least squares 
MedDRA 
medical dictionary for drug regulatory affairs 
o.d. 
once daily 
OS 
overall survival 
PFS 
progression-free survival 
PK 
pharmacokinetics 
PPS 
per-protocol set 
 
 
qd 
qua’que di’e / once a day 
 
 
RAP 
report and analysis process 
RECIST 
response evaluation criteria in solid tumors  
SAP 
statistical analysis plan 
SBP 
systolic blood pressure 
SOC 
system organ class 
TFLs 
tables, figures, listings 
T2DM 
type 2 diabetes mellitus 
UGE 
urinary glucose excretion 
WHO 
world health organization 


Novartis 
For business use only 
Page 7 
SAP 
 
CLIK066B2201 
 
1 
Introduction 
The purpose of this document is to outline the planned analyses to be completed to support end 
of phase 2 meetings with health authorities and the completion of the clinical study report (CSR) 
for protocol CLIK066B2201.  
Note that this version of the statistical analysis plan details the statistical methodology for the 
analyses planned and agreed to at the time of finalization of the protocol version 00 (original 
protocol).  
1.1 
Study design 
This is a multi-center, randomized, double-blind, parallel-group dose-finding study evaluating 
the effect on weight, tolerability and safety of LIK066 vs placebo (see Figure 1-1). The study 
planned to randomize approximately 432 subjects in total, allocated in the ratio of 
1:1:1:1:1:2:1:1:1:2 to the following 10 Epoch 3/Epoch 4 treatment groups: 
1. placebo/placebo  
2. placebo/LIK066 25 mg qd 
3. LIK066 2.5 mg qd/25 mg qd 
4. LIK066 10 mg qd/25 mg qd 
5. LIK066 50 mg qd/25 mg qd 
6. LIK066 150 mg qd/25 mg qd 
7. LIK066 2.5 mg bid/35 mg qd 
8. LIK066 5 mg bid/35 mg qd 
9. LIK066 25 mg bid/35 mg qd 
10. LIK066 50 mg bid/35 mg qd 
The randomization will be stratified by subjects’ glycemic status at screening: normoglycemic, 
dysglycemic and type 2 diabetes mellitus (T2DM).  
There will be no interim analysis for the study. The main analysis will be performed at the end 
of Epoch 3 when all subjects complete their treatment at Week 24 after randomization and data 
collected up to and including Week 24 (Visit 299) are cleaned (referred to as “Week 24 analysis” 
in sections below). The main analysis will be summarized in a report which will be used for 
internal and external decision making and will serve as the basis of end of phase 2 discussions 
with the health authorities. 
Data collected during Epoch 4 will be analyzed after the study ends (referred to as “End of study 
analysis” in sections below). Both Week 24 analysis and end of study analysis will be presented 
in the CSR. 
 


Novartis 
For business use only 
Page 8 
SAP 
 
CLIK066B2201 
 
Figure 1-1 
Study design 
 
1.2 
Study objectives and endpoints 
Table 1-1 
 
Objectives and related endpoints 
Objective 
Endpoint 
Analysis 
Primary objective 
To determine the dose-response signal and 
assess the dose-response relationship of two 
dose regimens of LIK066 as measured by the 
percent change from baseline (BL) in body 
weight relative to placebo after 24 weeks of 
treatment 
Percent change from BL 
at Week 24 in body 
weight  
Section 2.5.2 
Secondary objectives 
To assess the responder rates according to 
percent decrease in body weight either ≥5% or 
≥10%, from BL at Week 24, for the overall 
population 
and 
each 
of 
the 
subgroups 
(normoglycemic subjects, dysglycemic subjects, 
and subjects with T2DM) 
Proportion of patients 
with 
percent 
change 
from BL at Week 24 in 
body weight: 
• ≤ - 5% 
• ≤ - 10% 
Section 
2.7.2.1 
To assess the dose-response relationship for 
weight 
loss 
in 
normoglycemic 
subjects, 
dysglycemic subjects and subjects with T2DM 
after 24 weeks of treatment 
Percent change from BL 
at Week 24 in body 
weight  
Section 
2.7.2.1 
To evaluate the effect of all LIK066 doses and 
regimens vs placebo for the overall population 
Change from BL at 
Week 24 in:  
Section 
2.7.2.1 
Run-in
50 mg qd
2.5 mg qd
2.5 mg bid
150 mg qd
10 mg qd
25 mg bid
50 mg bid
Placebo
Epoch 2
Epoch 3
Epoch 4
4 weeks
24 weeks
24 weeks
2 wks
Epoch 1: Screening (n = ~600)
V1
V101
V202
V203
V204
V205
V206
V302
V303
V304
V399
Randomization (n=432)
25 mg qd
35 mg qd
25 mg qd or placebo qd
5 mg bid
V299 & V301
V199 & V201


Novartis 
For business use only 
Page 9 
SAP 
 
CLIK066B2201 
 
and by subgroups after 24 weeks of treatment 
on: 
• Waist circumference 
• Change from BL in glycated hemoglobin 
A1c (HbA1c) 
• Change from BL in fasting plasma 
glucose (FPG) 
• Changes in systolic blood pressure 
(SBP) and diastolic blood pressure 
(DBP) 
• Percent changes in the fasting lipid 
profile and high sensitivity C-reactive 
protein (hsCRP)  
• 24-h urinary glucose excretion (UGE) in 
a subset of subjects 
• Waist circumference 
• HbA1c 
•  FPG 
• SBP and DBP 
• 24-h UGE 
Percent change from BL 
at Week 24 in: 
• Lipid parameters 
• log10 
transformed 
hsCRP 
 
To evaluate the change in weight and other 
efficacy parameters listed above in the overall 
population by LIK066 treatment vs placebo 
between Week 24 and Week 48 
Change from Week 24 at 
Week 48 in efficacy 
parameters listed above 
Section 
2.7.2.2 
To evaluate safety (adverse events (AEs) and 
laboratory parameters) and tolerability of 
LIK066 over 24 weeks of treatment and over 48 
weeks of treatment for all subjects 
Safety outcomes include: 
• AEs/SAEs 
• Death 
• Laboratory data 
• Vital signs 
• ECG 
• Liver events 
• Renal events 
• Bone 
and 
renal 
biomarkers 
 
 
Section 2.8.1 
Section 2.8.2 
Section 2.8.3 
Section 2.8.4 
Section 2.8.5 
Section 2.8.6 
Section 2.8.7 
Section 2.12 
To evaluate AEs of interest and laboratory data 
in subjects treated with LIK066 25 mg qd, 
35 mg qd or placebo between Week 24 and 
Week 48 (during Epoch 4) 
 AE of special interest, 
diarrhea, 
ketoacidosis, 
hypoglycemic event, etc. 
Section 2.8.1 
 
To 
evaluate 
24-h 
urinary 
calcium 
and 
phosphorus excretion after 24 weeks of 
treatment and after 48 weeks of treatment in a 
subset of subjects 
Change from BL at 
Week 24 and at Week 48 
in 
the 
24-h 
urinary 
calcium and phosphorus 
excretion 
Section 2.8.3 
 


Novartis 
For business use only 
Page 10 
SAP 
 
CLIK066B2201 
 
To evaluate the pharmacokinetics (PK) of 
LIK066 
• Concentration 
• Lapsed time 
Section 2.10 
2 
Statistical methods 
2.1 
Data analysis general information 
Data will be analyzed by Novartis according to the data analysis Section 9 of the study protocol. 
Important information is given in the following sections and details are provided, as applicable, 
in Appendix 16.1.9 of the CSR. SAS Version 9.4 or higher will be used to perform all the 
statistical analyses in the report.  
Unless otherwise stated, summary tables/figures/listings will be on all subjects included in the 
population under consideration.  
In general, for continuous data, mean, standard deviation, median, lower quartile, upper quartile, 
minimum, and maximum will be presented. Categorical data will be presented as frequencies 
and percentages of patients in each category. For categorical variable summaries, an additional 
category ‘Missing’ will be presented if there are missing values for that variable. 
If not otherwise specified, p-values will be presented for two-sided hypothesis testing and two-
sided confidence intervals will be displayed; the level of significance will be 5% unless 
otherwise stated.  
2.1.1 
General definitions  
Baseline (Week 0) for Week 24 analysis and overall analysis including both Epoch 3 and Epoch 
4 data will be defined as the last measurement before or at the randomization visit. Baseline for 
End of study analysis including Epoch 4 data only will be defined as the last measurement in 
Epoch 3.  
The first day of administration of randomized study treatment (first dose) is defined as Day 1 
for the study. If the date of first administration is missing, then randomization date will be used 
as Day 1.  


Novartis 
For business use only 
Page 11 
SAP 
 
CLIK066B2201 
 
All other study days will be labeled relative to Day 1. For event dates on or after Day 1, study 
day for a particular event date is calculated as [Date of event] – [Date of first dose] + 1. For the 
dates before Day 1, study day for an event date is calculated as [Date of event] – [Date of first 
dose]. Duration of an event will be calculated as [Event end date] – [Event start date] + 1. The 
descriptor “Day 0” will not be used.   
For Week 24 analysis, the treatment groups presented are: 
• LIK066 2.5 mg qd 
• LIK066 10 mg qd 
• LIK066 50 mg qd 
• LIK066 150 mg qd 
• LIK066 2.5 mg bid 
• LIK066 5 mg bid 
• LIK066 25 mg bid 
• LIK066 50 mg bid 
• Placebo 
• Total (if applicable) 
For End of study analysis, unless specified otherwise, the following treatment grouping strategy 
will be used, expressed as per the Epoch 3 treatment/Epoch 4 treatments a subject is assigned 
to at randomization: 
• LIK066 qd any dose/LIK066 25 mg qd, shortened as LIK066 qd/LIK066 25  mg qd 
• LIK066 bid any dose/LIK066 35 mg qd, shortened as LIK066 bid/LIK066 35 mg qd 
• Placebo/LIK066 25 mg qd 
• Placebo/placebo, shortened as Placebo 
• Total (if applicable) 
For End of study AE listings, the 10 randomized treatments will be used, as shown in Section 
1.1 study design, along with the additional two pooled groups: 
• LIK066 qd any dose/LIK066 25 mg qd, shortened as LIK066 qd/LIK066 25  mg qd 
• LIK066 bid any dose/LIK066 35 mg qd, shortened as LIK066 bid/LIK066 35 mg qd  
• Total (if applicable) 
For overall analysis including both Epoch 3 and Epoch 4 treatment, the 10 randomized 
treatment grouping strategy will be used, as shown in Section 1.1 Study design.  
For the Week 24 analyses, data collected up to the end date of Epoch 3 will be included. For 
AEs and concomitant medications, this means that events with start dates prior to the end of 
Epoch 3 dates are included.  


Novartis 
For business use only 
Page 12 
SAP 
 
CLIK066B2201 
 
2.2 
Analysis sets 
Screened set (SCR): the SCR consists of all subjects who signed the ICF. 
Randomized set (RAN): All subjects who have received a randomization number, regardless 
of receiving trial medication.  
Run-in set (RUN): All subjects who enter the run-in epoch.  
Full analysis set (FAS): the FAS comprises all subjects to whom study treatment has been 
assigned, except those who are not qualified for randomization but were inadvertently 
randomized into the study and did not take any study drug. Following the intent-to-treat 
principle, subjects will be analyzed according to the treatment assigned to at randomization. 
Safety set (SAF): the SAF includes all subjects who received at least one dose of study 
medication. Subjects will be analyzed according to treatment received. Note that the safety set 
allows the inclusion of non-randomized subjects who received the study drug in error.  
Per-protocol set (PPS): the PPS is a subset of the FAS. It consists of all randomized subjects 
in the FAS who have been exposed to study medication for at least 22 weeks and have no major 
protocol deviations (PDs) affecting the primary endpoint analysis.  
Randomized set – Epoch 4 (RAN-Epoch 4): all randomized subjects who have been assigned 
a treatment in Epoch 4. 
Full analysis set – Epoch 4 (FAS-Epoch 4): all RAN-Epoch 4 subjects, excluding those who 
did not take any Epoch 4 study medication.  
Safety set – Epoch 4 (SAF-Epoch 4): all SAF subjects who received at least one dose of Epoch 
4 study medication.  
Protocol deviations will be pre-specified prior to un-blinding treatment codes for analyses. See 
Appendix Table 5-2 and Table 5-3 for list of protocol deviations and criteria that lead to 
exclusion from analysis sets, and related rules of exclusion criteria of analysis sets.  
2.2.1 
Subgroup of interest 
Subgroups of interest include: 
• Glycemic status (dysglycemic, normoglycemic, and T2DM) 
• Age (<65, ≥65) 
• Sex (Male, Female) 
• BMI (<30, ≥30; <35, ≥35) 
• Region (North America, Europe) 
Table 2-1 provides an overview of how subgroups are defined/derived and what type of analyses 
may be performed. Details are specified in relevant sections below. 
 


Novartis 
For business use only 
Page 13 
SAP 
 
CLIK066B2201 
 
Table 2-1 
Specification of subgroups 
Subgroup 
Method of 
derivation 
Disposition/ Background & 
Demographics / Exposure 
Efficacy 
Safety 
Glycemic status (dysglycemic, 
normoglycemic, and T2DM) 
Screening  
X 
X 
X 
Age groups:  
(<65, ≥65 years) 
Screening 
(derived) 
 
X 
X 
Sex (Male/Female) 
Screening 
 
X 
X 
BMI (<30, ≥30; <35, ≥35) 
Baseline 
 
X 
 
Region (North America, 
Europe)* 
Screening 
(pooled 
countries) 
 
X 
 
* North America: USA and Canada; Europe: Austria, Czech Republic, Hungary, Slovakia and United Kingdom. 
2.3 
Patient disposition, demographics and other baseline 
characteristics 
2.3.1 
Demographics and other baseline characteristics 
Week 24 analysis 
Demographics, BL characteristics, disease history and medical history will be summarized 
overall (total) and by treatment group for the FAS. Descriptive statistics (mean, Q1, median, 
Q3, standard deviation, minimum and maximum) will be presented for continuous variables for 
each treatment group and for all subjects (total). The number and percentage of subjects in each 
category will be presented for categorical variables for each treatment group and all subjects 
(total). Demographics and BL characteristics will be similarly summarized by the stratification 
factor (glycemic status at screening) as well. 
Continuous variables: 
• Age  
• Height 
• Weight 
• Body mass index (BMI) 
• Waist circumference (cm) 
• Smoking pack years 
• Baseline pulse (bpm) 
• Baseline systolic blood pressure (mmHg) 
• Baseline diastolic blood pressure (mmHg) 
• Baseline HbA1c (%) 
• Baseline FPG (mg/dL) 


Novartis 
For business use only 
Page 14 
SAP 
 
CLIK066B2201 
 
• Baseline eGFR MDRD mL/min/1.73m2 
Categorical variables 
• Age category (< 65, ≥ 65) 
• Gender 
• Subjects of child bearing status (females only) 
• Race 
• Ethnicity 
• Smoking status at baseline 
• Alcohol history (0, 1, 2, >=3 drinks/day) 
• BMI (<30, ≥30; <35, ≥35) 
• Glycemic status (dysglycemic, normoglycemic, and T2DM) 
• Baseline HbA1c category (<6.5, ≥6.5 - < 8%, ≥8%) 
• Baseline eGFR MDRD category (<60, ≥60 mL/min/1.73m2) 
BMI will be calculated using the following formula: 
 
BMI = (body weight in kilograms) / (height in meters)2 
For BMI, the last value of height and body weight prior to randomization will be used.  
Medical history will be coded with the medical dictionary for regulatory activities terminology 
(MedDRA) using the most recent version at the time of database lock. The number and 
percentage of subjects with each medical condition will be provided by treatment group, 
primary system organ class, and preferred term. 
The protocol solicited medical history events (hypertension, dyslipidemia, prediabetes, sleep 
apnea, type II diabetes, bariatric surgery, lactic acidosis, urinary tract infection, myocardial 
infarction, stroke and unstable angina) will be summarized by event type, event status (yes, no, 
unknown), and treatment.  
End of study analysis 
Demographics and other BL characteristics including medical history will be similarly 
summarized for FAS subjects who enter the study Week 24 to Week 48 period (Epoch 4) as for 
the Week 24 analysis. 
2.3.2 
Patient disposition 
RAN will be used for the summary and listing of patient disposition.  
Week 24 analysis 
Based on the SCR, the number and percentage of patients screened will be presented. In addition, 
the primary reasons for screen failures will be summarized by presenting number and 


Novartis 
For business use only 
Page 15 
SAP 
 
CLIK066B2201 
 
percentage of screen failed patients by category. The number and percentage of subjects entered, 
completed, and failed in run-in will be summarized using the RUN. The reasons for run-in 
failures will be provided. The number and percentage of randomized subjects who completed 
the Epoch 3, who discontinued the Epoch 3 and the reasons for discontinuation will be presented 
for each treatment group using the RAN.  
The number of randomized subjects included in each analysis set (FAS, SAF, and PPS) will be 
presented by treatment group. The number and percentage of subjects with protocol deviations 
as well as the criteria leading to exclusion from analysis sets will be presented in separate tables 
for the RAN. Subject exclusion from analysis sets will be listed with reasons for exclusion.  
The number of randomized subjects included in each analysis set (FAS, SAF, and PPS) will 
also be presented by treatment group and glycemic status.  
End of study analysis 
The number of RAN subjects who entered Epoch 4, completed Epoch 4, and who discontinued 
Epoch 4 and the reasons for discontinuation will be presented for each treatment group.  
Subject randomization number and whether they completed or were discontinued from Epoch 
3 and/or Epoch 4 will be listed, with date of last dose and primary reason for discontinuation, 
including unblinding date if applicable, by 10 randomized treatment arms. Flags will be 
included to indicate misrandomized patients and forced randomization.   
2.4 
Treatments (study treatment, rescue medication, concomitant 
therapies, compliance) 
2.4.1 
Study treatment / compliance 
Week 24 analysis 
The duration of double-blind treatment exposure in Epoch 3 will be summarized by treatment 
group both descriptively in days (mean, standard deviation, minimum, Q1, median, Q3, and 
maximum) and by duration category in weeks (≤2, >2-4, >4-8, >8-12, >12-16, >16-20, >20-24, 
and >24) for the SAF.  
• Duration of exposure (days) = last dose date of Epoch 3 – first dose date + 1 
• Duration of exposure (weeks) = (last dose date of Epoch 3 – first dose date + 1)/7 
Overall subject-years on-treatment in Epoch 3 will be reported by each treatment group. 
• Overall subject-years on-treatment = sum of duration of treatment exposure (in days) 
from all subjects / 365.25 
The duration of double-blind treatment exposure excluding treatment interruptions in Epoch 3 
will also be summarized descriptively and by duration categories as above.  
• Duration of exposure excluding treatment interruptions (days) = last dose date of Epoch 
3 – first dose date + 1– number of days of treatment interruption 
Treatment interruptions will be considered as following: 


Novartis 
For business use only 
Page 16 
SAP 
 
CLIK066B2201 
 
• For BID doses – patients taking 0 tablets for both morning and evening doses, 
• For QD doses – patients taking 0 tablets for the morning dose, 
• For Placebo – patients taking 0 tablets for both morning and evening doses.  
Number and percentage of subjects with treatment interruption and permanent treatment 
discontinuations in Epoch 3 will be provided by reason for treatment interruption or 
discontinuation. 
Duration of treatment interruption, frequency and duration of the PD after meal dose intake will 
also be summarized as appropriate.  
End of study analysis 
The duration of Epoch 4 will be summarized by treatment group both descriptively in days and 
by duration-category in weeks (≤4, >4-12, >12-24, and >24) for subjects in the safety set who 
enter the study Week 24 to Week 48 period (Epoch 4), respectively.  
• Epoch 4 duration of exposure (days) = last dose date – first dose date of Epoch 4 + 1  
• Epoch 4 duration of exposure (weeks) = (last dose date – first dose date of Epoch 4 + 
1)/7  
Duration of treatment interruption, frequency and duration of PD after meal dose intake will 
also be summarized as appropriate. 
The duration of overall treatment period (Epoch 3 + Epoch 4) will also be summarized by 10 
randomized arms both descriptively in days and by duration-category in weeks (≤4, >4-12, >12-
24, >24-36, >36-48, and >48), respectively.  
• Overall duration of exposure (days) = last dose date – first dose date + 1  
• Overall duration of exposure (weeks) = (last dose date – first dose date + 1)/7 
Number and percentage of subjects with treatment interruption and permanent treatment 
discontinuations in overall treatment period will be provided by reason for treatment 
interruption or discontinuation. Frequency and duration of PD after meal dose intake will be 
included for reporting as well.  
2.4.2 
Prior, concomitant and post therapies 
Week 24 analysis 
Prior medications are defined as any drugs taken and stopped prior to the first dose of study 
medication. Concomitant medications for Epoch 3 are any medications given at least once 
between the day of first dose of double-blind study medication and the end of Epoch 3, 
including those which started pre-BL and continued into the treatment period.  
The number and percentage of subjects receiving prior and concomitant medications will be 
summarized by treatment group and overall in the SAF in separate tables by therapeutic class 
and preferred term.  


Novartis 
For business use only 
Page 17 
SAP 
 
CLIK066B2201 
 
The number and percentage of subjects taking rescue medication, and duration of exposure to 
rescue medication during Epoch 3 will be summarized by treatment group. 
The number and percentage of subjects on anti-diabetic medications at BL (randomization visit) 
will be summarized by treatment, glycemic status, and medication types: 
• Any anti-diabetic medication (insulin or OADs) 
• Insulin 
• OADs (used as single pills) 
o Metformin 
o SU - Sulfonylureas (including Sulfonamides) 
o AGIs 
o TZDs 
o DPP-4 inhibitors 
• Combination of OADs 
o Phenformin + SU 
o Metformin + SU 
o Metformin + TZD 
o SU + TZD 
o Metformin + DPP-4i 
o Metformin + AGI 
o DPP-4i + TZD 
• Other 
The search criteria for the anti-diabetic medications by type are included in the appendix. 
The use of prohibited medications, defined in Table 2-2 below, will also be summarized.  
Table 2-2 
Prohibited medication for reporting 
Prohibited Medication  
Drug record No. or ATC 
Clarithromycin 
00984601 
Telithromycin 
01548701 
Itraconazole 
00780701 
Ketoconazole 
00532501 
Voriconazole 
01510101 
Posaconazole 
01762801 
Probenecid 
00045101 
Valproic Acid 
00228501 
Mefenamic Acid 
00044201 
SGLT2 inhibitors 
A10BK 


Novartis 
For business use only 
Page 18 
SAP 
 
CLIK066B2201 
 
Prohibited Medication  
Drug record No. or ATC 
GLP-1 receptor agonists 
A10BJ 
Weight loss medication 
A08A 
End of study analysis 
Concomitant medications for Epoch 4 are any medications given at least once between the start 
and the end of Epoch 4, including those which started before and continued into Epoch 4. 
Concomitant medications subjects take during Epoch 4 will be similarly summarized for 
subjects in SAF who enter Epoch 4. 
2.5 
Analysis of the primary objective 
2.5.1 
Primary endpoint 
The primary analysis variable is the percent change in body weight (kg) from BL at Week 24. 
BL is defined as the last body weight value measured prior to or at the randomization visit (Visit 
201). The analysis will be carried out on the FAS, with missing Week 24 values imputed as 
described in section 2.5.3.  
2.5.2 
Statistical hypothesis, model, and method of analysis 
The objective of determining a dose response signal and dose-response relationship in either qd 
or bid dosing regimen compared to placebo will be evaluated using an optimally weighted 
contrast test following the methodology described in Pinheiro et al. (2006) and Pinheiro et al. 
(2014). To this end, a candidate model set is defined corresponding to the range of expected 
mean response in each of the dosing regimen. The candidate model set is used to generate a set 
of weights for the calculation of optimal contrasts between the responses in the studied dose 
groups and the placebo group. A statistical test comparing all doses in the different dosing 
regimens simultaneously to the control group is used, hence a multiplicity adjustment is applied 
that accounts for the multiple possible dose response behavior considered as well as the 
common placebo between the dosing regimens. A critical value is derived from a multivariate 
t-distribution using the correlation matrix induced by the correlations between the weights 
corresponding to the candidate sets as well as the correlation between the tests of shapes in the 
dosing regimens to the common placebo group.  
Test of the dose response signal  
The null hypothesis of a flat dose-response relationship for the percentage reduction in body 
weight compared to placebo will be tested at a one-sided significance level of 2.5% against the 
alternative hypothesis of a dose-response relationship leading to a significant decrease in 
percent body weight.  
Hence, the following null and alternative hypotheses will be tested: 
• 
H01: there is no dose-response relationship for LIK066 given qd  
• 
H11: there is a dose-response relationship for LIK066 given qd 
• 
H02: there is no dose-response relationship for LIK066 given bid 


Novartis 
For business use only 
Page 19 
SAP 
 
CLIK066B2201 
 
• 
H12: there is a dose-response relationship for LIK066 given bid 
Given that we suspect the dose-response may behave differently between qd and bid regimens 
based on the data we have seen from the proof-of-concept study LIK066X2201, we define 
separate sets for the dose-response candidate models for each dosing regimen. In order to 
preserve the family-wise error rate at one-sided significance level of 2.5%, the optimal contrasts 
derived from the model candidate set for each dosing regimen will be individually compared to 
the critical value derived using a multiplicity adjustment accounts for all tests of comparing 
LIK066 doses to placebo across regimens simultaneously as described above. The rejection of 
the null hypothesis for each dosing regimen will be achieved using the maximum test statistic 
in each dosing regimen from each estimated contrast test in the candidate set.  
The candidate models generating the contrast weights are described in table 2-3 and depicted 
in Figure 2-1, with the doses used to define parameters of interest being defined as total daily 
dose.  
The analysis to derive the test statistics is based on an analysis of covariance (ANCOVA) model 
with the percent change in body weight from BL to Week 24 as a response variable, treatment 
(placebo and all LIK066 doses from each regimen), stratum indicator (dysglycemic/ 
normoglycemic/T2DM) and region as factors and BL weight as a covariate. Centers will be 
pooled according to country and region for the purpose of analysis.  
Table 2-3 
Candidate dose-response models in consideration 
# 
Candidate models for qd regimen 
Candidate models for bid regimen 
1 
Emax model: ED50 = 5 mg 
Emax model: ED50 = 5 mg 
2 
Emax model: ED50 = 50 mg 
Emax model: ED50 = 50 mg 
3 
Sigmoid Emax: ED50 = 75 mg, H = 3.5 
Sigmoid Emax: ED50 = 75 mg, H = 3.2 
4 
Sigmoid Emax: ED50 = 25 mg, H = 0.7 
Linear log-dose: null, c = 0.8 
5 
β-model: α = 0.8, β = 0.2, scale = 180 
Linear 
6 
Exponential: λ = 125 
Quadratic: δ = -0.007 
Figure 2-1 
Dose-response curve of candidate models (left panel: qd regimen) 
 
 
 
 
 
 
 
 
 


Novartis 
For business use only 
Page 20 
SAP 
 
CLIK066B2201 
 
The response variable of percent change in body weight from BL to Week 24 used in the above 
ANCOVA is from an imputed dataset, where the missing Week 24 weight is imputed using the 
multiple imputation method as described in Section 2.5.3. In order to account for the imputation 
uncertainty, this ANCOVA model will be repeated for each imputed dataset, which results in a 
set of least squares (LS) mean estimates for all dose groups for the two regimens and the related 
covariance matrices. Rubin’s rule will be used to combine the multiple sets of LS mean 
estimates and the related covariance matrices to a single set of LS mean estimates of percent 
changes of body weight as Week 24 for all dose groups and the related covariance matrix.  
The optimal contrasts derived from the candidate model sets will be applied to the combined 
estimated dose means and covariance matrix to obtain the t statistics for each candidate model 
in the two regimens and the common critical value C0.025. C0.025 is the common critical model 
derived from the reference multivariate t-distribution with the 12 × 12 correlation matrix 
induced by testing the candidate dose response models with respect to comparing all candidate 
models in both dosing regimens to the common placebo group.  
The intersection hypotheses H01 and H02 will be rejected and the statistical significant of dose-
response in body weight reduction established if the max (t1, t2, t3, …, t11, t12) ≥ C0.025. In 
other words, the intersecting null hypothesis requires the rejection of either H01 or H02.  
Model averaging to obtain the dose responses for qd and bid dosing regimens 
A parametric bootstrap-based model averaging approach will be implemented to obtain the dose 
response estimates for qd and bid dosing regimens according to the following steps: 
1. The parametric bootstrap procedure will draw a sample of mean percent changes in body 
weight from baseline to Week 24 for all doses (including placebo) from a multivariate 
normal distribution, with mean and covariance matrix was determined using Rubin’s 
rule, as described earlier. This sample corresponds to the mean response for each dose 
(including placebo). 
2. Model selection will be performed as follows: general dose-response models as 
specified in Table 2-3 will be fit to this bootstrap sample for qd and bid regimen 
separately, i.e. Emax, Sigmoid Emax, β-model and Exponential model will be fit to 
mean response data from placebo and qd doses, and Emax, Sigmoid Emax, Linear log-
dose, Linear and Quadratic model will be fit to mean response data from placebo and 
bid doses. The best model based on the gAIC criterion will be selected for qd and bid 
regimen separately. 
3. After selecting the best models for qd and bid separately, a combined model with 
parameters corresponding to the individually selected models but with a single 
parameter for the placebo group will be fitted to the bootstrap sample, i.e. the sampled 
mean responses for all doses (including placebo).  
4. The dose response estimate will be calculated for each dose group, including placebo, 
using this combined model. The difference in estimated dose response between each 
dose and placebo will also be calculated. The target doses of interest in each dosing 
regimen will be calculated based on this common model as well. 


Novartis 
For business use only 
Page 21 
SAP 
 
CLIK066B2201 
 
5. The above procedure (steps 1-4) will be repeated 5,000 times. The mean dose-response 
estimates by dose group and mean differences of dose-response estimates between each 
LIK dose and placebo, the target doses of interest, as well as their 95% confidence 
intervals will be calculated based on the quantiles (median, 2.5th and 97.5th percentiles) 
of these multiple sets of dose-response and target dose estimates generated in step 4. 
2.5.3 
Handling of missing values/censoring/discontinuations 
Missing data for the primary endpoint will be imputed using a multiple imputation approach 
that assumes that the missingness mechanism can be retrieved from observed data (missing at 
random; MAR). The imputation model will be fitted within each treatment and stratum, using 
MCMC method, based on the longitudinal sequence of body weight data collected at each visit 
up to and including Week 24. 
2.5.4 
Supportive analyses 
As a sensitivity analysis, the dose-response modeling as described in Section 2.5.2 will be 
conducted in the PPS as well. In addition, the same dose-response modeling will be conducted 
in the FAS using on-treatment weight data only. On-treatment data refer to those collected 
during the double-blind period, and prior to or within 7 days of the final study medication intake 
date in Epoch 3.  
Summary statistics for body weight will be presented by visit and treatment for observed and 
imputed values. The summary statistics n, mean, standard deviation, median, minimum, 
maximum, Q1 and Q3 will be presented for the BL values and similarly for absolute values at 
post-BL and percent changes from BL to the post-BL visits. Summary statistics for body weight 
will also be presented by visit and treatment for observed values by subgroups of interest: age 
group, gender, BMI categories and region. 
Figures will be produced to visually show the raw and the imputed mean percent changes as 
well as the estimated mean percent changes from the dose response modeling by visit over 24 
weeks of Epoch 3 for each treatment group.  
In addition, the individual patients’ percent change in body weight from BL at Week 24 will be 
depicted by waterfall plot as appropriate. 
2.6 
Analysis of the key secondary objective 
There is no key secondary objective for the study. 
2.7 
Analysis of secondary efficacy objective(s) 
2.7.1 
Secondary endpoints 
2.7.1.1 
Week 24 analysis variables 
• Responder rates based on percent decrease in body weight from BL at Week 24 ≥ 5 %, or 
≥ 10 %. 
• Dose-response relationship in normoglycemic subjects, dysglycemic subjects and subjects 
with T2DM after 24 weeks of treatment. 


Novartis 
For business use only 
Page 22 
SAP 
 
CLIK066B2201 
 
• Change from BL at Week 24 in waist circumference. 
• Change from BL at Week 24 in HbA1c. 
• Change from BL at Week 24 in FPG. 
• Change from BL at Week 24 in SBP and DBP. 
• Percent changes from BL at Week 24 in the fasting lipid profile (TG, total cholesterol, high 
density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, 
lipoproteins, calculated very low density lipoprotein (VLDL) cholesterol and non-HDL 
cholesterol). 
• Percent change from BL at Week 24 in hsCRP (log10 transformed). 
• Change from BL at Week 24 in 24-h UGE. 
2.7.1.2 
End of study analysis variables 
Changes from Week 24 to study end in each efficacy variable, body weight, FPG, HbA1c, SBP, 
DBP, lipid parameters, hsCRP (log10 transformed), 24-h UGE and waist circumference. 
2.7.2 
Statistical model and method of analysis 
All analyses on secondary variables will be performed using the FAS. 
2.7.2.1 
Week 24 analysis 
Responder analysis 
For the responder analysis, a logistic regression model will be performed using the percent 
decrease in body weight from BL at Week 24 ≥ 5% or ≥ 10% (yes/no) as a response variable, 
treatment, glycemic stratification factor and region as fixed factors and BL body weight as a 
covariate, respectively. The Week 24 missing values will be imputed using the multiple 
imputation method as described in Section 2.5.3. In order to account for the imputation 
uncertainly, this logistic regression model will be repeated for each imputed dataset, which 
results in a set of estimated odds ratio and associated 95% confidence intervals for each LIK066 
dose vs placebo contrast, for all dose groups and regimens. Rubin’s rule will be used to combine 
the multiple sets of odds ratios and 95% confidence intervals to a single set of odds ratio and 
its 95% confidence interval of an LIK066 dose vs placebo. Similar analysis by glycemic status 
stratification factor will be performed to assess the responder rate for each of the subgroups 
(normoglycemic subjects, dysglycemic subjects and subjects with T2DM). 
In addition, subjects meeting the predefined response criteria (percent decrease in body weight 
from BL at Week 24 ≥ 5 % or ≥ 10 %) will be summarized by treatment for all subjects and by 
glycemic stratification factor. A Cochran-Mantel-Haenszel-test will be performed to compare 
each qd or bid dose to the common placebo. 
Dose-response relationship by glycemic stratification factor  
For the dose-response relationship in normoglycemic subjects, dysglycemic subjects and 
subjects with T2DM, the dose-response modeling with the same candidate model sets for the 


Novartis 
For business use only 
Page 23 
SAP 
 
CLIK066B2201 
 
primary variable as described in Section 2.5.2 will be performed on percent change of body 
weight from BL at Week 24 for these three subsets of subjects separately. 
Summary statistics for body weight will be presented by visit and treatment for observed and 
imputed values by glycemic stratification factor. Figures will be produced to visually show the 
raw mean percent changes and the adjusted mean percent changes from the dose response 
modeling by visit over 24 weeks of Epoch 3 for each treatment group by glycemic stratification 
factor as well. 
Other secondary endpoints 
For changes from BL at Week 24 in HbA1c, FPG, SBP, DBP, waist circumference and 24-h 
UGE, a repeated measure ANCOVA model with treatment, visit, stratification factor 
(normoglycemic, dysglycemic, and T2DM), pooled center or region, and treatment by visit 
interaction as fixed-effect factors, BL and BL by visit interaction as covariates, and a common 
unstructured covariance matrix among visits between treatments will be performed separately 
for each variable. The adjusted mean changes at Week 24 within each treatment, the differences 
in mean changes at Week 24 between the LIK066 and placebo treatments, and their 95 % 
confidence intervals obtained from the above model will be presented. The analysis is based on 
likelihood method with an assumption of MAR for missing data. 
The same repeated measure ANCOVA model will be fitted for each stratum (normoglycemic, 
dysglycemic, and T2DM) as well, and the adjusted mean changes at Week 24 within each 
treatment, the differences in mean changes at Week 24 between the LIK066 and placebo 
treatments for each stratum, and their 95% confidence intervals obtained from the above models 
will be presented by strata for each efficacy endpoint. 
Similar repeated measure ANCOVA models will be performed for percent changes of lipid 
parameters and log10 transformed hsCRP from BL at Week 24. 
Summaries of absolute values and change from BL by treatment group and visit will be 
presented for all secondary efficacy variables for all subjects and by strata. Figures will be 
produced to visually show the raw mean changes by visit over 24 weeks of Epoch 3 for each 
treatment group, for overall and by strata separately.  
2.7.2.2 
End of study analysis  
All analyses will be performed in subjects in the FAS who enter Epoch 4. 
A repeated measure ANCOVA model with treatment, visit, pooled center or region, and 
treatment by visit interaction as fixed-effect factors, BL and BL by visit interaction as covariates, 
and a common unstructured covariance matrix among visits between treatment will be 
performed separately for the changes from Week 24 to study end in each efficacy variable (body 
weight, FPG, HbA1c, SBP, DBP, lipid parameters, hsCRP in log10 transformation, 24-h UGE 
and waist circumference). The adjusted mean changes from Week 24 to Week 48 within each 
treatment, the differences in mean changes from Week 24 to Week 48 between the LIK066 and 
placebo treatments, and their 95% confidence intervals obtained from the above models will be 
presented. The analysis is based on likelihood method with an assumption of MAR for missing 
data. 


Novartis 
For business use only 
Page 24 
SAP 
 
CLIK066B2201 
 
Note that for lipid parameters and hsCRP in log10 transformation, the percent changes (instead 
of absolute change) from Week 24 to study end will be used as a response variable in the above 
repeated measure ANCOVA model. For HbA1c and FPG, the repearted measure ANCOVA 
will be fitted for each stratum (normoglycemic, dysglycemic, and T2DM); and for 24-h UGE, 
the repeated measure ANCOVA will be fitted for both overall population and for each stratum.  
Summaries of absolute values and changes (and/or percent changes for body weight and lipid 
parameters) from Week 24 by treatment group and visit will be presented for all efficacy 
variables, for all subjects, and by stratification strata if applicable.  
2.7.3 
Handling of missing values/censoring/discontinuations 
Missing body weight at Week 24 will be imputed using the multiple imputation method as 
described in Section 2.5.3.  
Repeated measure ANCOVA models, which use all available data, will be used to analyze other 
secondary variables. The approach yields valid results, i.e. confidence intervals with correct 
coverage and tests with the correct size under a missing at random (MAR) process (Siddiqui 
et.al. 2009).   
2.8 
Safety analyses 
All Week 24 safety analyses will be performed in the SAF, and all End of study safety analyses 
will be performed for subjects in the SAF who enter Epoch 4. 
2.8.1 
Adverse events (AEs) 
Week 24 analysis 
A treatment-emergent AE for Week 24 is defined as any AE in Epoch 3 that develops after 
initiation of the study treatments or any event already present that worsens following exposure 
to the study treatment. Following the definition, AEs occurring after treatment discontinuation 
will also be considered as treatment-emergent AEs. Treatment emergent AEs will be 
summarized for Week 24 analysis. The number and percentage of subjects having AEs will be 
summarized by system organ class, preferred term, and treatment group.  Unless otherwise 
specified, primary system organ will be sorted alphabetically and, within each primary system 
organ class, the preferred terms will be sorted in descending order of frequency in the 
investigational study drug arm (LIK066 150 mg qd). If a patient reported more than one AE 
with the same preferred term, the AE will be counted only once. If a patient reported more than 
one AE within the same primary system organ class, the patient will be counted only once at 
the system organ class level. The number and percentage of subjects having AEs will be 
summarized by system organ class, preferred term, treatment group, and subgroups of interest 
(glycemic status, age group and sex) as well.  
The most frequent AEs (>=2% in any treatment group) will be presented by preferred term in 
descending order of frequency in the investigational study drug arm, LIK066 150 mg qd.   
AEs will also be presented by greatest severity. If a patient reported more than one AE with the 
same preferred term, the highest severity will be presented. All AEs will be summarized by 
highest severity, primary system organ class, preferred term, and treatment. If a patient reported 


Novartis 
For business use only 
Page 25 
SAP 
 
CLIK066B2201 
 
more than one AE within the same primary system organ class, only one AE will be counted 
for that patient at the highest severity level in the total row for each primary system organ class. 
Missing severity will be assumed to be severe in the summary table.   
AEs suspected to be related to study drug, serious AEs, fatal AEs, and AEs leading to study 
drug discontinuation, study drug interruption will be summarized by presenting number and 
percentage of patients with an event by primary system organ class, preferred term, and 
treatment.  
Week 24 on-treatment AEs are defined as any treatment-emergent AEs occurred while patients 
were on Epoch 3 treatment (captured using treatment start and end date). On-treatment AEs, 
serious AEs, fatal AEs, AEs leading to study drug discontinuation, and AEs of special interest 
will also be summarized.  
End of study analysis 
A treatment-emergent AE for the End of study analysis is defined as any AE that develops after 
the start of Epoch 4 or any event already present in Epoch 3 that worsens following exposure 
to the study treatment during Epoch 4. AEs occurring after treatment discontinuation will also 
be considered as treatment-emergent AEs. The number and percentage of subjects having AEs, 
SAEs, AEs leading to study medication permanent discontinuation and study drug interruption 
occurring after start of Epoch 4 will be summarized and presented, in similar way as for the 
Week 24 analysis.  
Overall treatment emergent AEs for the overall 48 weeks of Epoch 3 plus Epoch 4 by 10 
randomized treatments will be generated. 
All AEs in the database will be listed by 10 randomized arms. The listings will include those 
AEs reported during the run-in epoch, and AEs reported after study completion or 
discontinuation.  
Legal requirement for AE reporting 
For the legal requirements of ClinicalTrials.gov and EudraCT, two required tables on treatment 
emergent AEs which are not SAEs with an incidence greater than 2% and on treatment emergent 
SAEs and SAEs suspected to be related to study treatment will be provided by system organ 
class, preferred term, and 10 randomized treatment arms on the SAF for overall study duration. 
If for a same patient, several consecutive AEs (irrespective of study treatment causality, 
seriousness and severity) occurred with the same SOC and PT: 
• a single occurrence will be counted if there is  ≤ 1 day gap between the end date of the 
preceding AE and the start date of the consecutive AE 
• more than one occurrence will be counted if there is > 1 day gap between the end date 
of the preceding AE and the start date of the consecutive AE 
For occurrence, the presence of at least one SAE/SAE suspected to be related to study 
treatment/non SAE has to be checked in a block e.g., among AE's in a ≤ 1 day gap block, if at 
least one SAE is occurring, then one occurrence is calculated for that SAE. 


Novartis 
For business use only 
Page 26 
SAP 
 
CLIK066B2201 
 
The number of deaths resulting from SAEs suspected to be related to study treatment and SAEs 
irrespective of study treatment relationship will be provided by SOC and PT. 
2.8.1.1 
Adverse events of special interest / grouping of AEs 
AEs of special interest, such as risks defined in the development safety profiling plan (DSPP), 
or topics of interest regarding signal detection or routine analysis, are defined in the electronic 
case retrieval sheet (eCRS) that is stored in GPS. 
The pre-defined issues of special interest for LIK066 including identified risks, potential risks, 
and special assessments are listed below: 
• Bone fractures 
• Cardiotoxicity 
• Diarrhea  
• Electrolyte disturbances 
• Genital  infections 
• Hepatotoxicity 
• Hypersensitivity 
• Hypoglycemia 
• Impaired renal function 
• Increased LDL 
• Intravascular volume depletion 
• Ketoacidosis 
• Malignancy 
• Pancreatitis 
• Urinary tract infections 
• Venothrombotic and embolic events 
• Lower limb amputation 
Week 24 analysis 
Treatment-emergent AEs of special interest which occur during Epoch 3 will be summarized 
by risk category and preferred term, by treatment. The AEs of special interest will be 
summarized by risk category, preferred term, treatment, and subgroups of interest (glycemic 
status, age group, and sex) as well. 
In addition, exposure-adjusted incidence rates per 100 patient years regardless of study drug 
relationship, by treatment will be provided by risk category and preferred term. The 95% 
confidence interval for the overall exposure-adjusted incidence rates per 100 patients will also 
be presented for each risk category, along with relative risk and 95% confidence interval. 


Novartis 
For business use only 
Page 27 
SAP 
 
CLIK066B2201 
 
Additional analyses for the pre-defined risks of diarrhea, ketoacidosis and hypoglycemia will 
be performed as described below: 
Diarrhea events of special interest 
Number of days with on-treatment diarrhea events will be calculated for all patients with at least 
one incidence of on-treatment diarrhea and will be summarized descriptively by treatment. 
• Number of days for one diarrhea incidence = AE end date – AE start date +1.  
• Number of days with diarrhea events for a patient = sum of days on diarrhea over all 
incidences that occurred in Epoch 3. 
The number and percentage of patients with diarrhea events during the double-blind treatment 
period (while patients on study medication) will also be summarized by treatment over time in 
the following time window: 0 - <2, 2 - <4, 4 - <8, 8 - <12, 12 - < 16, 16 - < 20 and >= 20 weeks. 
The number of days with diarrhea events while on-treatment in Epoch 3 will be analyzed using 
a generalized linear model assuming a negative binomial distribution. The negative binomial 
model accounts for any over dispersion that may result from assuming a Poisson distribution 
by allowing a different Poisson rate for each patient and assuming that these rates as a set are 
distributed across subjects according to a gamma distribution. The log(overall days on study 
medication) will be used as the offset variable in the model. The model will be adjusted for 
treatment, glycemic status, and region. 
Ketoacidosis events of special interest 
All cases of ketoacidosis will be adjudicated by an independent committee. The frequencies and 
percentages of the adjudication confirmed ketoacidosis events will be provided by treatment.  
The site-reported ketoacidosis events will also be summarized by treatment. In addition, the 
ketoacidosis events will be listed at individual patient level, with the site-reported event profile 
and symptoms and the adjudication outcome displayed as well. 
Hypoglycemic events of special interest 
Hypoglycemic events entered into the study Hypoglycemic event eCRF are included in all of 
the AE summaries in Section 2.8.1.  
In addition, there are two categories clinically significant of hypoglycemic events defined: 
• Severe hypoglycaemia: An event, requiring assistance of another person (third party 
assistance) to actively administer carbohydrate, glucagon, or other corrective actions, 
confirmed or not by a blood glucose measurement  
• Other clinically significant hypoglycaemia: Plasma glucose < 3.0 mmol/l (54 mg/dl) 
with or without typical symptoms of hypoglycaemia, and which is handled by the 
subject himself/herself. 
Hypoglycemia classification is included in the Appendix Table 5-1.  
Patients reporting at least one clinically significant hypoglycemic event, and the subgroup of 
patients reporting >2 such events, patients discontinued study medication or withdrew from the 
study due to clinically significant hypoglycemic events, patients reporting severe hypoglycemic 
events, and patients reporting other clinically significant hypoglycemic events will be 


Novartis 
For business use only 
Page 28 
SAP 
 
CLIK066B2201 
 
summarized by numbers and percentages in each  treatment group.  The exposure-adjusted 
incidence rates, relative risks and the related 95% confidence intervals of LIK groups versus 
placebo for the overall, severe and other clinically significant hypoglycemic incidences will be 
calculated respectively, and presented along with other safety risks/events of interest. 
The clinically significant hypoglycemic events will also be summarized by event profile as 
follows: 
• Severity (Mild, Moderate, Severe) 
• Meeting the definition of an SAE (Yes, No) 
• Seriousness (Death, Requires or prolongs hospitalization, Life threatening, Congenital 
anomaly or birth defect, Significant disability, Other medically importance serious 
event) 
• Discontinuation due to hypoglycemic events (Yes, No) 
• Relationship to the study treatment (No, Investigational treatment, Other study 
treatment, Both and/or indistinguishable) 
• Action taken with study treatment (Dose increased, Dose not changed, Dose reduced, 
Drug interrupted, Drug withdrawn, Unknown, Not applicable)  
• Medication or therapy taken (Yes, No) 
• Outcome (Not recovered/not resolved, Recovered/resolved, Recovered/Resolved with 
sequelae, Fatal, Unknown) 
• Time of the day in 24-hour clock (>00:00–06:00, >06:00–12:00, >12:00–18:00, 
or >18:00–24:00) 
• Time between last meal and event 
• Time between last dose and event 
• Precipitating factors (None, Missed/delayed meal, Strenuous exercise, Alcohol 
consumption, Other) 
• Third party assistance (Yes, No) 
• Medical assistance received (Yes, No) 
In addition, for pre-defined risk and selected AEs including hypotension, hypoglycemia, 
hyperkalemia, diarrhea, genital infections and UTIs, a by-stratification factor of BL glycemic 
status subgroup analysis will be provided. 
A listing of AEs of special interest will be presented by treatment group and patient number.  
End of study analysis 
The AEs of interest collected during Epoch 4 will be summarized as appropriate separately. 


Novartis 
For business use only 
Page 29 
SAP 
 
CLIK066B2201 
 
2.8.2 
Deaths 
Any deaths up to and including Week 24 will be included in a separate AE table by treatment 
group for Week 24 analysis summarizing fatal events. Additional deaths in Epoch 4 will be 
included in a separate AE table similarly for the End of study analysis.  
Deaths will also be listed by treatment groups for both Week 24 analysis and End of study 
analysis. 
2.8.3 
Laboratory data 
Table 2-4 
Laboratory data 
Category 
Parameter(s) 
Hematology 
RBC (total), WBC (total), platelet count (direct), hemoglobin, hematocrit, 
basophils (absolute, %), eosinophils (absolute, %), lymphocytes 
(absolute, %), monocytes (absolute, %), neutrophils (absolute, %) 
Biochemistry 
ALT, albumin, alkaline phosphatase (ALP), AST, bicarbonates, bilirubin 
(direct, total), blood urea nitrogen (BUN), calcium (total), chloride, 
creatinine, cystatin C, eGFR (MDRD), magnesium, phosphates, 
potassium, protein (total), sodium, uric acid, γ-GT, amylase, lipase 
Urinalysis 
pH, specific gravity, protein, glucose, ketones, nitrites, blood, leucocytes, 
Urine albumin to creatinine ratio (spot urine) 
All laboratory samples will be processed through the central laboratory. Laboratory data consist 
of hematology, clinical chemistry, and urinalysis.  
Hematology data are collected at Visit 1, 201, 205, 299/301, 302, 303, and 399; clinical 
chemistry data are collected at Visit 1, 201, 203, 205, 299/301, 302, 303, and 399; and 
Urinalysis are collected at Visit 201, 205, 299/301, 303,  and 399.  
Week 24 analysis 
Descriptive summary statistics including for the change from BL to each study visit up to and 
including Week 24 visit will be presented by treatment group for each laboratory parameter, as 
well as for the maximum change from BL. In addition, shift tables will be provided for all 
parameters with available ranges to compare a subject’s BL laboratory evaluation relative to 
the most extreme post-BL value. For the shift tables, normal ranges as well as specifically 
defined clinically notable/abnormality limits, if available – will be used. 
A listing of all patients with notable laboratory values will be provided.  
Urinary calcium and phosphorus excretion will be collected for a subset of subjects participating 
in the PK analysis. The change from BL in the 24-h urinary calcium and phosphorus excretion 
will be descriptively summarized by treatment and visit. 
Clinically notable laboratory abnormalities for selected tests based on a percent change from 
baseline are shown in Table 2-5. 
 
 


Novartis 
For business use only 
Page 30 
SAP 
 
CLIK066B2201 
 
Table 2-5 
Clinically notable laboratory abnormalities for selected tests 
Parameter 
Criteria (based on a percent change from baseline or change 
from baseline) 
Hematology 
  
RBC (total) 
>50% increase, >20% decrease 
WBC (total) 
>50% increase, >50% decrease 
Platelet count  
>75% increase, >50% decrease 
Hemoglobin  
>50% increase, >20% decrease 
Hematocrit 
>50% increase, >20% decrease 
Clinical chemistry 
  
ALT 
>150% increase  
AST 
>150% increase 
BUN 
>50% increase 
Creatinine 
>50% increase 
Total bilirubin 
>100% increase 
ALP 
>100% increase  
Sodium 
>5% increase, >150 mmol/L, <130 mmol/L  
Potassium 
absolute values < 3.0 mmol/L, > 5.9 mmol/L 
Chloride 
>10% increase, >10% decrease 
Calcium 
>10% increase, >10% decrease, hyper > 2.6 mmol/L 
Uric acid 
>50% increase 
Plasma glucose 
>50% increase  
Plasma glucose 
< 3.0 mmol/L (54 mg/dL) 
End of study analysis 
Descriptive summary statistics including for the change from Week 24 to each post-Week 24 
study visit during Epoch 4 will be presented by treatment group for each parameter, as well as 
for the maximum change from BL. In addition, shift tables will be provided for all parameters 
with available ranges to compare a subject’s Week 24 laboratory evaluation relative to the most 
extreme post-Week 24 value. 
The change from Week 24 in the 24-h urinary calcium and phosphorus excretion will be 
descriptively summarized by treatment and visit (for post-Week 24 visits only) for a subset of 
subjects participating in the PK analysis.  
A listing of all patients with notable laboratory values will be provided as well.  
2.8.4 
Vital signs  
Week 24 analysis 
For vital sign data collected during Epoch 3, descriptive statistics will be provided for absolute 
values and change from baseline at each assessment time point by treatment group as 
appropriate. 
The number and percentage of patients with newly occurring or worsening notable values, 
including notable change from baseline will be summarized by vital sign parameter at each 


Novartis 
For business use only 
Page 31 
SAP 
 
CLIK066B2201 
 
assessment time point by treatment group. Notable absolute values and notable changes from 
baseline for each vital sign parameter are defined in Table 2-6 and Appendix 1 of the protocol.  
A listing of all patients with notable vital sign values and changes will be provided. 
End of study analysis 
Similar analysis to that done at Week 24 will be conducted for the end of study analysis for vital 
sign data collected during Epoch 4.  
Table 2-6 
Vital signs notable range deviations 
Vital signs 
 
Notable abnormalities 
Pulse (beats/min) 
 
either ≥ 120 + increase ≥ 25* or > 130 
 
 
either ≤ 50 + decrease ≥ 30* or < 40 
BP (mmHg) 
systolic 
either ≥ 180 + increase ≥ 30* or > 200 
 
 
either ≤ 90 + decrease ≥ 30* or < 75 
 
diastolic 
either ≥ 105 + increase ≥ 20* or > 115 
 
 
either ≤ 50 + decrease ≥ 20* or < 40 
* Refers to post-BL value as compared to BL value. 
 
2.8.5 
ECG 
The following quantitative variables will be summarized: QTcF duration (msec), Heart rate 
(beats/min), PR duration (msec), RR duration (msec), and QRS duration (msec). 
Week 24 analysis 
Changes from baseline for ECG variables will be provided; for QTcF and heart rate, inferential 
statistics will be generated as well.  
The number and percentage of subjects with the following criterion will be presented.  
• QTcF > 500 msec 
• QTcF > 480 msec 
• QTcF > 450 msec 
• QTcF increases from baseline ≥ 30 msec 
• QTcF increases from baseline ≥ 60 msec 
• PR > 200 and ≤ 220 msec 
• PR > 220 msec 
• PR increases from baseline > 25%  and to a value > 200 msec 
• QRS > 110 and ≤ 120 msec 
• QRS > 120 msec 
• QRS changes from baseline > 25 % and to a value > 110 msec 


Novartis 
For business use only 
Page 32 
SAP 
 
CLIK066B2201 
 
• Heart rate > 100 beats/min 
• Heart rate < 50 beats/min 
In addition, shift tables comparing baseline ECG results (normal, abnormal, not available, total) 
with the maximum on-study result (normal, abnormal, not available, total) will be provided for 
each variable. 
Cutoff points below are used to define normal or abnormal criteria: 
• QTcF: >450 or =<450 msec for male and >460 or =<460 msec for female 
• QRS: >120 or =<120 msec 
• PR: >200 or =<200 msec 
• HR: >100 or =<100 beats/min 
A listing of ECG parameters together with newly occurring or worsening abnormalities will be 
provided.  
End of study analysis 
Similar analyses outlined for Week 24 will be provided for the End of study analysis.  
2.8.6 
Liver events 
Week 24 analysis 
Liver events and laboratory trigger definitions and follow-up requirements are defined in 
Appendix 2 of the protocol.  
The laboratory parameters for liver function will be shown in the laboratory standard tables as 
discussed in Section 2.8.3. In addition, summary tables will be provided on the number and 
percentage of subjects who meet the following liver toxicity criteria post baseline by Week 24.  
Listings of patients with clinically notable LFT values will be provided.  
Table 2-7 
Criteria for evaluating liver toxicity 
Parameter 
Criterion 
ALT or AST 
ALT or AST > 3xULN 
 
ALT or AST > 5xULN 
 
ALT or AST > 8xULN 
 
ALT or AST > 10xULN 
 
 
Hy’s category 
ALT or AST >3x ULN and TBL >1.5x ULN 
 
ALT or AST > 3xULN & TBL > 2xULN 
 
ALT or AST > 5xULN & TBL > 2xULN  
 
ALT or AST > 8xULN & TBL > 2xULN  
 
ALT or AST > 10xULN & TBL > 2xULN 
 
ALT or AST > 3xULN & TBL > 2xULN & ALP ≤ 2xULN 
 
 


Novartis 
For business use only 
Page 33 
SAP 
 
CLIK066B2201 
 
Parameter 
Criterion 
TBL&ALP 
TBL >1.5x ULN and ALP >2x ULN 
 
TBL >2x ULN and ALP >2x ULN 
 
 
Isolated TBL 
TBL >1.5x ULN & ALT and AST <3x ULN and ALP <2x ULN 
 
TBL >2x ULN & ALT and AST <3x ULN and ALP <2x ULN 
 
TBL >3x ULN & ALT and AST <3x ULN and ALP <2x ULN 
 
 
Isolated ALP 
ALP >1.5x ULN &  ALT and AST <3x ULN and TBL <1.5x ULN 
 
ALP >2x ULN &  ALT and AST <3x ULN and TBL <1.5x ULN 
 
ALP >3x ULN & ALT and AST <3x ULN and TBL <1.5x ULN 
 
ALP >5x ULN & ALT and AST <3x ULN and TBL <1.5x ULN 
ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBL: total bilirubin; 
ULN: upper limit of normal.  
End of study analysis 
Summary tables will be provided on the number and percentage of subjects who meet the liver 
toxicity criteria after Week 24 until end of the study (Epoch 4). 
2.8.7 
Renal events 
Week 24 analysis 
The overall frequency of events and percentage of patients with renal events during the 
treatment period will be provided for the Week 24 analysis. Furthermore, the frequency and 
percentage of patients with renal events during Epoch 3 will be provided by treatment and the 
first identified criterion. The frequency of patients with renal events and percentage will be 
provided for clinical signs and symptoms by the treatment. 
Renal event overview data, pathology data, and imaging data will be provided in listings.  
The renal function lab data will be analyzed in Section 2.8.3 Laboratory data.  
End of study analysis 
Similar analyses will be conducted for the End of study analysis for those patients who entered 
Epoch 4 of the study.  
Table 2-8 
Specific renal alert criteria  
Criteria 
Action required 
Serum event 
Serum creatinine increase 
25 – 49 % compared to BL 
Confirm 25 % increase after 24-48h  
Follow up within 2-5 days 
Acute kidney injury: serum creatinine increase 
≥50 % compared to BL 
Follow up within 24-48h if possible 
Consider study treatment interruption  
Consider subject hospitalization /specialized treatment 
Urine event 
New dipstick proteinuria ≥ 1+ 
Confirm value after 24 to 48-h 


Novartis 
For business use only 
Page 34 
SAP 
 
CLIK066B2201 
 
Albumin- or protein-creatinine ratio increase ≥2-fold 
Albumin-creatinine ratio (ACR) ≥30 mg/g or 
≥3 mg/mmol; 
Protein-creatinine ratio (PCR )≥150 mg/g 
or >15 mg/mmol 
Perform urine microscopy 
Consider study treatment interruption / or 
discontinuation  
New dipstick hematuria ≥ 1+ not due to trauma 
Urine sediment microscopy 
Perform serum creatinine, ACR  
2.9 
Pharmacokinetic endpoints   
Not applicable.  
2.10 
PK analyses 
PK sampling will be performed at visits 205, 299/301, and 303. Blood samples will be collected 
at time-points: 0h (pre-dose) and approximately 1h, 2h, 4h, and 6h post dose.  
Plasma concentration of LIK066 and scheduled time from dosing will be summarized by 
treatment and visit/sampling time point. PK parameters (Cmax, Tmax, AUClast, AUC0-t) will 
be listed and summarized. Descriptive statistics includes n, mean, standard deviation, minimum, 
median, maximum, coefficient of variation (%) for arithmetic mean, geometric mean, and 
coefficient of variation (%) for geometric mean.  
Concentrations below the lower limit of quantification (LLOQ) will be treated as zero in 
summary statistics and for PK parameter calculations. A geometric mean will not be reported 
if the dataset includes zero values.  
Individual LIK066 plasma concentration data will be listed by treatment, subject, and visit / 
sampling time point.  


Novartis 
For business use only 
Page 35 
SAP 
 
CLIK066B2201 


Novartis 
For business use only 
Page 36 
SAP 
 
CLIK066B2201 
 
2.12 
Biomarkers 
Serum samples for bone and renal biomarkers, and urine bone biomarkers will be collected 
from subjects who participate in the PK substudy. Biomarkers are collected at Visit 201, 205, 
299/301, 303, and 399.  Data will be analyzed based on SAF.  
Table 2-9 
Biomarkers 
Category 
Parameter(s) 
Bone biomarkers 
β-c-terminal telopeptide (β-CTX1), serum procollagen type 1 N-
propeptide (sP1NP), ), intact parathyroid hormone (iPTH), 25-hydroxy 
vitamin D, 1,25 dihydroxy vitamin D, osteocalcin, estradiol, calcium, 
magnesium, phosphates 
Renal biomarkers 
Serum cystatin, urinary cystatin cystatin C/creatinine ratio (spot urine)  
Week 24 analysis 
Summaries of absolute values and change from BL in each of the bone, renal, and inflammatory 
biomarkers by treatment group and visit will be presented using statistics: n, mean, SD, median, 
minimum, maximum, Q1, Q3, geometric mean and coefficient of variation. Figures will be 


Novartis 
For business use only 
Page 37 
SAP 
 
CLIK066B2201 
 
produced to visually show the mean values by visit over 24 weeks of treatment in Epoch 3 for 
each treatment group. 
End of study analysis 
The absolute values and change from Week 24 in each of the bone, renal and inflammatory 
biomarkers will be similarly summarized and depicted as for the Week 24 analysis.  
2.14 
Interim analysis 
Not applicable.  


Novartis 
For business use only 
Page 38 
SAP 
 
CLIK066B2201 
 
3 
Sample size calculation 
The study planned to randomize approximately 432 subjects in total, allocated in the ratio of 
1:1:1:1:1:2:1:1:1:2 to the following 10 Epoch 3/Epoch 4 treatment groups: 
1. placebo/placebo 
2. placebo/LIK066 25 mg qd 
3. LIK066 2.5 mg qd/25 mg qd  
4. LIK066 10 mg qd/25 mg qd  
5. LIK066 50 mg qd/25 mg qd  
6. LIK066 150 mg qd/25 mg qd  
7. LIK066 2.5 mg bid/35 mg qd  
8. LIK066 5 mg bid/35 mg qd  
9. LIK066 25 mg bid/35 mg qd  
10. LIK066 50 mg bid/35 mg qd  
This randomization scheme implies that the Epoch 3 treatment and Epoch 4 treatment for a 
specific subject is determined simultaneously at randomization visit. The randomization will be 
stratified by subjects’ glycemic status at screening: normoglycemic, dysglycemic and T2DM. 
As the dose-response assessment is conducted in qd and bid regimens separately (while an 
overall family-wise type I error is controlled at a one-sided significance level of 2.5 %), power 
calculation was done for testing dose-response signal by regimen as well. Table 3-1 summarizes 
the average power and the lowest power across the candidate dose response shapes in Figure 2-
1 by regimen, under different scenarios with the assumptions on effect size of body weight loss 
(percent change from BL) for the dose of maximum effect, and the related standard deviations. 
Note that a dose-response signal is detected (ie the primary objective is met) as long as either 
of the dose-response signals for the two regimens is detected. Therefore, the overall study power 
is at least the maximum of the powers between two regimens for each scenario considered. 
Table 3-1 
Power for detecting a significant dose response signal* 
Dose 
regimen 
Effect size for best dose 
SD 
Average 
power** 
Minimum 
power† 
Qd 
5 % 
5.5 % 
99.99 % 
99.98 % 
 
5 % 
6.5 % 
99.71 % 
99.57 % 
 
6 % 
5.5 % 
99.99 % 
99.99 % 
 
6 % 
6.5 % 
99.99 % 
99.98 % 
Bid 
5 % 
5.5 % 
99.16 % 
95.84 % 
 
5 % 
6.5 % 
96.50 % 
86.79 % 
 
6 % 
5.5 % 
99.90 % 
99.43 % 
 
6 % 
6.5 % 
99.28 % 
96.36 % 


Novartis 
For business use only 
Page 39 
SAP 
 
CLIK066B2201 
 
Dose 
regimen 
Effect size for best dose 
SD 
Average 
power** 
Minimum 
power† 
* Assumes 432 subjects in LIK066 and placebo arms with effective sample size of 367 subjects due to an effect of 
missing data equivalent to 15 % fewer subjects. Calculations were performed using the DoseFinding package in R. 
† Power for a significant dose-response contrast test across all scenarios within each regimen in Table 3-1. The 
candidate model #5 in bid regimen has the lowest power. 
It was assumed that the effect of losses to follow-up is equivalent to effectively having 15 % 
fewer subjects than randomized, even if the multiple imputation approach used to handle 
missing values should be able to recover some information for such subjects. 
4 
Change to protocol specified analyses 
 
 
 
 
 
In protocol section 9.5.1.1 change from BL at Week 24 in hsCRP was listed as one of the 
secondary efficacy variables, and this has been modified to percent change from BL at Week 
24 in hsCRP in log10 transformation in the SAP.   


Novartis 
For business use only 
Page 40 
SAP 
 
CLIK066B2201 
 
5 
Appendix 
5.1 
Imputation rules 
5.1.1 
Study drug 
Any partial dates will be imputed as the earlier day of  
• The last day in the month and  
• The end day of the corresponding epoch 
5.1.2 
AE date imputation 
AE date imputation need to be done twice, once for Week 24 analysis, and once for the End of 
study analysis. 
AE end date imputation 
1. If ‘month’ is missing, the end date will be set to the earliest of the (min (last visit date, 
last dose date), 31DECYYYY, and date of death).  
2. If ‘day’ is missing, the end date will be set to the earliest of the (min (last visit date, last 
dose date), 31MONYYYY, and date of death). 
3. If ‘year’ is missing or AE is ongoing, the end date will not be imputed.  
AE start date imputation 
Before imputing AE start date, find the AE start reference date.  
• If the (imputed) AE end date is complete and the (imputed) AE end date < treatment 
start date then AE start reference date = min (informed consent date, earliest visit date). 
• Else AE start reference date = treatment start date 
After finding the AE start reference date: 
1. If ‘year’ is missing, the date uncertainty is too high; therefore the imputed AE start date 
will be set to NULL. 
2. If ‘year’ is less than the treatment start date ‘year’, the AE started before treatment; 
therefore:  
a. If ‘month’ is missing, the AE start date will be set to 01JULYYYY. 
b. If ‘day’ is missing, the AE start date will be set to 15 MONYYYY.  
3. If ‘year’ is greater than the treatment start date ‘year’, the AE started after treatment; 
therefore: 
a. If ‘month’ is missing, the AE start date will be set to 01JANYYYY.  
b. IF ‘month’ is not missing, the AE start date will be set to the later of 
(01MONYYYY, AE start reference date + 1). 


Novartis 
For business use only 
Page 41 
SAP 
 
CLIK066B2201 
 
4. If ‘year’ is equal to the treatment start date ‘year’ 
a. If ‘month’ is missing, the AE start date will be set to the AE reference start date 
+1. 
b. If ‘month’ is less than the treatment start ‘month’, the AE start date will be set 
to 15MONYYYY. 
c. If ‘month’ is equal to or greater than the treatment start ‘month’, the AE start 
date will be set to the later of (01MONYYYY, AE start reference date+1). 
If complete (imputed) AE end date is available and the imputed AE start date is greater than the 
(imputed) AE end date, imputed AE start date will be set to the (imputed) AE end date.  
5.1.3 
Concomitant medication date imputation 
CM date imputation need to be done twice, once for Week 24 analysis and once for the End of 
study analysis.  
CM end date imputation  
1. If ‘day’ is missing and ‘month/year’ are non-missing then impute date as the earlier of 
(treatment end date, and 31MONYYYY).   
2. If ‘day/month’ are missing and ‘year’ is non-missing then impute date as the earlier of 
(treatment end date, and 31DECYYYY). 
3. If imputed end date is less than the start date, use the start date as the imputed end date.  
CM start date imputation  
1. If ‘year’ is missing, the start date will be set to one day prior to treatment start date.  
2. If ‘year’ is less than treatment start ‘year’, the CM started before treatment. Therefore: 
a. If ‘month’ is missing, the start date will be set to 01JULYYYY. 
b. If ‘month’ is non-missing, the start date will be set to 15MONYYYY. 
3. If ‘year’ is greater than treatment start ‘year’, the CM started after treatment. Therefore 
a. If ‘month’ is missing, the start date will be set to 01JANYYYY. 
b. If ‘month’ is non-missing, the start date will be set to 01MONYYYY. 
4. If ‘year’ is equal to the treatment start date ‘year’ 
a. If ‘month’ is missing or equal to the treatment start ‘month’, then the start date 
will be set to one day prior treatment start date. 
b. If ‘month’ is less than the treatment start ‘month’, the start date will be set to 
15MONYYYY.  
c. If ‘month’ is greater than the treatment start ‘month’, the start date will be set to 
01MONYYYY. 


Novartis 
For business use only 
Page 42 
SAP 
 
CLIK066B2201 
 
If complete (imputed) CM end date is available and the imputed CM start date is greater than 
the (imputed) CM end date, then imputed CM start date will be set to the (imputed) end date.  
5.1.3.1 
Prior therapies date imputation 
See Section 5.1.3. 
5.1.3.2 
Post therapies date imputation 
See section 5.1.3. 
5.2 
AEs coding/grading 
AEs will be coded according to MedDRA dictionary. The MedDRA version used for reporting 
will be described in the footnotes. Missing severity will be assumed to be severe in the summary 
table. 
Hypoglycemia classification is presented in Table 5-1. 
Table 5-1 
Hypoglycemia classification 
Category 
Definition 
Criteria as specified in the 
Hypo eCRF 
 
Severe 
hypoglycemia 
An event, requiring 
assistance of another 
person (third party 
assistance) to actively 
administer 
carbohydrate, glucagon, 
or other corrective 
actions, confirmed or not 
by a BG measurement 
An event with answer = ‘YES’ 
for any one of the two 
questions: 
• Was third party 
assistance required? 
• Was medical assistance 
received? 
 
 
Other clinically 
significant 
hypoglycemia 
Plasma glucose < 3.0 
mmol/l (54 mg/dl)* with 
or without typical 
symptoms of 
hypoglycaemia, and 
which is handled by the 
subject himself/herself. 
An event with answer = ‘YES’ 
to the question ‘Glucose 
measurement taken’ and the 
plasma glucose < 3.0 mmol/l 
(54 mg/dl), and answer = NO 
to both questions: 
• Was third party 
assistance required? 
• Was medical assistance 
received? 
 
*Blood glucose values need to be converted to plasma glucose values. 
A plasma glucose of 3.0 mmol/L (54 mg/dL) corresponds to a whole blood glucose of 2.7 mmol/L (48 mg/dL) 
Plasma glucose = blood glucose * 1.12. 
5.3 
Laboratory parameters derivations 
Not applicable.  


Novartis 
For business use only 
Page 43 
SAP 
 
CLIK066B2201 
 
5.4 
Rule of exclusion criteria of analysis sets  
Protocol deviations are identified prior to clinical database lock/unblinding and entered into a 
dedicated data panel as part of the locked database. Details are provided in the PD Specs and 
Edit Checks tab of LIK066B2201 Edit Check Specification document.  
The protocol deviations resulting in exclusion of subjects from an analysis population are 
outlined in Table 5-1 below. 
Table 5-2 
Protocol deviations that cause subjects to be excluded 
Deviation ID 
Description of Deviation 
Exclusion in Analyses 
INCL01 
Informed consent not obtained 
Excluded from SCR, RUN, 
RAN, FAS, SAF, and PPS 
TRT19 
Subject withdrew consent and not 
discontinued from the study 
Data 
collected 
after 
withdrawal of IC, excluded 
from FAS and SAF  
TRT34 
Patients mis-randomized in IRT 
Excluded from FAS and 
PPS 
INCL03 
BMI not within range or BMI missing Excluded from PPS 
EXCL04 
Subject taking prohibited medication 
Excluded from PPS 
EXCL05 
Patient with a history of malignancy 
Excluded from PPS 
EXCL06 
Pregnant patient 
Excluded from PPS 
EXCL08 
Use of active weight-loss medications Excluded from PPS 
EXCL09 
Bariatric surgery 
Excluded from PPS 
EXCL10b 
Not 
compliant 
with 
lifestyle 
intervention 
Excluded from PPS 
EXCL19 
Substances or alcohol abuse 
Excluded from PPS 
TRT06 
Study treatment adjusted 
Excluded from PPS 
TRT11 
Study 
treatment 
unmasked 
and 
subject not discontinued from the 
study 
Excluded from PPS 
TRT15 
Use of prohibited medication and not 
discontinued from the study 
Excluded from PPS 
TRT22 
Use of another investigational drug 
while on study 
Excluded from PPS 
TRT35 
Study medication taken after the 
morning or evening meal  
Excluded from PPS 
TRT28 
Misdispensed medication and taken 
by patient 
Excluded from PPS 
Table 5-3 
Subject Classification 
Analysis 
Set 
PD ID that cause subjects to be 
excluded 
Non-PD criteria that cause subjects to be 
excluded 
SCR 
INCL01 
Not having screening epoch disposition page 


Novartis 
For business use only 
Page 44 
SAP 
 
CLIK066B2201 
 
Analysis 
Set 
PD ID that cause subjects to be 
excluded 
Non-PD criteria that cause subjects to be 
excluded 
RUN 
INCL01 
Not in ENR; 
Not having run-in epoch disposition page 
RAN 
INCL01 
Not randomized 
FAS 
INCL01, TRT19, TRT34 
Not in RAN; 
PPS 
INCL01, INCL03, EXCL04, 
EXCL05, EXCL06, EXCL08, 
EXCL09, EXCL10b, EXCL19, 
TRT06, 
TRT11, 
TRT15, 
TRT22, TRT35, TRT 28, and 
TRT34 
Not in FAS; 
Overall exposure on DB medication < 22 
weeks unless premature discontinuation due to 
adverse events 
SAF 
INCL01, TRT19 
No double-blind study drug taken 
5.5 
Anti-diabetic medications search criteria  
The documents attached detail the search criteria of anti-diabetic medications for reporting.  
Combos - Codes 
match.pptx
List of 
_ingredients_anti 
5.6 
Unblinding plan at the Week 24 database lock 
5.6.1 
Unblinding plan for the Week 24 analysis at the 24-week DBL 
The unblinding plan for the Week 24 (Epoch 3) analysis was specified in Section 5.4 “Treatment 
blinding” of the study protocol. The logistic and operational details of this unblinding plan were 
provided here. 
• A restricted study folder will be set up in the Global Programming System (GPS) for 
the Week 24 analysis activities.  
• Access to this GPS restricted folder is given only to statisticians and programmers 
(analysis group 1) who are directly involved in performing Week 24 analyses. This 
analysis group 1 will not be involved in any study conduct activities related to the study 
Week 24 to Week 48 period (Epoch 4) after the unmasking.  
• A separate analysis group (analysis group 2, including final analysis TS and TP), who 
does not have access to the analysis results and the identity of treatments at Week 24 
analysis, will perform the pre-planned final analysis at the end of the study. 
• The randomization datasets will be uploaded to the 24-week restricted folder by 
Novartis Randomization Office upon the DBL for the Week 24 analysis; 
• When the analysis group 1 runs the Week 24 analyses using the actual treatment code 
in the GPS restricted folder, they must keep all the outputs confidentially.  
• It was not planned to generate patient listings for the Week 24 analysis.  


Novartis 
For business use only 
Page 45 
SAP 
 
CLIK066B2201 
 
• The core study team (including the study leader(s), study physician and data manager), 
who are directly involved in study conduct activities during the study Week 24 to Week 
48 period (Epoch 4), will not have access to the subject level data with identity of 
treatments such as subject listings at Week 24 analysis. 
• In general, the Global Program Medical Director (GPMD) will not have access right to 
the patient listings. However, for the preparation of the future study(s) and other internal 
decision making, the GPMD may request analysis group 1 to provide the patient listings 
to review for specifically selected and interested safety parameters and may request 
additional analysis for further investigation.  
• For scientific and management discussions and presentations, the GPMD can decide 
which group of people and at what extent the group can receive the Week 24 analysis 
results and the results from additional post-hoc analysis. 
• Investigators and patients will not be allowed to access to any unblinded patient level 
data or analysis results until the end of the entire study.  
5.6.2 
Documentation of outputs 
All outputs for the Week 24 analysis will be stored in the GPSII restricted folder, as described 
in section 5.6.1. 
The outputs related to summary results will be imported and stored in a restricted folder in 
Novartis Documentation System webEDI. Relevant summary reports based on the Week 24 
analysis results will be stored in the restricted folder in webEDI as well. The study leader, on 
behalf of the GPMD, will be in charge of the access to this restricted folder in the webEDI.   
The restriction to these resctricted-acess folders will be removed after the final DB lock at the 
end of the study. 
5.6.3 
List of unblinded personnel 
A separate document to include the list of names for personnel who are unblinded to the Week 
24 analysis data and outputs will be created and stored in the study folder in webEDI.  


Novartis 
For business use only 
Page 46 
SAP 
 
CLIK066B2201 
 
6 
Reference 
Pinheiro J, Bornkamp B, Bretz F (2006) Design and analysis of dose finding studies combining 
multiple comparisons and modeling procedures. Journal of Biopharmaceutical Statistics; 16(5): 
639-56. 
Pinheiro J, Bornkamp B, Glimm E, et al (2014) Model-based dose finding under model 
uncertainty using general parametric models. Statistics in Medicine; 33(10): 1646-661. 
Siddiqui O, Hung J HM, and O’Neill R (2009) MMRM vs. LOCF: a comprehensive comparison 
based on simulation study and 25 NDA datasets. Journal of Biopharmaceutical Statistics; 
19(2):227-246